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ABSTRACT 
The structure in solution of the N-terminal region of the GABAB receptor R  a was investigated 
using nuclear magnetic resonance (NMR) spectroscopy as well as other biophysical techniques. 
The data obtained on recombinant fragments expressed in yeast supported the presence of two 
complement control protein (CCP) modules. Initial findings indicated that the module pair was 
not amenable for structure determination. 
Further work on individual modules revealed the co-existence of two stable conformers 
for the second CCP module that differ in the isomerisation state of Proline 119. These two 
isoforms are stable on the NMR time scale and do not appear to interconvert. Subsequent 
production of a (13C, '5N) isotopically labelled sample of the second module allowed complete 
assignment of the two conformer resonances. A new protocol for structure calculation was 
devised to attempt simultaneous structure calculation of both conformers. The results of the 
structure calculation are presented. 
In contrast, the first CCP module is not a compactly folded entity, despite formation of 
the expected disulphide bonds. It exhibits many of the characteristics of a molten globule. To 
ensure that this disordered state did not arise from inaccurate domain boundary prediction, 
different length constructs were expressed in yeast. In addition expression of this module in 
insect cells was attempted to rule out the possibility that the lack of ordered structure arose from 
a yeast-specific artefact. In parallel, the structure of the first CCP module was probed by 
various biophysical techniques, and the data collected showed a secondary structure content 
similar to that of a typical, folded CCP module. This can be considered to be consistent with a 
molten globule state. Interestingly, this module has some tertiary structure according to near 
UV circular dichroism, which could arise from disulfide-bonding. 
In a yeast two hybrid system, the first module interacts with the fibulin-type 
module found in the fibulin extracellular matrix protein family. One possibility is that this 
module is functional despite its lack of compactness, and folds upon complex formation. 
Expression of different fragments containing the fibulin-type module from fibulin-2 was carried 
out using different expression systems in an attempt to assess such possibility. 
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Introduction 
CHAPTER ONE: INTRODUCTION 
1.1 	The metabotropic GABAB  receptor 
Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in mammalian brain. 
There are two distinct categories of target receptors for GABA each of which mediates synaptic 
inhibition: the ionotropic GABA-types A and C (GABANC) receptors; and the metabotropic GABA-
type B (GABAB) receptors. 
Upon activation by two molecules of GABA, the pentameric GABAA receptor induces a rapid 
inhibition of neuronal electrical activity. This comes about because the GABAA receptor is an ion 
channel which opens upon appropriate ligation allowing the inward flux of Cl- and a subsequent 
hyperpolarisation of the postsynaptic membrane [1]. In contrast, activation of postsynaptic GABAB  
receptors produces a slower, more prolonged inhibition [2]. Presynaptic GABAB receptors also exist 
and these may act as autoreceptors by suppressing GABA release from GABA-ergic nerve terminals, 
or they may act as heteroreceptors by blocking the release of other neurotransmitters, including L-
glutamate (the main excitatory neurotransmitter), from the appropriate nerve terminals [3]. These 
effects are believed to be mediated by coupling of GABAB receptors to the heterotrimeric guanine-
nucleotide binding (G)-proteins, Gi and Go. GABAB receptors are thus able to modulate adenylyl 
cyclase activity, and to cause inwardly rectifying K channels to open and voltage-dependent Ca 2+  
channels to close [4, 5] (Figure 1 .1). 
GABAB autoreceptors in the hippocampus can regulate the induction of the long-term 
'potentiation' (LTP) of synaptic transmission [6]. The phenomenon of LTP represents an important 
model system for studies of associative enhancement of synaptic strength as it is thought to underlie 
cognitive processes such as learning and memory. Other physiological actions have also been 
attributed to the stimulation of GABAB receptors, including analgesia, modulation of respiratory 
activity, and muscle relaxation [2]. GABAB receptors are thought to be potential therapeutic targets in 
a range of conditions. Lioresal, a racemic mixture of baclofen, is a receptor agonist used clinically in 
the treatment of spasticity arising from multiple sclerosis or spinal injury [7]. Other possible clinical 
applications of GABAB agonists/antagonists include epilepsy [2, 8], drug withdrawal [9, 10]. anxiety, 
depression, hypertension, and cognitive dysfunction [4, 11]. 
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The GABAB  receptor was first classified and pharmacologically characterised by Hill and 
Bowery in 1981 [12]. Much additional pharmacological and biochemical information was gleaned 
over the subsequent decade-and-a-half. Despite this, the cloning of a gene encoding a GABAB  
receptor proved very difficult. The much awaited breakthrough came in 1997 with the first report of 
the successful cloning of cDNA encoding a GABAB receptor subunit (GABAB receptor type 1, 
GABAB RI). This work, carried out by a team led by Bernhard Bettler at Novartis in Basel [13], 
represents an important landmark. Significant progress in our understanding of the structure and 
function of the GABAB receptor has ensued rapidly, revealing several surprising and possibly unique 
aspects of the receptor. In the original report of the cloning work, two splice variants, named GABAB 
Ria and GABAB Rib, were identified. Subsequently, the gene encoding a second subunit of the 
receptor (GABAB R2) was cloned [14-20]. Both the RlaJb and R2 subunits are members of the 
family of G-protein coupled receptors possessing seven transmembrane domains. Only when GABAB 
RI (either Ria or Rib) and GABAB R2 are co-expressed is full activity obtained, and the GABAB 
receptor is a heterodimer composed of GABAB Ria/b and GABAB R2 subunits (Figure 1.1). 
Despite these successes, the number of receptor genes cloned to date may not be sufficient to 
explain the results of numerous studies obtained over the last 15 years which have suggested 
considerable heterogeneity of GABAB  receptors [2, 21]. It is not unlikely that other splice variants, 
and perhaps even additional subunits remain unidentified. The area is one of intense activity. 
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Extracellular GABA1JR In 
human/rat 
GABAB  R le-human 
(f etal brain 
(;ABA,, R Iii 
143 aa 
CA BA,, R 1c-rat:+ 31 aa 
R 20,in,n: -26 aa 
(ABA,, R 2c-h,inian: 4( aa 
57 aa 
('.AJIA 
Figure 1.1: The GABAB heterodimer and splice variants 
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Figure 1.1 (continued):The GABAB heterodimer and splice variants 
The GABAB RI subunit is a protein of approximately 100 kDa. In the GABAB Rib 
subtype (human/rat), the N-terminal extracellular domain is the ligand binding domain 
and consists of a region with sequence homology to a family of bacterial periplasmic 
binding proteins (LIVBP). 
The GABA_R R1  splice variant (human/rat) differs at the N-terminus by the presence 
of a tandem pair of CP modules, the GABAI Ric-human splice variant differs from 
GABAB Ria in that is missing the second CP module, while the GABAR Ric-rat 
differs from RI in the 5th transmembrane region and the 2nd extracellular loop by the 
insertion of an additional 31 amino-acids. 
GABA Rid-rat differs in the intracellular C-terminal domain where an insertion of 
566 base pairs that includes a stop codon could generate a truncated receptor. 
The GABAR Rie-human subtype represents a soluble isoform of the GABAB RIa 
splice variant, which doesn't seem to bind GABA or its analogues. 
Note that the GABAB RlaIb subunit has a consensus motif for PDZ domain binding 
at its C-terminus. 
The GABAR2 subunit (human/rat) is 35% identical at the amino acid level to the 
GABAB RI subunit but has a longer intracellular C-terminal tail (80 extra residues) 
compare to GABAB RlaJb, and has no affinity for GABA or its analogues 
GABAB R2 splice variants include GABAR2b-human which contains a deletion of 
26 amino acids at the C-terminus whereas GABARR2c-human diverges 13 amino 




Contact between the two subunit C-terminus seems to be mediated by a "coiled-coil" 
region in each subunit and is needed for receptor trafficking. GABAB RI "coiled-
coil" interacts directly with the transcription factors CREB2 and ATFx. 
The dirnerization motif is contained within the extracellular binding domain. Upon 
ligand binding it has been suggested that the amino-terminal domain undergoes a 
hinge-bending motion, as in LIVBP described as a "venus fly trap" mechanism. 
Receptor activation causes adenylyl cyclase inhibition. This effect is believed to be 
mediated by the a subunit of Gi/o type G proteins. Postsynaptic receptors cause 
inwardly rectifying K channels to open allowing K to move down its 
electrochemical gradient, while presynaptic receptors cause voltage-dependent Ca 21  
channels to close. The effect on K channels is mediated by the 3/y subunits of Gi/o 
type G proteins and effect on Ca 2+  channels is mediated by the f3/y subunits of Go type 
G protein [22]. 
1.1.1 Cloning of the first subunit and first discovered splice variants 
The key to the first successful cloning of complementary DNA for a GABAB receptor was the 
development of the high affinity antagonist [1251]CGP64213 [13]. Such antagonist was developed by 
Novartis, and has activity at pre- as well as postsynaptic GABAB receptors, as shown by complete 
suppression of L-baclofen-induced responses in electrophysio logical recordings from rat CAI 
hippocampal slices [13]. Subsequent photoaffinity labelling revealed two candidate receptor 
glycoproteins with molecular weight of 100 kDa and 130 kDa (90 kDa and 110 kDa respectively after 
treatment with N-glycosidase) in the cortex, cerebellum and spinal cord of human, rat, mouse, 
chicken, frog and zebra fish. Expression cloning was then used to identify a 4.4 kb cDNA insert in a 
rat cortex and cerebellum library that had been transfected into COS-1 cells. The first gene to be 
identified encodes a 960 amino acid protein (GABAB  Ria) including a 16-residue signal sequence and 
corresponds, after post-translational N-glycosylation, to the 130 kDa glycoprotein photoaffinity 
labelled in native brain tissue. Subsequent low-stringency hybridisation cloning using the GABAB  
Ria cDNA as a probe identified a 2.9 kb cDNA which encodes a protein corresponding to the 100 
kDa glycoprotein (GABAB Rib), and which represents a splice variant of GABAB Ria. mRNA for 
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both variants is abundant in brain, and transcripts for the receptor are found in all cerebral cortical 
areas, the pyramidal cell layers of the hippocampus, the granular cell layers of the dentate gyrus, and 
basal ganglia. As confirmation that GABAB  RlaIb indeed correspond to variants of a functional 
GABAB  receptor, the cloned proteins, heterologously expressed in Human Embryonic Kidney (HEK) 
293 cells, were shown to couple negatively to adenylyl cyclase. Although when expressed 
heterologously in cell lines, the antagonist pharmacology of the cloned receptor was shown to be 
similar to that of native receptors, the potency of agonist ligands was about 100-fold less than 
expected from studies of brain membranes [13]. 
Human homologues of the two proteins were later reported, and share 99% sequence identity with the 
rat proteins [23]. 
1.1.2 Classification of GABAB  Ria and ib, and sequence similarities 
The primary sequence of GABAB  RI, and analysis of its hydropathy plots, places it within the 
superfamily of G-protein coupled receptors, all of which encompass seven putative transrnembrane 
domains (7TMD) [13]. There are five classes of 7TMD receptors [24], each containing proteins that 
are related by sequence similarity, but there is no significant similarity between classes. Class A 
members are most numerous and related to rhodopsin; class B members are related to the vasoactive 
intestinal peptide and glucagon receptors; class C receptors are homologous to the metabotropic 
glutamate receptors (mGlu R) and include the Ca 2+  sensing receptor (CS R); class D contains the 
pheromone receptors; and class E contains the cAMP receptors of Diclyostelium [24]. The sequence 
of GABAB  Rlalb is 18-23% identical to the eight subtypes of mGlu R and therefore it is grouped in 
class C [13]. The mGlu R subtypes are receptors for the major excitatory neurotransmitter [25], while 
CS R is involved in calcium homeostasis in humans and other mammals [26]. The similarity with 
mGlu R extends over the length of the sequence, and is striking since 27 out of 208 residues 
conserved within all mGlu R subtypes are present in GABAB Ri. Seventeen of these are in the -550 
residue N-terminal, extracellular domain of GABAB Ri. GABAB Ri, however, lacks a domain 
present in the mGlu R's and in the CS R that contains nine closely spaced cysteines [27]. 
All class C G-protein coupled receptors share a similar molecular architecture consisting of a large 
extracellular amino-terminal domain encompassing a ligand-binding site [28-30], followed by seven 
transmembrane domains and the intracellular C-terminal tail. Coupling to G-proteins is mediated by 
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the intracellular loops connecting the seven transmembrane domains, and the C-terminal region. The 
short, third intracellular loop, which is highly conserved among class C 7TMD receptors and is 
essential for G-protein activation [31]. 
There is a marked similarity between the N-terminal domains of class C members and a 
family of bacterial periplasmic amino acid-binding proteins which include the leucine-binding protein 
(LBP) and the leucine/isoleucine/valine-binding protein (LIVBP) [32] (Figure 1.2 & 1.3). These 
binding proteins are found in Gram-negative bacteria and are essential to the uptake of low molecular 
weight compounds such as amino-acids and sugars. The recognition and specific binding of these 
molecules is an essential first step for transmembrane transport. This theme is elaborated further 
below since the similarity has been used as a basis for construction of a structural and functional 
model of the N-terminal domain of GABAB RI  [33]. 
There is also a striking similarity between the N-terminal 143 residues of GABAB  Rla and 
proteins of the mammalian complement system (Figure 1.1 & 1.2) [34]. The complement protein 
(CP) category of protein modules (also called sushi domains) was first identified [and called the short 
consensus repeat (SCR)] [35] as a common feature in the sequences of the family of proteins that 
regulate complement activation. In GABAB  Rlb, these 143 residues are replaced by an unrelated 
sequence of 18 amino acids. 
Finally, the C-terminus of GABAB  Rla/b contains several features of interest. There are 
consensus substrate sites for casein kinase and protein kinase C suggestive of modulation by 
phosphorylation [13]. There is also a "coiled-coil" sequence of 35 residues (Figure 1.1) [16, 36] and a 
putative PDZ recognition sequence (SRV) at position —6 from the C-terminus. (Figure 1.1) [5]. As 
seen for NMDA and AMPA receptors, which C-termini are involved in synaptic targeting through 
interactions with PDZ-domain containing adaptor proteins. These proteins, in turn, have additional 
binding sites that allow interactions with the cytoskeleton and with signal transduction molecules [37]. 
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GABA Ala 	28 -GCQIIHPPWEGGIRYRGLTPDQVKAXNFL t-VDYE I EYVcRGEPEVVGPKVRKCLA- - 
Hikaru-2 -3 713 -TCPR1TE-- - - ?LAPLI.RL------EGNKLGQRAflYECPESLDGAW.TCLA- - 
SEZ- 6-3-4 	760 PSCQRVTSCRDPGDVEHSR --- RLISSPKFPVGATVQYVcQGFVLTGSAILTCHDRQ 
fH-15-1 6 869 -PCSQ --- PPQIERGTINSSRSSQESY- --ABGTXLSYTcEGGFRISEENETTCYM- - 
GABAB  Ala 	83 NG--SWTD)TPSRCVRI-CSK5YL1%EN--GKVFLTGGDLPALDGARVEFRCDPDFH 
Hikaru-2 -3 157 SG- -S SSL'T-P-TCHAIQCPRLELDDP---HLSLIELNT- -SWGRAV-FRCQWGFK 
SEE- 6-3-4 	815 AGSPKWSDRA-P--KCLLKPCHGLSAP --- GARSE1L- -HPAGATIHFSCAPGYV 
fR-15-16 917 -G- -I(WSSP- -P-QCEGLPCXSPPEISH- --GVVAm6St- - SYQYGEEV'rYKCFEGFG 
GABA3 Ala 	136 LVGSSRSVc!SQ-__GOWSTPKPHCQ 	 Mh - 
Rikaru-2 -3 806 LTGPAQLDCEP-- SGVWSGPVPRCK- — 
SEZ-6-3 -4 	869 LKGQASXKCVPGHPSRWSDPPPIcRA 
fR-15-16 965 IDGPAI.AKCI.G---EKWSHP-PSCI- 
- 	Bd bod 
GABAs Ala 	164 SERRAVYIGALPPMS ------ Gi 	 D 
LIVEP 	 24 - --EDIXVAVVGM ------ GPVA ----------- QYGDQEFTGAEQAV3DINAKGG 
mGlu Ri 40 RGDVIIGALFSVH ------ HQPPAE- -<X>--REQYGIQRVEMHThDKflThDPV 
CS R 	 28 K-KGDIILGGLWPTHFGVAAIWQDLKS- -<I>- -NF-RGSRWLQ7+}ffFMINSSPS 
GABAB  Ala 204 ILPDYELKLIHHDSKCD 	 Y ------------- NDPIXIILMPGC SV 
LIVBP 62 IKGN-KLQIAKYDDACDPRQAVAVMR(VV -------------- NDGIKYVIGHLC SR 
Mr.lu RI 95 LLPNITLGSEIRDSCWRSSVALEQSIEFIRD- -<II>- ---RTKKPIAGVIGPGS SIT 
CS R 87 LLPNMTLGYRIFDTCNTVSKALEATLSFVAQ--<II> -------- STIAWGATG GV 
GABAB Ala 249 ST 	 LIVLSYC,SSS 	QRFETFFRTH 	 EKWGW 
LIVBP 105 TQPASDIYDEGII2dITPAATAPZLmRG-YQLILRGLDSDQGPTAA1ctILEKV1(P 
mGlu RI 168 AxQVQNLLQLFDxpQIAYsATsxoLsDxL1xYFLRwpsoTLQRLDv-IcnYEw 
CS R 150 STAVBLLGYIPQVSYASSSRLLSQYKSFLRTIPNDERQATNdADXX-EYFRW 
GABAB  Ala 306 KKIATIQQT 	 AGIEITFRQSFF-----S 
LIVBP 162 QRIAIV DKQQYGEGL 	VQDGLXKGNANVVFRDGIT- -AGEKDFSTLVABLRKE- - 
mGlu Ri 225 TYVSAVEGNYGESAELAAQEGLCIA1iSDKIYS1.KSFDRLLRKLRERLP 
CS R 201 NVGTIAABDDYGRPGIEXFREEAEERDICXDFSELXSQYSDEEEXQQVVEVIQN- -s 
GABAB Ala 357 -DARIIVCLF 	C 	LFGKKYVWFLIGWYAD- 	SINCTVE 
LIVBP 216 -NIDBVYYGGYEP4GQILRQABAA --- GLKTQFI4GPEGVAB-VSLSNIAG------- 
mGiu Ri 283 KARVVCFE-1'VPGLLSARLGWGE-FSLIGSDThDRDEVIEGYE------- 
CS R 263 TAXVIVVTSS-GPOLEPLI1IVRPNITG- -RIWLASEAWASSSLIAMPEY------- 
GABAB Ala 413 FZAVEGHITTEIV1LNPANTRSISN 	 KRI.KR ----------- HPE 
LIVE? 262 --- ESAEGLLVTK-----PICNYDQV--PANXPI-VDAIKAKKQ--------------- 
inG1, 	Ri 332 --- VEMGGITIKLQS- -P 	RSD-DYFLKLR-LOTN?RNPWFP--<III>- -N!VQ 
CS R 311 --- FHVVGGrIGFGLK- -AGQIPGF-REFLQKVRPRKSVHNGFAK- -<III>- -DYER 
GABA9 Ala 459 ETGG 	 TSGGGSGVRLFWYNNQT 
LIVBP 292 -DPSGA3VWTTYAALQSLQAGLNQS ------------------- ODPAEIA-KYLKAN 
mGlu Ri 407 DS4GFVflaIYAW.BGLQNBALcPGHVG -----LCDA(PIDJL-DFLIKS 
CS R 414 LRISYNVYLAVYSIAHALQD-- IYTCLPGRG------LFNGSCADIXKVEAWQVLKH 
GABAB Ala 516 SF ----- EGVsGIf-VVFDASGS --- PMCWTLIEQL--QGGSYKKIGYYD8T 
LIVE? 331 SIT ----- DTVP-LTWDEXGDLKG-FEFGVFDWH- -ANGTATDAX----- 
mGlu Ri 458 SF ----- VGVSGEEVWFDEKGDAPGRYDfl1LQYT-EANRYDYVHVGTWRE 
CS R 464 LRBLNFTNNMGEQ-VTTDECLVGNYSIXNWBLSPEDGSIVFIVGYYNV 
Figure 1.2: 	Top An alignment of the GABAB Ria pair of CP-modules with CP-pairs found in 
the CNS (the 2nd and 3rd CPs from the Drosophila melanogaster Hikaru genki 
protein, and the 3rd and the 4th CPs from the rat Sez-6 protein), and a well 
characterised CP-pair found in the complement system (the 15th and the 16th CPs 
from the human factor H protein). 
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Figure 1.2 (continued): 	Bottom: alignment of the extracellular domain from the rat GABAB  
Ria with the LIVBP (E. co/i), the extracellular domain from the rat 
mGlu RI, and the extracellular domain from the rat CS R according 
to Galvez et al. (1999) [33] and Brauner-Osborne et al. (1999) [30]. 
Note that Cys101 and Cys 236 of CS R align with Cys109 and 
Cys254 of the mGlu RI respectively - two residues involved in the 
covalent, disulphide-linked homodimerization of the CS R [38]. 
Amino acid numbering includes signal peptides, three insertions 
found in the N-terminal domain of mGlu RI have been removed and 
indicated by <I>, <II>, and <III> [33]. 
Hyphens in the sequences indicate gaps introduced for optimal 
alignment. 
1.1.3 Cloning of a second subunit - the metabotropic GABA receptor is a heterodimer 
Despite the convincing demonstration by Kaupmann et a/. (1997) [13] that GABAB Ria/ib fulfilled 
many of the criteria of a functional metabotropic GABA receptor there remained some discrepancies 
between properties observed for the recombinant proteins on the one hand, and the native brain 
receptor on the other [13, 23]. Agonists showed significantly lower potencies for the recombinant 
receptors. This was attributed, at least in part, to inefficient coupling to G-proteins within the 
heterologous expression system tested. Indeed, coupling to adenylyl cyclase was weaker than 
anticipated and coupling to ion-channels difficult to demonstrate. Subsequently, Couve et al [39] 
showed that heterologously expressed recombinant GABAB Rla/b were not transported efficiently to 
the cell surface and that these proteins were instead largely retained in the endoplasmic reticulum. 
There was thus considerable excitement when five groups simultaneously reported the existence of a 
second subtype of the GABAB receptor (GABAB  R2) [14-18], (later reported by a sixth group as 
GPR51 [19, 20]). Not only did this discovery resolve many of the earlier difficulties raised by the 
work of Kaupmann et a/.[13, 23], and Couve et a/. [39], but it also opened a new chapter in the story 
of 7TMD receptors. 
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The discovery of a second subunit was made in 1998 using a combined bioinformatics and 
molecular biology approach. The human homologues of GABAB RlaIb had been identified and 
shown to be 98% identical to the rat sequences. The human cDNA sequence was then used to mine a 
database of expressed sequence tags ultimately revealing a second receptor subunit (GABAB R2). The 
GABAB R2 subunit has 941 residues and is 35% identical and 54% similar to GABAB Rib. The N-
terminal extension present in GABAB RIa is not found in the R2 subunit. Furthermore, the R2 
subunit has an unusually long, intracellular C-terminal tail containing 80 residues more than the 
equivalent region of GABAB RlaIb (Figure 1.1). 
GABAB R2 assembles with GABAB RI by means of parallel coiled-coil a-helices located in 
the respective carboxy-terminal intracellular domain of each subunit as demonstrated by yeast-two-
hybrid (YTH) technique. Further studies showed that the intracellular carboxy-termini of GABAB RI 
contain an endoplasmic reticulum retention signal that prevents the immature, non-glycosylated 
protein from being expressed at the cell surface [40-42]. The coiled-coil interaction with the 
corresponding carboxy-terminus of GABAB R2 masks the signal and enables the release of GABAB  
RI from the ER [42]. GABAB R2 which itself is expressed at the cell surface, therefore serves to 
chaperone GABAB RI to the cell surface. 
However, GABAB Ri that lacks the ER retention signal is not sufficient to form a fully 
functional receptor, and heterodimerisation is thus required to form a fully functional GABAB  
receptor, the GABAB receptor is an heterodimer made of two subunits: GABAB RI and GABAB R2. 
Unlike GABAB Ri, GABAB R2 does not bind either agonists or antagonist with measurable potency 
but when the two subunits were co-expressed in a 1:1 ratio in HEK293T cells [14], binding studies 
revealed agonist potencies comparable with the native brain receptors and coupling to G-proteins. A 
ten-fold increase in binding potency is observed, as measured by the inhibition of antagonist 
[1251]CGP64213 binding to receptor by agonists [15]. Co-expression of GABAB RI, GABAB R2 (in 
combination with Ga01, a G-protein (x-subunit) in HEK293T cells resulted in agonist-dependent 
stimulation of [35S]GTP-7S binding [16]. Finally, and critically, when co-expressed in Xenopus 
oocytes the two subunits produced a GABA-sensitive coupling with inwardly rectifying K channels 
[14-17]. 
Early reports suggested that recombinant GABAB R2 could display some functionality [17, 18]. 
Although it now appears unlikely that wild type GABAB R2 subunit can function alone. The lack of 
detectable GABAB response in tissue from mice lacking the gene for GABAB RI subunit argues 
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against GABAB R2 as an autonomous receptor. GABAB R2 is also heavily down-regulated in such 
null-mutant mice, a finding which support the notion that in wild-type mice, most of the GABAB R2 
protein is associated with GABAB  RI, in agreement with biochemical studies [43]. The same 
biochemical studies strongly suggest that GABAB Ria and GABAB Rib do not homo- or hetero-
dimerize and that GABAB Rla, GABAB Rib, and GABAB R2 exist exclusively in heteromeric form 
in the rat brain. 
Further evidence for the formation of a heterodimer has been provided by peptides derived form the 
carboxy-terminal domains of GABAB  RI and GABAB R2 that form heterotypic parallel a-helical 
coiled-coil domain structures when combined in vitro [36]. Upon sedimentation equilibrium the 
GABAB Ri! GABAB  R2 coiled-coil domain peptides assemble in a i :1 stoichiornetry. 
GABAB  RI null mice exhibit spontaneous seizures, hyperalgesia, hyperlocomotor activity, 
and memory impairment [44]. Such findings suggest that use of GABAB agonists may be of benefit 
in the treatment of psychiatric and neurological disorders in which attentional processing is impaired, 
and epilepsy. 
1.1.4 Splice variants amongst the subunits of the metabotropic GABA receptor 
More splice variants of the GABAB  receptor subunits have now been described, both in 
human and rat. However most variants have not been fully characterised in both terms of function 
and localisation, some are unpublished and have simply been reported through Genbank (Human 
GABAB RI c, Human GABAB R2b, Human GABAB R2c). 
Two splice variants, GABAB Ric and GABAB Rid were subsequently identified in rodent 
[45]. GABAB Ric is identical to GABAB Rib but with an insertion of 93 base pairs (bp) that 
generates an additional 31-amino-acids in the second extracellular loop and fifth transmembrane 
region, between GIy-654 and Ile-655 (Figure 1.1). Note that the fifth transmembrane domain is, in 
general, the most solvent-exposed domain according to modelling studies of 7TMD proteins [46] and 
is conceivably available for protein and drug interaction. For example, a non-covalent dimerization 
consensus motif ( LMALGFLIGYTCL, consensus residues in bold), originally found in the unrelated 
13-adrenegic receptors, is present in the fifth transmembrane domain of the CS R, and has been 
proposed to mediate homodimerisation via hydrophobic interactions [47]. When co-expressed with 
GABAB R2, GABAB  Ric is targeted to the cell membrane, and gives rise to a functional heterodimer 
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with similar properties to those of the GABAB Ria - GABAB R2 heterodimer [48]. The GABAB Rid 
variant has an additional insertion of 566 bp that generates a divergent C-terminal region (Figure 1.1). 
This insertion includes a stop codon that results in the replacement of 57 residues of Rib with 25 
residues of unrelated sequence. No functional studies on such variant have been reported to date. 
The human GABAB RI c-splice variant identified by Marshall and colleagues (unpublished - 
Genbank accession number AJ0I2187) is unrelated to rat GABAB Rlc and differs from GABAB Ria 
in that it has a 62 amino acids deletion that removes the second CP module. This subtype function 
was never been investigated; only RT-PCR studies have shown a up-regulation of this variant in the 
foetal brain [49]. 
The GABAB  Rie subtype represents a soluble isoform of the GABAB Ria variant detected in 
both rats and humans, encoding only the CP-module pair and the extracellular ligand binding domain 
[50]. When expressed in heterologous system, this truncated receptor is both secreted and membrane 
associated but lacks the ability to bind radiolabeled antagonist ([3H] CGP 54626A), activate GIRK 
channels, and inhibit forskol in- induced cAMP production, either alone or co-expressed with GABAB  
R2. Interestingly when co-expressed with GABAB R2 the truncated receptor is able to disrupt the 
GABAB Ria/GABAB  R2 association but doesn't disrupt GIRK channels activation by the full-length 
heterodimer. Because GABAB  Rie lacks an intracellular domain and therefore would not be able to 
dimerize via a coiled-coil interaction, it was speculated that GABAB Rie and consequently GABAB  
receptors could dimerize using a motif located within the amino-terminal domain like other 
metabotropic receptors (mGlu R). To determine the region of GABAB Rie responsible for 
dimerization, Schwarz et al used a series of progressive N-terminal truncations to show that the 
critical domain resides at the beginning of the ligand-binding domain (residues 166-439, the 
numbering system used here includes the 16 residues of signal sequence) and is outside the limits of 
the CP-module pair. 
Human GABAB R2 splice variants include two human splice forms, GABAB R2b 
(unpublished —Genbank accession number AF095 723) contains a deletion of 26 amino acids at the C-
terminus whereas GABAB  R2c (unpublished —Genbank accession number AF095 724) diverges 13 
amino acids from the C-terminus and has a different C-terminal tail of 46 amino acids [49]. The 
functional properties of these variants are currently unknown. 
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1.1.5 Expression profiles of the GABAB receptor subunits and splice variants 
1.1.5.1 Postsynaptic versus presynaptic 
The initial identification of the GABAB  Ria and Rib splice variants led to the rather attractive 
hypothesis that the Ria and Rib variants might provide the basis for the distinction between 
presynaptic, and postsynaptic, GABAB receptors [5]. As these two splice variants have identical 
intracellular regions, a differential subsynaptic association would presumably be due to differential 
membrane targeting or co-assembly with yet unidentified membrane proteins capable of 
distinguishing between the extracellular domains of Ria and Rib. 
A focal point for the investigation of this issue has been the rat cerebellum where GABAB  
binding sites are at their highest density in the classically termed "molecular layer" of the cerebellum. 
Granule cell bodies located in the morphologically distinguishable granule cell layer send parallel 
axon fibres through this "molecular layer" where they form excitatory presynaptic nerve terminals 
impinging upon the dendrites of Purkinje cells. The Purkinje cell bodies themselves form a highly 
characteristic morphological feature, the Purkinje cell layer. In situ hybridization studies were 
performed to determine whether there was a differential distribution of GABAB Ria and Rib mRNA 
in this region of the brain [51]. GABAB  Rla mRNA was found to be expressed predominantly in the 
granule cell layer (approximately 16-fold higher grain density than in the Purkinje cell layer) whereas 
RI b mRNA was localized primarily to Purkinje cell bodies (approximately 8-fold higher grain density 
than in the granule cell layer). These results predict that Ria-containing receptor proteins are 
preferentially expressed in granule cells, the source of the presynaptic terminals, while on the other 
hand, GABAB  Rib-containing receptor proteins are differentially produced in the postsynaptic 
Purkinje cells, whose dendrites form synapses, albeit excitatory ones, with the granule cell terminals. 
These observations appear to support the hypothesis of a differential association of GABAB Ria with 
presynaptic structures and Rib with postsynaptic membranes. 
In a biochemical approach to the question of differential presynaptic versus postsynaptic 
association of GABAB  Ria and Rib splice variants [43], a subcellular fraction of postsynaptic 
densities (PSD) from rat brain membranes was prepared and enriched by differential centrifugation. 
Immunoreactivity against both Ria and Rib was observed in fractions containing synaptic plasma 
membranes, suggesting a significant synaptic localisation for both splice variants in vivo. A further 
purified PSD fraction, however, which is enriched in postsynaptic membranes and associated 
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submembranous proteins appear deficient in Rib immunoreactivity but give a strong signal with the 
antibody specific for Ria. These results suggest, contrary to earlier expectations, that it is the Ria 
splice variant which may be preferentially associated with postsynaptic structures. In summary, the 
question of differential localisation of Rib and Ria splice variants remains unresolved, although 
biochemical studies are favoured as mRNA quantification is not always reliable. 
1.1.5.2 Localisation in the CNS and peripheral tissues 
GABAB  RI splice variants are expressed ubiquitously in rat and human either in the CNS or 
peripheral tissues. The most interesting differences are observed in the uterus, spleen and lung, in 
which the sum of the RI subunit expression is higher than in many areas of the CNS [49]. GABAB  
R2 splice variants are also expressed throughout the CNS, with the possible exception of the pituitary 
gland, and at relatively lower levels in the basal ganglia (striatum), white matter tracts (corpus 
callosum) and spinal cord but strikingly are almost completely absent in all human peripheral tissues. 
GABAB  RI and R2 are also detected in cardiomyocytes where they can be activated and 
induce electrophysiological alterations through Kir channels [52]. In man, hypertension is associated 
with the activation of the sympathetic nervous system but the mechanisms for this are unclear. 
GABA B receptors have been implicated at several levels. GABA-ergic axons are found throughout 
superior cervical (sympathetic) ganglia consistent with a neuromodulatory role for GABA in the 
peripheral nervous system [53]. Also there is evidence that spinal GABAB receptors regulate 
sympathetic vasomotor tone [54]. Likewise, alterations in central nervous system GABAB receptors 
have been implicated in the regulation of cardiovascular function in hypertension. 
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1.1.6 Structural insights into the metabotropic GABAB receptor 
On the basis of sequence comparisons, the expression and characterisation of truncated fragments of 
GABAB  Ri a/b, and construction of chimeric receptors, a picture of the global architecture of GABAB  
RI is emerging (Figure 1.1). To date, there are no differences in the pharmacological profile of 
GABAB heterodimers containing alternatively spliced forms of GABAB RI subunit [13, 28, 33, 48]. 
1.1.6.1 CP-modules of GABAB Ria 
The 143 residues distinguishing GABAB Ria from GABAB Rlb form a tandemly arranged 
pair of CP-modules [34]. This is the first example of CP-modules occurring in a seven 
transmembrane domain receptor. There are two other 7TM receptors known to possess extracellular 
modules. These belong to class B, the secretin receptor family, and have various numbers of EGF-
like modules, rather than CP-modules, in their large N-terminal domains [55]. In the case of one of 
these receptors, the leukocyte activation antigen, CD97, alternative splicing results in three, four or 
five EGF-like modules and a corresponding modulation in affinity for its ligand [56]. 
The CP-modules are the predominant module type within several cell surface complement 
regulatory proteins with single transmembrane domains such as CD46 (which is the measles virus 
receptor) and CD35. They are also found in a GPI-linked complement regulator (CD55) and in 
soluble complement proteins. In addition CP-modules have been found in many non-complement 
proteins including the 1L213 receptor. There are several other examples of CNS proteins that contain 
CP-modules (Figure 1.2) including the Drosophila protein "hikaru genki" which has four CP-modules 
[57], the human protein, neurocan, which has a single CP-module [58], and mouse SEZ-6 a single 
transmembrane domain protein possessing five CP-modules [59, 60]. SEZ-6 was identified as a 
protein whose expression was enhanced by the perfusion of brain slices with convulsant drugs; the 
human equivalent is a hypothetical 87.6 kDa foetal brain protein which is 49% identical to the C-
terminal 746 residues of the SEZ-6 protein. A CP-module containing protein has also been found in 
the retina [61]. Although some examples of CP-modules function as structural or spacer units in 
bigger proteins, wherever they occur towards the N-terminus of a well-studied cell-surface protein, 
they have been shown to participate in specific protein-protein interactions. It was therefore 
speculated that the N-terminal CP-modules of GABAB Ria might prove to be of importance in 
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recognising another, extracellular or membrane-bound protein. This putative interaction might be 
important for anchoring the receptor at a particular cellular location, or might have a modulatory 
influence on receptor activity and signal transduction. The only 7TM receptor known to possess a 
cellular ligand is CD97, mentioned earlier. As it happens, its ligand has been identified as CD55 
which is a GPI-anchored CP-module containing protein [62]. The interaction is between an EGF-like 
module of CD97 and the N-terminal CP-module of CD55 [63]. 
A fragment of GABAB Ria corresponding to residues 24-159 has been recombinantly 
expressed in Pichia pastoris, purified to homogeneity and shown to adopt a stable, soluble fold in 
isolation from the rest of the protein [34]. Sequence comparisons (Figure 1.2), differential scanning 
calorimetry, and circular dichroism were consistent with the presence of two CP modules (also called 
short consensus repeats, CCPs or sushi domains) separated by a linker sequence of three amino-acids - 
CP module I extends from residue 28-95, and CP module 2 from residue 99-158 [34]. 
On the basis of homology with a tandem pair of CP-modules for which a structure had been 
solved by NMR, a model was built for residues 28-158 [34]. This indicated that each module adopts a 
typical CP-module like fold in which a compact hydrophobic core containing highly conserved 
residues is sandwiched between antiparallel J3-sheets made up from short n-strands. Four cysteines, 
disulphide linked in the pattern 1-3 (i.e. Cys29-Cys80/Cys99-Cys1 44) and 2-4 (i.e. Cys-66-
Cys95/Cys-430-Cys156), stabilise each module. Module I is a less typical example of a CP-
module than module 2 and has a large insertion of 12 residues (Arg-43-Asn--54) that appears as a 
looped out segment in the model. This is also an N-terminal extension of seven residues in module 1 
that are not part of the CP-module consensus sequence and include an N-glycosylation site. On the 
basis of precedent, the two modules are probably joined flexibly in an end-to-end fashion generating a 
highly extended structure with a large surface area available for binding with another domain within 
GABAB  Ria, or with another protein. N-glycosylation sites are surface-exposed at positions Asn-23 




1.1.6.2 GABA binding domain 
The sequence immediately beyond the distinct N-terminal sequences of GABAB Rla/b, and 
prior to the first putative transmembrane domain is referred to as the N-terminal domain (NTER). 
The role of these residues (Ala168-Gly550) has been investigated extensively. As with the 28-158 
fragment, it is possible to express this domain as a recombinant protein that is both soluble and folded 
[28]. This recombinant protein is able to bind agonists and antagonists in a comparable fashion to the 
native receptor and is a candidate for X-ray or NMR-derived structure determination. 
As mentioned above, the sequence of the NTERs of class C 7TM receptors is significantly 
similar to that of a family of bacterial periplasmic amino acid binding proteins (LIVBP etc). The 
three-dimensional structures of several of these bacterial proteins have been solved by Quiocho's 
group in Houston [64, 65], and these structures provide a basis for modelling the three-dimensional 
structure of the ligand-binding, NTER of GABAB Ria (Figure 1.2). A similar exercise had already 
proved useful in the case of mGlu R [32]. 
The LIVBP (Figure 1.3) is a prolate ellipsoid with dimensions 35 A X 40 A X 70 A, 
composed from distinct globular domains (lobes I and II). The domains are linked by three short 
stretches of residues which are widely spaced within the primary structure such that each domain 
contains contributions from both the N- and C-terminal halves of the sequence. The two lobes are 
similar in structure and composed of a seven stranded 13-sheet flanked by (X-helices. The linking 
sequences form the bottom of a cleft between the lobes which has a depth of about 15 A and a base of 
14 Ax 16 A. The leucine binding site is in a crevice to the side of the cleft, within the lobe that 
contains the N-terminal residue (lobe I). L-leucine is held in place by hydrogen-bonding of its -NH3+ 
and -COO- group (with the a -CO of Ala— 100/-OH of Thr- 102, and the -OH of Ser-79, respectively), 




Figure 1.3: Crystal structure of the LeucineIlsoleucine/Valine-binding protein from E. coil [64] 
Colored, are the secondary structure predictions for the GABAB RI N-terminal domain [33] (Figure 
1.2), that is sufficient to specify agonist and antagonist binding [28]. 
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A plausible model of the NTER of GABAB  RlaIb was built using the programme MODELER 
[33]. The model resulted in several interesting observations. There are five cysteines within the 
NTER of GABAB  Rib (compared to 17 in the NTER of mGlu R), and in the model these are seen to 
pair up such that Cys-219 and Cys-245 could form a disulphide bond, as could Cys-375 and 
Cys-409; the remaining Cys, 187, is buried in lobe I and not in the proximity of the other Cys 
residues. The model also supplied predictions of the residues of GABAB RlaJb likely to be involved 
in binding of GABA, assuming that these are equivalent to the residues of LIVBP involved in binding 
leucine. For example, Ser-'246 and Ser269 of GABA B RlaIb are equivalent to Ser79 and Thr-102 
of LIVBP. 
S246A, and another mutant, Y470A suppressed ligand binding altogether [33, 66]. Ser246 
(Ser-79 in LIVBP) is almost certainly involved in a direct interaction with GABA, and it is pertinent 
that the equivalent residue in mGlu R (Ser165) is also critical for ligand-binding. The mutation 
S269A exerted a small selective influence on ligand binding. The equivalent residue, Thr102 of 
LIVBP, is critical for H-bonding to the a-NH3  of leucine, a moiety which is lacking in GABA, so the 
lack of a major effect for this mutation may be rationalised. The equivalent residue in mGlu R 
(Thr-.4 88) is functionally critical, as expected. Interestingly, the equivalent residue in GABAB R2 of 
GABAB  RI S269 is a proline, and therefore could explain the lack of GABA potency at this subunit. 
Hence mutagenesis studies supported the reliability of the model. This encouraged 
speculation that amongst these proteins there might be parallels between the molecular mechanisms 
underlying function. In the case of the bacterial periplasmic amino acid binding proteins, 
crystallographic evidence has accumulated for a ligand-induced hinge-bending motion. This so-called 
"venus flytrap mechanism" in which binding of the ligand is followed by a conformational change 
that buries the ligand between the two domains, might exist also in GABAB RI (and other class C 
receptors). Indeed, two mutants, S247A in lobe I and Q3 12A in lobe II were proposed to manifest 
their functional effects - a small loss of antagonist affinity accompanied by a gain in agonist potency - 
by influencing directly the hinge-bending motion. 
Because GABAB  receptors share sequence similarity with mGluRs and CaSR, two types of receptors 
that are sensitive to Ca2 , a possible regulation by Ca2  ions was investigated [67]. A large effect of 
Ca2  was observed on GABA-binding, where the affinity is decreased by a factor >10 in the absence 
of Ca 2' but not in the case of binding to baclofen and two other antagonists. The potency for Ca2 in 
regulating GABA affinity was 37 jtM. Investigation of the Ca2  sensitivity of a series of GABAB RI 
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mutants identified residue S269 to be critical; the S269A mutation decreased affinity for GABA but 
abolished Ca 21_sensitivity [67]. 
More recent mutagenesis studies from Jean-Philippe Pin's team [66], suggest that S246 and D471 
located within lobe I form hydrogen bonds and a salt bridge with the carboxylic and amino groups of 
GABA, respectively, demonstrating the pivotal role of lobe I in agonist binding. Interestingly their 
data also suggest that residue Y366 in lobe II interacts with the agonists in the closed state, Y366A 
mutation convert agonist baclofen into an antagonist. Taken together these results strongly suggest 
that a closed state of the binding domain is required for receptor activation. 
1.1.6.3 Allosteric interactions between GABAB Ri and GABAB R2 subunits 
The recent crystal structure of the extracellular ligand binding domain region of mGluRl 
(Figure 1.4.1) offers an insight into the activation mode of the Family 3 G protein coupled receptors 
[68]. Three different crystal structures were determined, two unliganded forms, called free form I and 
II, and a complex form with glutamate. All three structures showed disulphide-linked homodimers, 
where each monomer is structurally related to LIVBP, and has the two expected globular domains 
(lobes I and II) forming a 'clamshell'-like shape. The intermonomer disulphide bond between Cys 140 
of each monomer is located within a disordered fragment and lobe I provides the dimer interfaces in 
all three forms. mGlu RI shows an "open-closed" conformation (similar to LIVBP); the complex 
form has one monomer in the open conformation and the other in the closed conformation. Each 
monomer binds glutamate at similar sites in lobe I, and all ligand-binding residues correspond to the 
ones previously identified by mutagenesis studies. The monomers differ in the relative orientation of 
lobe I and lobe II. In contrast to the complex form, the free form I consist of two open conformers 
while the free form II maintains the same "open-closed" conformation as the complex form despite 
the absence of ligand. Comparison of free form I and complex form revealed a 700 rotation on the 
dimer interfaces of lobe I but which is uncoupled to the open-closed conformational change. 
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Figure 1.4.1: Crystal structures of mGlu RI in the liganded and unhiganded states. Taken 
from reference 1681. (a), Diagram of full-length mGlu RI. Functional regions are boxed. The Lobe 
I (LB 1) and Lobe H (LB2) domains, which constitute a ligand-binding region, are coloured blue and 
red, respectively. Numerical positions of amino-acid residues are indicated according to the primary 
amino-acid sequence. (b), Drawing of the spatial arrangements of mGluRl domains. The molecule 
1 (MOL1) and molecule 2 (MOL2) molecules of the dimer are distinguished by dark and light 
colouring, respectively. The ligand, glutamate, is shown as yellow spheres. CF, cysteine-rich 
region; IC, intracellular region; TM, transmembrane region. (c), Three orthogonal views of the 
dimer structures of the complex form and the free form I. The perspectives are indicated by arrows 
in b. Bound glutamate molecules are shown as yellow space-filling models. Disordered regions with 
a potential interprotomer disulphide bridge are indicated by dotted lines. The B helix, constituting 
the dimer interface between subunits, is coloured green. 
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The two distinct intermonomer orientations of Lobe I were designated as the 'Resting' state ('R' 
conformation) and the 'Active' state ('A' conformation) for the free form I and the complex form / 
free form II respectively (Figure 1.4.2). These findings suggest that the unliganded protein undergoes 
a dynamic change between an open and a closed conformation, and that the ligand stabilizes the 
closed conformation. 
	
Resting state 	 Active state 
Glutamate - 
(LB15 Glutamate + i 




Crystal form Free form I Free form II and Complex form 
LB2-LB2 spacing (A) 63 (88) 
	
36 (63) 
Figure 1.4.2: Diagram of the two states of the ml-LBR in dynamic equilibrium. Taken 
from reference [68]. Open and closed conformations of mGlu RI are distinguished by light 
and dark colouring,respectively. Lobe TI-Lobe II (LB2±LB2) spacings are shown between the 
centres of masses or C termini (in parentheses) of the two LB2 domains in each conformer. 
Kunishima et al [68] propose that unidentified conformations of the mGluR binding-domain 
in various open-closed combinations might be present in solution and that glutamate binding could 
therefore change the equilibrium between multiple conformers to activate the receptor. A 
rearrangement in the dimer will probably cause a change in the spatial arrangement of the two lobes II 
and as a consequence induce the approach of two transmembranes regions linked to intracellular 
regions thereby activating G proteins, as previously described in the case of the dimeric erythropoietin 
receptor [69, 70]. Interestingly, further modelling studies on diverse combinations of the homodimer 
(closed-open/R, closed-closed/F, open-open/A, closed-closed/A) shows two families of lobe II - lobe 
II spacings determined exclusively by the intermonomer R-A conformations. This supports the idea 




In a more recent study, Galvez et at [71] shows that the GABAB receptor requires the presence of both 
subunits RI and R2 for efficient coupling, the only known example of such phenomenon among 
GPCRs. Using chimeric receptors, it was shown that the helical domain (the seven cc-helices, loops 
and the C-terminus) of GABAB R2 contains the molecular determinants required for G-protein 
signalling. Reciprocally, the GABAB RI heptahelical domain improves coupling efficacy. Taken 
together these data strongly suggest that multiple allosteric interactions between the two subunits are 
required for proper functioning of the receptor. This is in agreement with Kunishima's hypothesis 
[68] where the closure of a single extracellular domain is sufficient to bring about the proposed active 
state of the dimer [71]. 
1.1.7 Developmental regulation 
The distinct sizes of the GABAB Ria and Rib splice variants, together with specific antibodies 
capable of distinguishing Ria, Rib and R2 on Western blots, allows investigation of the 
developmental regulation of these GABAB receptor subunits in the rat central nervous system. Using 
an antibody (Ab174.l) raised against a C-terminal stretch of 59 amino acids common to both RI  and 
Rib, Malitschek et at. [72], examined GABAB RI expression in rats from postnatal days two to 28. 
The summed levels of Ria and Rib decrease in the cortex, the cerebellum and most dramatically in 
the spinal cord between postnatal day seven and adulthood. In these regions, GABAB Ria levels 
appear significantly higher than Rib between days two and 14 although no quantitation of the 
Western blot immunoreactivity was included in this report. As GABAB Ria levels decrease over this 
time period there appears to be a slight increase in Rib levels. After day 28, some reduction in 
expression of both RIa and Rib is observed in the midbrain but not in the striatum, brainstem or 
hippocampus. 
Using the photo-affinity label, [1251]CGP64213, the developmental changes in the affinity of 
rat cortical membrane GABAB receptors for L-baclofen were examined in competition-binding 
assays. The potency for L-baclofen increases about ten-fold between postnatal days one and 60. 
Furthermore, SDS gel analysis of the cross-linked membranes demonstrate that the Ria and Rib 
isoforms do not differ in their affinity for L-baclofen between day four and adult. 
The issue of the developmental regulation of GABAB Ria and Rib was further examined 
with another antibody (gbia,b922-944) prepared against a synthetic peptide corresponding to a 
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sequence (922-944) common to both Ria and Rib [69]. It is expected that this antibody (like Ab 
174.1) would have identical affinity for both Ria and Rib on Western blots and thus, following 
separation of the two isoforms on SDS gels, it could be used to quantitate expression levels. On the 
basis of the immunoreactivity observed in Western blots, it was shown that Ri a levels are highest in 
rat brain at birth through postnatal day five during which time, Rib levels are about five-fold lower. 
Rib levels then increase about three-fold from day five to day ten but decrease again between day ten 
and adulthood to a level of about twice that seen at birth. Ria levels decline steadily after day five 
and in the adult rat brain there appears to be about twice as much Rib immunoreactivity as Ria. 
The antibody (gbla,b922-944) was used to examine the regional distribution of GABAB Ria 
and Rib in membranes prepared from various regions of the adult rat brain. Rib levels were highest 
in the cortex, thalamus and cerebellum where Ria levels ranged from 50-60% of Rib levels. In the 
striatum and olfactory bulb regions, Ria levels exceeded Rib levels but the immunoreactivity of Ria 
in these regions was only about 20% of that seen for Rib in the adult cerebellum. 
A similar Western blot analysis with an antibody (AbC22) specific for R2 revealed that 
GABAB  R2 is expressed at high levels in the cortex and cerebellum throughout postnatal 
development. in the cortex, GABAB  R2 levels increase between day two and 28 with a slight 
apparent decrease in the adult (60 days) [15]. GABAB R2 levels in the cerebellum appear highest at 
four days, the earliest time point examined, and decline slightly after that. In contrast, R2 levels are 
detectable in spinal cord from postnatal days seven (the earliest time examined) to 14 but decline 
sharply thereafter. It is of interest from the perspective of potential heterodimer configurations, that 
while R2 levels are still increasing in the cortex between day two and 28 [15], the combined levels of 
RI  and Rib in the cortex decrease somewhat over this same period [72]. 
Recently, a detailed study of the developmental regulation of other GABAB subtypes showed that the 
expression of the GABAB  RI c subunit was up-regulated in foetal brain, suggesting a role for this 
variant in neural development [49]. 
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1.1.8 Receptor heterogeneity 
The cloned GABAB receptors do not reproduce the pharmacological diversity of native 
receptors [73]. Such diversity could arise from diverse sources: differential distribution, isoforms, 
posttranslational modification of the GABAB subunits, and interaction of the subunits with other as 
yet unidentified subunits or chaperone molecules. Alternatively the differences in the potency of a 
particular drug in functional studies could relate to differences in the neuronal effector systems and 
not necessarily to the existence of numerous subtypes. Also the location of GABAB receptors at 
particular subcellular sites might ensure their interactions with selective effector systems and thereby 
display particular pharmacological actions. In this respect, sucrose gradient centrifugation analysis of 
deoxycholate extracts of rat brain membranes identified a discrete population of heterodimer, which 
has an apparent molecular weight in excess of 250 kDa [43]. This larger material might consist of 
complexes between the heterodirner and an as yet unidentified associated synaptic protein(s). 
The lack of expression of GABAB R2 mRNA in peripheral tissues [49], also suggests that 
many functional GABAB receptors (as shown by previous studies [4, 21, 73]) in these tissues result 
from the association of GABAB RI with yet unidentified GABAB subunits or associated chaperones 
proteins. These findings were confirmed at the protein level in uterus and spleen by western blotting, 
two types of tissues were GABAB RI protein is present at a high level [49]. 
Recently, three GABAB subunits were identified from Drosophila melanogaster [74], while 
the first two subunits show high sequence identity to mammalian GABABRI and GABABR2 , the 
third subunit does not relate to any known mammalian counter part and therefore could be insect-
specific or simply related to yet unidentified subunit(s) in mammals. 
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1.2 	The extracellular matrix protein family-fibulins. 
Our collaborator, Dr. Julia White ( GlaxoSmit!iKline - Stevenage - UK ) has used a YTH 
screen against the N-terminal CP-modules of GABAB Ria to look for potential interacting protein 
partners. Al! five known variants of fibulin were recovered. The fibulins are an emerging family of 
secreted glycoproteins, designated fibu!in-1-5. Fibulins are part of extracellular matrix structures such 
as connective tissue fibers, basement membranes, and blood clots and are present in the brain. Further 
screenings have identified the C-terminal domain that is common to all five variants to interact with 
the first CP-module of GABAB Ria. The YTH system has been extensively used to screen for 
intracellular interactions, but it is only recently that such system was applied to extracellular 
interactions [75]. A growing number of extracellular interactions have been detected using YTH [76-
79], despite concern about the lack of disulfide bonds formation and the absence of post-translational 
modifications (nuclear environment). Among these extracellular interactions, several involved 
extracellular matrix proteins, most which contain disulfide bonds. In particular, examples of 
interactions involving EGF containing ECM proteins were first identified using YTH [80, 81], a 
protein motif that contain three disulfide bonds. Although uncertain, the YTH interaction between the 
first CP-module of GABAB Ria, and the C-terminal domain of the fibulin family represents the only 
clue that could lead to an understanding of the role of the CP-modules in GABAB RI variants. To 
date, no report has been made on the function of the CP-modules in GABAB RI variants. 
Fibulins could influence GABAB receptor biology in many ways. GABAB Ria and GABAB  
Rib show profound differences in neuronal localisation as well as differences in expression 
throughout development. Moreover, not all the reported pharmacology attributed to the GABAB  
receptors can be explained simply by heterodimerization. A further possibility is that the fibulins 
could mediate protein contacts between GABAB receptors and other extracellular proteins, either 
within the same cell to achieve a clustering effect that could also involve an effector (ion channel for 
example), or with a second cell, to provide cell-cell contacts. Such clustering roles are well described 
in the case of intracellular linking proteins such as the PDZ-containing proteins [37, 82], and 
extracellular matrix proteins could be likewise involved. Occurrence of receptor clustering by ECM 
protein in CNS synapses has been reported; NARP (neuronal activity-regulated pentaxin) [83] is an 
ECM protein that can induce clustering of AMPA-type glutamate receptors [84, 85]. 
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1.2.1 The extracellular matrix 
The extracellular matrix (ECM) can be viewed simplistically as a three dimensional network 
of interacting molecules that surrounds cells. The ECM contains both collagens and noncollagenous 
glycoproteins, such as proteoglycans, a group of glycoproteins that have covalently bound sulfated 
glycosaminoglycan chains (aggrecan, versican, perlecan, brevican, neurocan, etc) and multiadhesive 
matrix proteins, which bind cell-surface adhesion receptors. Multiadhesive matrix proteins are long 
and flexible molecules that contain different binding regions for various collagen types, other matrix 
proteins, polysaccharides, cell surface proteins, growth factors, and hormones. The laminins are a 
family of cross-shaped multiadhesive proteins and an essential component of the basal lamina, a thin 
sheet-like network of ECM proteins where most epithelial cells rest. Laminins have a large 
heterotrimeric structure and are able to bind type IV collagen, sulfated lipids, integrins and heparan 
sulfate. Fibronectin is another major class of multiadhesive matrix proteins. Fibronectin is a large 
multidornain glycoprotein that attaches cells to collagen and thereby regulates the shape of the cells 
and the organisation of the cytoskeleton. Fibronectins are disulphide-linked dimers, each chain 
having similar sequences and composed of three types of repeating motifs. Fibronectin also binds a 
wide range of ECM components such as fibulins, integrins, heparan sulfate, and fibrin. One further 
important component of the ECM, is hyaluronan, a large polysaccharide that forms a hydrated gel and 
gives the ECM its resistance to compression. The composition and organisation of ECM in tissues is 
variable and its interaction with cells shape differential patterns of gene expression and cellular 
behaviours including guidance of migrating cells during development. Fibulins are rod-shaped 
proteins that interact with many other ECM proteins such as fibronectin, laminins, nidogen, perlecan, 
fibrillin and fibrinogen. Fibulins contain three domains (Figure 1.5); one N-terminal domain (domain 
I), a central array of EGF/EGF-like calcium binding modules that differs in length depending on 
subtypes (domain II), and one C-terminal domain (domain III) that represents a novel sequence motif 
of approximately 120 residues, and is known as the fibulin type module. Subtypes differ in their 
domain I composition, and the number of EGF/EGF like modules in domain II. Fibulin-1 and fibulin-
2 are best characterised. They have been identified as basement membrane and microfibrillar proteins 
[86] with a broad range of binding range specificities to other extracellular ligands. Several of these 




Fibulin-1 was the first member of the fibulin family to be isolated [87]. Alternative splicing of 
fibulin-1 results in four different transcripts, fibulin-1 A-D (62-77 kDa), which differ in C-terminus 
length. Only the C-termini of fibulins 1C and 1D have the fibulin type module, although the fibulin 
ID fibulin type module is 20 residues longer than the fibulin type module of fibulin 1C [88]. Domain 
I of fibulin-1 contain three anaphylatoxi n- like modules sometimes known confusingly as complement 
repeats and domain II comprise an array of nine EGF-like repeats. Fibulin-1 has been shown to bind 
the extracellular matrix proteins fibronectin, nidogen [89], laminin and the coagulation protein 
fibrinogen to promote platelet adhesion (thrombosis). In addition, fibulin-1 is capable of self-
association [90]. Interestingly, both self-association and fibronectin-binding sites are identical and 
map to EGF modules five and six in domain II [91]. Fibulin —1 is also a ligand for the C-type lectin 
domains of aggrecan and versican [92], two proteogylcans that can be found in the brain, but it does 
not bind brain-specific brevican and neurocan. Recently, binding of fibulin-1 to the amino-terminal 
head of -amyloid precursor protein (APP) was demonstrated using YTH and confirmed by GST-pull 
down assays. The APP-binding site maps to EGF modules 3-7 in domain II. Furthermore, fibulin-1 
was found to be produced principally by neurons and to inhibit secreted APP-mediated neural stem 
cell proliferation [81]. 
1.2.3 Fibulin-2 
Fibulin-2 was first identified by cDNA cloning and sequencing [93]. Fibulin-2 is a 175-kDa protein 
that forms a disuiphide-linked homodimer in which the subunits are arranged in a head-to-tail manner 
with their disulphide bond connection through domain I and located in the center of the dimer [86]. 
Fibulin-2 has a larger domain I when compared to fibulin-1, which contains a cyteine-rich region 
followed by a cysteine-free region. Fibulin-2 is found in endocardial tissues, neural and bone forming 
tissues. In vitro binding studies have demonstrated affinities for basement membrane components 
nidogen [94], perlecan, collagen IV, fibronectin, and fibrillin that in most cases were dependent on 
calcium [95]. The proteoglycans aggrecan, versican and brevican form networks with fibulin-2 
through their lectin domain and their interaction sites were mapped to EGF modules 3 and 4 in 
domain II [96]. Fibulin-2 also interacts with laminins, and fibulin-2 functions in assembling the 
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laminin network in the basal lamina at the dermal-epidermal junction by bridging laminin-1 and 
laminin-5 with other matrix proteins [97]. 
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Figure 1.5: Schematic diagram depicting the domain organization of fibulin-1 (forms A-D), -2 
and —3 - Taken from Argraves WS - http://efwust1.edu/cartoons/flbulins.gf  
1.2.4 Fibulin-3 and -4 
Fibulin-3 (57 kDa) and fibulin-4 (54 kDa) are of similar composition: a short domain I that consist of 
a divergent EGF-like module, an array of five EGF-like modules and the fibulin-type module [98]. 
Both fibulin-3 and fibulin-4 are monomeric and are expressed in several human tissues to a variable 
extent. Nothern blot ananlysis showed strong expression of fibulin-3 and fibulin-4 in heart and weak 
expression in brain [99]. Electron microscopy indicated a short rod-like structure for fibulin-4. 
1.2.5 Fibulin-5 
Fibulin-5 is a 55 kDa protein similar in structure to fibulin-3 and -4, and was first identified as EVEC 
or DANCE proteins [100, 101]. Fibulin-5 has also a short domain I made of one modified EGF 
modules that contains a RGD sequence. This motif is recognised by many integrins, a large family of 
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cell surface receptors that mediate cell-cell and cell-matrix adhesion. Fibulin-5 domains II and III are 
homologous to those of fibulin-3 and -4. Northern blot analysis also shows strong expression in heart 
and weak expression in brain. 
Recently, studies on fibulin-5 null mice showed that fibulin-5 is an essential element for elastic fibre 
development, which acts as a scaffold protein that organizes and links elastic fibres to cells [102, 
103]. 
1.2.6 The fibulin type module 
Fibulins are distantly related to fibrillins with which they share the C-terminal fibulin type 
module (Figure 1.6). A sequence comparison of their C-terminal domains revealed 23% identity 
between fibulin-3/4 and Fibulin-IC/2, and 11-16% identity with the corresponding region of fibrillin-
1/2 [98]. The alignment shows two invariant cysteine residues and one proline at the N-terminus, and 
the consensus sequence IXXGNXXXXF in the central portion. Seven proteins share this recently 
described sequence motif. Fibulin-1 has different subtypes (A-D) that differ in their domain III. The 
C-terminus of fibulin-113 C-terminus has only 35 extra residues when compared to fibulin-1A, which 
does not contain the fibulin-type module. Fibulin-1C/D has the complete sequence motif. Several 
binding sites for fibulin ligands involve the fibulin-type module. For example, nidogen binds 
fibulinlC/D at domain Il/Ill, and deletion of the fibulin-type module induced a 30-fold reduction in 
binding [89]. Interestingly nidogen-binding to variant C is 100-fold stronger than for variant D [104]. 
The NOVH protein also binds fibulin-1C at domain II/111; NOVH belongs to the CCN family of 
growth factors [105]. Although the biological function of fibulin-type module remains to be 
established, its presence in fibrillins raises interesting comparisons. Furthermore it has been shown 
that fibrillin-1 and fibulin-2 are co-localised in some tissues (extra-CNS) and binding of fibulin-2 to 
the N-terminus of fibrillin-1 has been demonstrated [106]. Fibrillins are the major constituents of 
extracellular microfibrils. The two fibrillin isoforms are large glycoproteins (-350 kDa) with a 
complex multidomain structure, including 47 EGF-like modules [107]. 
How fibrillin molecules assemble into microfibrils is not known. Initial investigations suggest that 
microfibrils are stabilised by disulphide bonds, and the use of reducing agents abolishes their 
ultrastructure [108]. The N- and C-terminal domains of fibrillins display respectively four and two 
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cysteine residues. All four cysteine residues within the N-terminal domain are involved in intrachain 
disulphide bonds. 
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Figure 1.6: Sequence alignments of the C-terminal domains of fibulin and fibrillin isoforms 
Taken from reference [98]. Identical or similar amino acids in at least five sequences are shown in a 
in bold. The consensus sequence (cons) indicates similar (asterisk) or identical amino acids in all 
sequences. Hyphens in the sequences indicate gaps introduced for optimal alignment. All sequences 
compared were of human origin. 
A single non-conserved cysteine residue was found in fibrillin-1 and could therefore be available for 
intermolecular disulphide bond formation [108]. No information is yet available about the form of the 
two cysteine residues in the fibulin-type module. Fibrillins undergo proteolytic cleavage of both the 
leader sequence and their fibulin-type module. Cleavage of the fibulin-type module has been 
proposed to occur after arginine residue 2731 following the multi-basic sequence KRGRKR, and 
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results in the loss of the sequence that follows the conserved two cysteine residues and the proline 
residue (Figure 1.6) [109]. A recent study confirmed that the region is processed intracellularly, 
before fibrillin-1 secretion, by an enzyme that resides in the early secretory pathway. Proteases of the 
Furin family have affinity for such tetrabasic sequences, and it has been suggested that it is these 
enzymes that are responsible for this early processing. Interestingly, intermolecular disulphide bond 
formation occurs within the first hours after synthesis and secretion of monomeric fibrillin-1, and 
could indicate that C-terminal processing is involved in assembly of fibrillins. It is tempting to 
speculate about fibulin-type module function. Ritty et al have proposed that the fibulin-type module 
helps the association of monomers into rnultiiners, and once that function has been accomplished, the 
domain is processed. Assembly into multirners before secretion has already been described for other 
matrix proteins such as laminin or tenascin [110]. Disulphide bond exchange has also been proposed 
to explain this multimerisation process [107], and it could be that cleavage of fibulin-type module is 
required for such a mechanism. 
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CHAPTER TWO: NUCLEAR MAGNETIC RESONANCE THEORY 
2.1 	Basic principles of NMR 
2.1.1 Nuclei in magnetic field 
Atomic nuclei are composed of protons and neutrons. Each of these particles has a spin angular 
momentum (I). The magnitude of this vector quantity is expressed in units of spin quantum 
number (I). Protons and neutrons have I value of /2. Nuclei are also characterised by a spin 
quantum number and nuclei I value may have 21+1 discrete values in integral steps from —Ito +1(1 = - 
I, -1+1......, +1), where I = n12, IT II = [I(I+1)]"2 h , n is an integer, h (=%), and h is Planck's 
constant [111-113] . Only the ground states of nuclear spins are populated significantly. In general, 
there are no simple rules for which of the many possible states is the ground state, and such a state is 
best regarded as an empirical property of each isotope. If 1>0, the nucleus has a magnetic dipole 
moment, p,  and can be seen as a charged, spinning particle producing a small circular current. p is 
directly proportional to I: p = ?'• The proportionality constant y (rad 1 T 1 s-1 orrad1  Gauss-) is 
known as the gyromagnetic ratio of the nucleus. 'y  has either positive or negative value and is isotope 
specific. 
Iz, the z component of I (here the z axis is the applied static magnetic field) is quantified: Iz = 
in, h, as is the z component of p,  , = y in, h, where m1 is the magnetic quantum number and may 
have 21+1 values in integer steps. In the absence of an applied magnetic field, all nuclear spins are 
disordered, and there is no energy difference between them: they are degenerate. Since they have a 
magnetic moment, when we apply a strong external magnetic field (13o), they take their allowed 
orientations. The magnetic moment of a spin V2  nucleus e.g. 'H, '5N, 13C, 31P, '917, has only two 
permitted states in the static magnetic field, the a state which corresponds to the magnetic moment 






being anti-parallel to Bo (m,=-1/2) [111-113]. The interaction energy of a spin state in the static 
magnetic field 130  can be described as: E = - B • p. In z the direction, E = -Bo.t = -B0.7 m1 h. 
For the two possible spill states of a spin '/2 nucleus (m, = ± '/2), the energies are: 
The energy difference AE = E
18 
- E 	hv = ABO corresponds to the energy that can be absorbed 
or emitted by the system (Figure 2.1). Only transitions between adjacent energy level are allowed 
(Am ± 1) and the resonance condition is AE = ho = ha 0 , where w,, is the Larmor 
frequency. The 'H nucleus has a resonance frequency of 600 MHz in a magnetic field of-14.l T. 
For comparison, Earth's magnetic field is 50 [tT. 
Figure 2.1: Energy level diagram 
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When placed in a static magnetic field B), the force generated by Bo on the magnetic 
moment is a torque, which cause its precession about Bo. The Larmor frequency can be understood 
as the precession frequency of the spins about the axis of the magnetic field Bo, caused by the 
magnetic force acting up on them. 
The two energy states for 'H will be unequally populated, the ratio of populations being given by the 
N 
Boltzmann equation, —p- = e. The population difference is thus dependent both on the field and 
N,, 
also on the isotope. This population difference is remarkably small (10 to 10) and corresponds to a 
bulk magnetisation or macroscopic magnetic moment (Mo), which is in effect, the vector sum of the 




Figure 2.2: Bulk magnetisation vector - Mo is the vector sum of the magnetisation of the individual 
nuclear spins (black arrows) across the whole sample that precess around Bo. 
2.1.2 Effects of pulses 
The equilibrium magnetisation is aligned along the static field Bo and represents the starting 
point for all NMR experiments. If the magnetisation is moved away from the equilibrium position, its 
xy components will induce a small oscillating current in the receiver coil placed in the xy plane. This 
current is amplified, digitised, and recorded as a "Free Induction decay" (FID). Fourier 
transformation of the FID yields an NMR spectrum. 
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The magnetisation (M) can be tipped away from the z axis by introducing a second field 
Bi perpendicular to Bo, M will precess around the resultant field (Bo + Bi) and when Bi is switch 
off, M will no longer be aligned with Bo. The 13i field is induced from a current in a coil 
perpendicular to Bo, effectively the transmitter, which generates a linear oscillating field that is 
equivalent to the sum of two counter-rotating components, one being exactly in resonance with the 
precessing spins, i.e. its energy matches the energy difference between the c' and f3 levels. The effects 
of pulses on M are best described by switching from the laboratory coordinate system to one rotating 
"on resonance" with the spins (and 131) about the z axis. The magnetisation is static in this "rotating 
frame" (Figure 2.3). 
Z..- ' "'), -;;,4, 
M, 
ox 	I 	 x 
Laboratory Frame 	 Rotating Frame 
Figure 2.3: Magnetisation vector (x, y components) in the laboratory and rotating frames 
For resonance to occur, the excitation frequency (v1) needs to equal the nuclear precession 
frequency (vo): v1 = v0 = y B0 /27r. The final position of M will depend upon the length of time for 
which the Bi field is applied. This is commonly referred to as a radio frequency "pulse" of duration 
t. The flip angle 0 through which M is tipped away from 13o axis is given by: 0 = y B1 ti,, and can 
be changed by varying the duration or the intensity of the radio frequency field, Bi. If we measure 
M on the y axis (following a pulse applied along the x axis), there will be a sinusoidal variation of 
the signal intensity as a function of pulse duration. The signal will be a maximum for a tip angle of 
irJ2 (Figure 2.4), null at it when M is placed along the —z axis, a negative maximum at 37r/2, and a 
return to a null at 271 when back on the z axis. This test is used daily on the spectrometer to calibrate 
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Figure 2.4: Effect of a 90°x pulse 
When the 13i field is switched off, the transverse M (xy component or M) starts precessing 
about the z axis with the frequency w (in the laboratory coordinate system) under the influence of B0. 
Thus, after a 7t/2 or 900 x pulse, we have: M (t) = {M cos (wt) +M sin (wt)} exptrl), where T2 is 
the so-called transverse relaxation. This induces a current in the receiver coil (sometimes called the 
probehead), here located on the y axis, which decays with time i.e. the FID (Figure 2.5). The FID is 
therefore composed of exponentially decaying sine and cosine signals. 
(1) = 
M 
CO - (1)~ > % 
time 




The excited state of M in the xy plane is driven back to the Boltzmann equilibrium by two 
mechanisms: 
-spin-lattice or longitudinal relaxation, R1 (=1/T1 ). 
The 90° x pulse equalises the populations of the energy levels whereas a 1800 x 
pulse inverts the population ratio, but both cause a population change, effectively a change 
in the energy of the spin system. In order for M7 to return to its equilibrium position, the 
energy absorbed from the pulse needs to be transferred to the surroundings or lattice, which 
in reality are the neighbouring molecules in solution. The return to Mz equilibrium position 
occurs with a rate constant R1 1/T1 where T1 is the longitudinal relaxation time constant. 
-spin-spin or transverse relaxation R2 (= lIT2). 
Immediately after a 900 x pulse, the nuclear spins are precessing with identical phase, 
this condition is called phase coherence. The T2 relaxation corresponds to a loss of phase 
coherence; this means that the precessing spins, which were bunched together, are changing 
randomly their phases in the xy plane causing a decay of signal with a relaxation rate 
R2 1/T2, where T2 is the transverse relaxation time constant. Mxy relaxes to its equilibrium 
value of zero. Due to Bo being not perfectly uniform across the sample volume, some 
fanning out of signals occurs, which contributes to increase relaxation rates and results in 
additional line broadening. A symbol T2* is used to describe the effective spin-spin 
relaxation. 
T2 determines the maximum length of a series of pulses that can be used in a particular 
acquisition, and for how long it is necessary to acquire the FID. T1, on the other hand 
imposes a minimum "relaxation" delay between scans. 
In the Boltzmann equilibrium, all transverse magnetisation must have disappeared so T2 !~ T1 . 
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The T1 and T2 can be measured using the following pulse sequences: 
Measuring T: 
Inversion recovery experiment: 1800  x pulse-time delay (DE)-90° x pulse-
acquisition. Where the magnetisation M can be expressed as a function of time 
delays: M(DE) = M0 (1-2exp(-DE/T1 ). 
Measuring T2: 
Spin echo experiment is: 90° x pulse-[time delay(DE)-180° x pulse-time 
delay(DE)]- -acquisition. Where the magnetisation M can be expressed as a 
function of time delays: M(DE) = M0 exp(-2nDE/T2) 
The spin-spin relaxation is induced by fluctuating magnetic fields at the Larmor frequency. 
There are two major mechanisms by which these fluctuating fields are generated: dipole-dipole 
interactions between different spins, and the chemical shift anisotropy. Dipole-dipole induced 
relaxation is the main relaxation mechanism for spins close to one another in space. The magnitude 
of the induced field depends on the distance between the two spins, and on the angle formed between 
the inter-nuclear vector and the static field. The molecule tumbles and this angle changes 
permanently, causes the fluctuation of the local magnetic field. The chemical shift anisotropy arises 
from the non-spherical distribution of electron density that will cause a fluctuating field upon rotation 
of the nucleus. 
Both processes are connected to the movement of spins in space due to overall tumbling of 
the molecules or due to internal motions. Other relaxation mechanisms include relaxation arising 




2.1.4 Discrete Fourier transformation & Fast Fourier transformation 
The Fourier transformation only considered continuous functions f(t). If f(t) is a 
complex time series of length n, then the continuous Fourier transform is replaced with a sum, 
where (oj is the frequency of the th  point (j=O,1,2 ........ n-1) 
F(c) = { 	f(t,) e '1k  dt J A where A is the sampling interval and tk=  k A, and 
kisan integer from Oton-1 [114]. 
If f(t) is periodic and we have sampled over one complete period T so f(0)=f(n), then T = n A and 
o)j =j(2it/nA): 
n-I 
F(o) = [ I f(t) e -2/n ] A 
k=O 
and the discrete inverse FT is f(tk) = [ 1/n 	F((,)) e i27tJk/n 	1/A 
n—I 
If A is one: F(u) = 	f(tk) e i27tjkln 
k=O 
n—I 
and the discrete inverse FT is : f(tk) = 1/n I F((o) e 
k=O 
When using the discrete Fourier transformation, the frequency spectrum for positive frequencies is 
reflected in negative frequencies, there is an "alias" or "Nyquist pair" of the transform (Figure 2.6). 
The reflection occurs at the mid-point of the frequency axis. Usually, the spectral region 0 to +Vinax 
and 0 to Vmax are "swapped" and the frequency axis reversed to display a spectrum with +Vinax to - 
Vmax running from left to right. Recall that the frequency is given here by w = j(2ir/n A) so the 
critical or Nyquist frequency co is co, = it! A( effectively Vmax ). If the alias overlaps with the 
transform, it will be impossible to sort out which is the transform and which is the alias. This happens 
for a rectangular function that is too narrow and that will obviously become wider after Fourier 
transformation in the reciprocal space. But if we sample such that the critical frequency is equal to 
the upper frequency limit we want to observed, we will have completely determined f(t). If a signal 
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has a higher frequency than the critical frequency, then it will be "aliased " into the region from 
Nyquist frequency 
ma,, 
	 +Vma 	 0 
1/ 
Figure 2.6: The Nyquist pair of the Discrete FT 
We use this type of FT because we don't know f(t) from - 00 to + ce, but only from 0 to AQ (=length 
of acquisition time) and we don't acquire a continuous, but a digitised FID signal, with values known 
only for t = n DW, where DW is the dwell time or A in the equations above. The spectral window or 
SW in NMR corresponds to two-times the 	we want to observed i.e. from -vumx to +vmax  so that: 
DW=1/2 v,,,,=1Isw 
with Digital resolution = 1/n DW 1/AQ 
Usually, the "carrier" sits on the reflection axis in the above description at a particular frequency, in 
general water, or protein NH protons resonance frequency. 
In practice, the discrete Fourier transform is calculated using the fast Fourier transform (FF1) 
algorithm, where the discrete FT is implemented in the form of a matrix multiplication. The FFT 
algorithm uses symmetry properties in this matrix form of the discrete FT, to reduce the amount of 
computer time required for an FT by a factor of nJ(log2n). 
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2.1.5 Pre and post Fourier transformation manipulations 
2.1.5.1 Basic manipulations 
Description of the "traditional" manipulations prior FT (zero filling, and appodisation) or 
after FT (phase correction, and baseline correction) can be found in references [115] and [116]. 
2.1.5.2 Maximum entropy method 
One limitation of NMR is that data have to be accumulated over long periods. The time to 
acquire a multidimensional NMR experiment is proportional to the number of data points in the 
indirectly detected dimensions, causing the data for these dimensions to be almost always truncated. 
Although data can be zero-filled and apodised in such dimensions, apodisation technique before FT is 
always a "trade-off' between noise suppression and resolution enhancement. In the case of three-
dimensional experiments, the truncation is severe and there are advantages in improving the 
resolution. Maximum entropy reconstruction is a better alternative to FT for processing severely 
truncated indirectly detected dimensions [116-118]. Maximum entropy is done only on indirectly 
detected dimensions, after FT of the directly detected dimension. 
Maximum entropy reconstructs the frequency domain spectrum directly by determining the spectrum 
that maximises the entropy function. This function allows choosing one spectrum from the possibly 
infinite set of spectra which FID reproduces the experimental FID [116]. The entropy function that 
describes one spectrum can be viewed as inverse quantity of data it contains; therefore the chosen 
spectrum will be the one where the smallest amount of data was needed to reconstruct the original 
data set, the one that maximises the entropy function [116]. 
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2.1.6 Chemical shift 
The resonance frequency of a nucleus is defined as v=yB0/27c. However not all nuclei have 
the same frequency; even nuclei of the same nature do not have necessarily the same resonance 
frequency. In fact, the resonance frequency of a nucleus depends on the chemical "enviromnent" 
that it experiences. This phenomenon is called chemical shift. It arises because the effective 
magnetic field B experienced by a nucleus differs slightly from the applied magnetic field B0. This 
is due to the circulation of electrons within their atomic orbital, which creates a small local magnetic 
field 1310 affecting the overall field experienced by a nucleus: the nucleus is shielded from B0 by its 
surrounding electrons. The effective field for a nucleus is B=B0—B101=B0(1-) where (Y is the 
shielding constant. As a result, the resonance condition becomes: v=yBo( 1 -o)/2n. 
If we consider the magnetisation in the xy plane, after a 90°x pulse for instance, Mxy will be 
static along the y axis in the rotating frame, but because of the chemical shift, the frequency of 
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Figure 2.7: Evolution under chemical shift 
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2.1.7 Spin-spin coupling 
The nuclear spins interact with one another by spin-spin coupling that acts through the 
electrons in the chemicals bonds. There are a number of factors that determine the strength of the 
coupling: the hybridisation of the atoms involved, bond lengths, bond angles and torsion angles etc. If 
two '/2 spins, I and S, are coupled, spin S is aware of the presence of neighbouring spin I since the 
latter generates a small magnetic field at its site and reciprocally spin I is aware of spin S. This 
magnetic field is either positive or negative depending on the sign of a constant, the coupling constant 
Jis and on whether I is aligned or antiparallel to B0. This splits the S signal into a doublet with a 
splitting of Js Hz, reciprocally the I signal is split into a doublet at its resonance frequency (Figure 
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Figure 2.8: Effects of scalar coupling on energy levels 
Spin I in the rotating frame precesses with the angular velocity o, and may be considered as the sum 
of two counter-rotating vectors (Figure 2.9). Their evolution will then depend on the magnitude of J15. 
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Figure 2.9: Evolution under J coupling 
2.1.8 Nuclear Overhauser effect (NOE) 
The Nuclear Overhauser Effect (NOE) is one of the ways in which a spin can release energy, and is 
therefore related to relaxation processes. The NOE is related to the exchange of energy between two 
spins that do not necessarily have scalar coupling but have dipolar coupling [111]. 
The NOE is evidenced by enhancement of certain signal in the spectrum when the populations 
of other spins nearby are altered. If we consider a two Y2  spin I and S system energy diagram, where 
xo, c43, Pa, and 00 refer to states IcSJ3.  ..etc (Figure 2.10); if W represents a transition probability, at 
equilibrium we have W11 and Wjs transitions, which represent single quantum transitions, and are 
related to Ti relaxation. W015 and W215 are double quantum transitions also known as cross-relaxation 
transition probabilities; these are theoretically forbidden and have lower probability, because such 
transitions are not directly excited by radio frequency pulses or cause directly detectable NMR 
signals. Nevertheless, these transitions are not forbidden in the context of relaxation. Relaxation 
occurs when the spins give away energy by processes that have frequencies close to =y130, which 
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Figure 2.10: Energy level diagram for a two spin system with J15=0. The probabilities W for the 
six allowed relaxation transitions are shown. 
If now we saturate the S transition to equalise its energy levels (Figure 2.11), W1s  and  Wit 
transitions are not observed because we have the same population in W1s  and we did not affect spin I, 
but both are auto-relaxation pathways. Wols and W21S  transitions are, in addition to the auto-relaxation, 
two other ways through which spin S can relax. These transitions also involve spin I, thus there will 
be a change in spin I populations. Wois  will give a negative enhancement, spin I (so far undisturbed) 
has deviated from its Boltzmann equilibrium towards a decrease in its a,f3 population difference. W215 
will give a positive enhancement, and spin I population difference increases. 
w11/w21 w15 
I3ct (*) 
'yls \ 	I' Wil \ V i' 
Figure 2.11: Energy level diagram for a two spin system with Js=0  after saturation of spin S 
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In this four level system, the different transition probabilities are: 
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where po  is the permeability constant in a vacuum, r is the inter-nuclear distance, and ; is the 
correlation time for molecular reorientation. 
The enhancement caused by the NOE can be quantified: 
= 7S 	'V/21S - 'Wois 	= 's cis 
'i 2Wu+W21s+W0Is 	't PIS 
where als is the cross-relaxation rate between spin I and S, and it is this term that controls how 
quickly a NOE enhancement is transferred between the two spins; Pis  is the auto-relaxation rate or 
dipolar longitudinal relaxation rate for relaxation of spin I. 
Cross-relaxation results from fluctuations of the magnetic field at zero or double quantum 
frequencies, and therefore the NOE depend on the rate at which molecules reorient in solution. Only 
reorientation or "tumbling" is important, vibrations are too rapid, and translational motion involves 
large inter-nuclear distances. The dominance of W21s or W01s relaxation mechanism depends on ; of 
the molecule. W21s dominates in small molecules with short; and Wojs dominates in macromolecules 
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with long ; (proteins). This is due to the fact that the fluctuating magnetic fields that induce such 
relaxation processes need to contain frequencies that are equal to the sum of (01 and 0s (double 
quantum transitions), or to their small difference (zero quantum transitions). The size of the NOE 
effect is therefore also dependant on the magnetic field, i. e. it will be different at 300 and 600 MHz. 
The product () -cc  reflects the NOE properties: 
-When o) cc <<1 (W215 > W015), condition known as the "extreme narrowing limit", the 
maximum NOE is i= 1/2 	. This means that the molecule tumbles fast and we have 
positive enhancements. 
-When w cc  >>l (W21S <W015),, the maximum NOE is i= - Ys/. This means that the molecule 
tumbles slowly and we have a negative enhancement (proteins). 
-When (t) t -1 (W215  W01s), the NOE goes to zero. This happens for certain medium sized 
molecules. The NOE can also be defined in terms of the resulting intensity I{S}, of spin I 
when spin S is saturated and its normal intensity I: 
ii=(I{S}-Io)/Io 
A NOE enhancement can be accomplished by two means: 
A saturation of a resonance that causes the corresponding a and 13  states to be 
equally populated. In the steady-state NOE experiment [Ill, 119], one spin is 
selectively saturated by a long, low-power continuous wave irradiation prior to 
recording a spectrum. A reference spectrum without irradiation is also recorded 
and when subtracted from the spectrum, only resonances having NOEs with the 
saturated spin are observed. 
An inversion pulse (180°) that inverts the relative populations of a and (3 states. 
In this so-called transient NOE experiment [111, 119], a resonance is selectively 
inverted with a selective 180°  pulse. After a delay for NOE build up, a 90° pulse 
is applied and a one-dimensional spectrum is acquired. Again spectra acquired in 
experiments with and without the selective 180°  pulse are subtracted. 
When analysing NOESY spectra, one has to be aware of an indirect NOE transfer, also called spin-
diffusion. This indirect effect is a three-spin effect; magnetisation is further transferred from spin two 
to spin three, despite the fact that there is no direct NOE between spin one and three. Spin diffusion is 
very effective in macromolecules and steady state NOE measurements are therefore not used. 
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The transient NOE enhancements are symmetrical. In transient NOE experiments on large molecules, 
direct NOE peaks can be recorded at short mixing times, and spin diffusion can be recognised from 
the build up curves of NOEs from NOESY experiments that are recorded with increased mixing 
times. 
2.1.9 Referencing 
The shielding constant is an inconvenient measure of the chemical shift, in practice we use a 
relative scale, and refer all signals in the spectrum to the signal of a particular compound: 
8= (v — vref) 106  ppm 	 (1) 
vref 
In biomolecular NMR, referencing [120] is often done on the water signal and is dependent on pH, 
salt concentration, and temperature: 
8H20 = 4.776 - 0.0119 (T-25) - 0.002 (pH-7) - 0.09 (salt concentration) 	(2) 
where T is temperature in celsius, pH is the pH of the sample and the salt concentration is the molar 
concentration of salt in the sample. 
From here, the absolute frequency at 0 ppm for 'H can be calculated from the frequency of water 
using equation (I). This absolute frequency of 'H, v is then used to calculate the absolute frequency 
3 	C 	 H 	 N 	 H of the other nuclei c (0 = YC'YH v0 ) and N (V0 = YN/YH v0 )• Again, equation (1) can be used 
to calculated the chemical shift of reference of the heteronuclei with the help of the absolute 
frequencies previously calculated and the nuclear frequencies at the position of the carrier. 
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2.2 	Multidimensional NMR 
2.2.1 Models used for the description of NMR experiments 
There are several approaches for the analysis of pulsed NMR experiments, such as the vector 
model, density matrix evolution, and product spin operators. The vector model satisfactorily 
describes many basic NMR experiments but fails for example in the description of experiments 
involving multiple-quantum coherences. The most general description of a spin system is via 
evolution of a density matrix, which can handle also high order spin effects. 
The initial state of a spin system is described by the spin density matrix p(t) [121]. If we discard 




Where H is a Hamiltonian that describes the different events happening in the system: 
chemical shift evolution, coupling and interaction with pulses. The spin density matrix describes the 
state of a large number of spins, and all observable and non-observable coherences can be extracted 
from the spin density matrix. The solution to the Liouville-Von Neumann equation will give the state 
of the magnetisation: 
-iHt 	il-It p(t)e Po e 
The calculation of the time dependent evolution of the system corresponds to transformation or 
rotation (can be expressed as a matrix) of the density matrix with the proper Hamiltonian-a pulse, 
chemical shift evolution, J coupling etc. This calculation is rather complicated, and hides the physical 
meaning of individual operations. It is more convenient to follow the evolution of a spin system on 
the basis of so-called product spin operators, which can, to a certain extent, be identified with the 
simple vector model. 
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2.2.2 General rules and description of product operators 
When using some properties of matrix calculation, p(t) becomes greatly simplified. If we call 
P0, B, the matrix that describes the initial position of the magnetisation and H, A, a rotation (also a 
matrix) of angle cot, then we have e° B eI0, and the following rules applied: 
- A and B commute: e" "'A B e=B then thus A has no effect on B 
- A and B anti-commute e' B e'°= cos cot B + sin cot C where C=[A,B]. 
This means that B (initial magnetisation) has been rotated in respect to A by an angle 
cot towards a new element C (Figure 2.12). The same description applies for a 90° 




Figure 2.12: A and B anti-commute 
Note: Pulse flip convention will be anticlockwise from now on. 
Therefore for a simple 90°x pulse and acquisition, we have: 
initial magnetisation along z : m0 Iz 	1y[Jz Ix] 
pulse 900 x operator: 90° Ix 	
~'~< 
in0 Iz {cos 90° =0} 	 -rn0 ly {sin 90° =1} 





 -in0 cos(c)It) ly 	m0 sin(cot) Ix 
The effect of one of the evolution operators acting on one of the operators describing the state of the 
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Figure 2.13: Sign conventions for the evolution operators ly, Iz, Ix and 2IzSz acting on the 
product operators ly, Iz, Ix, 2IxSz and 2IySz. Taken from reference 11121 
Many building blocks of pulse sequences can be analysed using product spin operator. Effective 
Hamiltonians describing cumulative effects of different events lead to simple equations (Figure 2.14). 
2.2.3 Quadrature detection 
If detection is only carried out along one axis in the rotating frame then it is impossible to 
discriminate between the signs of frequencies i.e. determine the sense of precession of the 
magnetisation vectors. Use of two orthogonal detectors along the x and y-axes allows detection of the 
sense of rotation. This is known as quadrature detection [122]. The signals are sampled 
simultaneously by two analogue-to-digital converters (ADC), or if we cannot digitise the two FIDs 
simultaneously, then only one of each FID is digitised at a time, alternately. These two FIDs are then 
used as the real and imaginary parts for complex FT. 
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Figure 2.14: Description of the reduced product operators (double bars represent 1800 pulse) 
In practice the placement of the detectors in the rotating frame is dependant on the phase of 
the carrier frequency which is subtracted from the signal: two detectors in quadrature are fed with the 
same absolute frequency, but one is shifted in phase by 900.  The acquisition of real and imaginary 
data points can be carried out either in a simultaneous or alternative fashion. In the alternative mode, 
also known as the Redfield method, real and imaginary points are sampled alternately by switching 
the detector phase by +1- 900; this is equivalent of moving the detector around the axes of the rotating 
frame. Compared to the simultaneous manner, or true complex acquisition, the alternative mode has a 
dwell time half as long (1/2 SW). When using the alternative mode, after FT, the spectrum has twice 
the SW of the spectrum that would be obtained with true complex acquisition, it also contains mirror 
images of all signals which are symmetric to SW/2. This effectively places the carrier frequency at the 
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edge of the spectrum when compared to true complex acquisition mode. We obtain two mirror images 
of the spectrum but we just discard the half outside the chosen spectral range. 
The methods described above allow sign discrimination in the acquired dimension, but in 
multidimensional spectroscopy we also need sign discrimination in the indirectly acquired dimension. 
Again we have two methods. The States (-Ruben-Haberkorn) method is analogous to the true complex 
acquistion mode in 1D. For each time increment in the indirectly acquired dimension, the pulse 
sequence is performed twice with the phases of the pulses adjusted such that we observe the 
magnetisation from two orthogonal viewpoints. The phase of the first pulse is shifted by 90°. The 
second method is analogous to the Redfield method and is known as the TPPI (Time Proportional 
Phase Incrementation) method. Only the real data points are recorded in the indirectly detected 
dimension, but twice as many, with half the time increment. 
2.2.4 Composite pulses and broadband decoupling 
High resolution NMR requires perfect pulses. In order to compensate for pulse imperfection 
e.g. radiofrequency inhomogeneity, resonance offset error (precession of the magnetisation around an 
effective B1  field), and miscalibration; composite pulses are employed. A composite pulse is a 
combination of different pulses that achieve the same effect that would be obtained from a single 
pulse, but here the imperfections are compensated for and we have a better result [123]. Composite 
1800 pulses are routinely used in modern NMR to achieved basic tasks like spin-locking, and 
broadband decoupling. One of the first composite 180° pulses to be developed was the following 
pulse scheme: 90° x -180° y - 90° x, and was further used as a buliding block in more complex 
composite pulses. A common composite pulse is the MLEV-16 sequence [124], where several repeats 
of this block and its phase inverted equivalent are put together. This sequence allows isotropic mixing 
and is used in TOCSY experiments. Composite 180° pulses are also used for broadband decoupling, 
particularly in heteronuclear experiments. 
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2.2.5 Pulsed field gradients 
The use of pulsed magnetic field gradients (PFG) is nowadays almost compulsory in high 
resolution NMR. Fields gradients are used to destroy temporarily the homogeneity of the magnetic 
field in a controlled manner and perform a variety of functions in pulse sequences. A PFG consists of 
an additional pair of coils inside the probe, on both sides of the sample. When a direct current is sent 
through this coil pair in opposite directions, we have a resulting magnetic field parallel to B0 on one 
side of the sample and antiparallel on the other side which create an overall linear field along the 
direction of the coil pair, Le. along z if one coil is above and one below the sample (z gradient). 
Routine use of PFGs is due to the implementation of so called "shielded gradients" which increase the 
gradient strength without the need for long recovery delays and reduce the induction of eddy currents 
elsewhere in the probe. Typical gradient strength is of the order of 30 to 70 Gauss per cm. Their 
principal applications are the selection or destruction of coherences. 
During the application of a PFG, how the resonance of a nucleus will be affected depends on 
its spatial location. The phase twist L\pG  caused by the gradient is given by L\PG = /\WG TG y BG 'CG, 
[113] where TG is the gradient duration, L\ATOQ is the change in precession frequency caused by the 
gradient, and BG  is the gradient strength. A gradient applied on a transverse magnetisation results in 
twisting its phase at the edges of the sample several hundred times and the detectable net 
magnetisation is null. The signal defocused by a PFG cannot completely be refocused by a second 
gradient if it has diffused away between the two gradients. This has implications for gradient spin 
echoes where a gradient is performed before and after a 1800  pulse. Since the 180° pulse reverses the 
twist caused by the first gradient, a second gradient of equal strength and sign is used to refocus the 
signal. The result is a clean up of the magnetisation components that were not refocused by the 180° 
pulse due to miscalibration. Such spin echoes are used in diffusion experiments where the two 
gradients are separated by a variable delay to allow measurement of the molecular diffusion, and to a 
certain extent in several water suppression schemes. 
PFGs are also useful to destroy unwanted magnetisation components in pulse sequences. For 
example, when using z gradients, only the x and y components of the magnetisation are affected and 
all z components remain unaffected. This is of particular interest in heteronuclear coherence transfer 
steps where the magnetisation of interest is in a zz-ordered state during the application of the gradient. 
The third category of applications, coherence selection, requires precisely reproducible 
gradients. The phase twist caused by a gradient depends on its length and strength but also on the 
type of coherence it affects. 'H coherences dephase four times as fast as ' 3C coherences under the 
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same gradient and 'H-'H double-quantum coherences dephase twice as fast as 'H single-quantum 
coherences under the same gradient. These features are used to selectively refocus only specific 
combinations of coherences with a pair of gradients. 
2.2.6 Water suppression 
Water signal suppression is of particular interest in biomolecular NMR. Signals of interest 
arise from protein which usually has a concentration of half to few mM, while the water signal arises 
from protons at a concentration of 110 M. Thus, several methods have been developed to reduce the 
signal produced by water: presaturation, semi-selective excitation, trim pulses and the use of PFGs. 
Best solvent suppression is generally achieved with PFG techniques. 
2.2.6.1 Prestaturation 
The most common method of water suppression is selective presaturation. In this method the 
populations of the two energy states for water protons are equalised, resulting in no net magnetisation. 
This is accomplished by a rf pulse set on the water resonance frequency for a long period of time (1-2 
s), and effectively in a vector model causes the solvent magnetisation to rotate in the vertical plane. 
Because of the radio frequency inhomogeneity of the presaturation pulse, the magnetisation is 
randomly distributed in this plane by the end of the pulse with no net component in the xy plane. 
Presaturation is performed immediately prior to the pulse sequence. Presaturation is not the best 
water suppression technique since it often saturates protein frequencies close to water, or protein 
frequencies in exchange with water like NH protons. The SCUBA (Stimulated Cross-relaxation 
Under Bleached Alphas) [125] sequence is of particular use to avoid such problems. 
2.2.6.2 Semi-selective excitation 
A better solvent suppression method than using presaturation can be achieved with semi-selective 
excitation. If we place the carrier frequency on water, then after a 900 x pulse, water will be static 
along the y axis in the rotating frame, while protein resonances will be precessing. After a delay, a 
second 90° -x pulse will then return the water magnetisation along z, and the protein resonances will 
be in the xz plane. Their x component that evolved during the delay remains and therefore can be 
acquired without any contribution from water. Such scheme is known as the jump-and-return 
sequence [126] and is performed at the end of pulse sequence, prior to acquisition. 
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2.2.6.3 Trim pulses 
Trim pulses use for solvent suppression are of a few milliseconds duration and applied along the x or 
y axis, effectively spin locking the magnetisation along an axis while rf inhomogeneity dephases the 
magnetisation not aligned with the spin lock. Trim pulses are also useful to dephase unwanted 
coherence in pulse sequences. 
2.2.6.4 Use of pulsed field gradients 
A popular alternative for solvent suppression is the use of PFG. Several methods using PFG have 
now been developed. In the Watergate scheme [127], a combination of water-selective and non-
selective pulses with PFG is used at the end of the pulse sequence. This building block ensures that 
water is completely dephased while the protein signal is refocused. Another, very effective water 
suppression scheme based on PFG uses the DPFGSE (Double Pulsed Field Gradient Spin Echo) 
sequence [128] which has been used in some experiments performed for this study. 
2.2.7 Phase cycling 
Phase cycling involves shifting the phase of the pulses and/or the receiver by a controlled amount 
between individual scans. This is used to achieve coherence selection, and to cancel out residual 
magnetisation arising from pulse imperfections, as well as, to perform quadrature detection in the 
indirectly acquired dimension. 
A system has coherence when its elements, here the spins, have a common relationship, in this a 
common phase. At equilibrium, the magnetisation is not coherent since every spin is precessing with 
a random phase. In contrast after a 900  pulse, a system of spins is coherent, and T2 relaxation can be 
explained as a loss of coherence. In a one-spin system, we have two possible states, a and 13,  and 
consequently a change of only one quanta is involved; this is a single-quantum transition, and the 
coherence order (p) equals +/- 1. Single quantum coherences are the only type of coherence that 
generates a current in the receiver coil, and they are also known as observable coherences. We can 
select to detect p = -1 by selecting the phase of the pulses and receivers. A 90° pulse excites single-
quantum transitions and its effect can be represented in a diagram also known as a coherence transfer 
pathway. By convention, coherence order p = —1 is associated with +(00 and p = +1 with -u 0. In a 
two-spin system, we have four possible states, and have zero-, single-, and double-quantum 
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transitions; p = 0, p = +1-1, and p = +/-2 respectively. It is also possible to generate higher order 
coherences which can be selected using Bodenhausen's rules [129]. 
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2.2.8 Two-dimensional NMR experiments 
NMR experiments can be subdivided into four stages: preparation, evolution, mixing, and 
detection. 
2.2.8.1 Homonuclear two-dimensional correlated spectroscopy or COSY experiment 
The COSY experiment (Figure 2.15) [130] is based on the transfer of coherence from one spin 
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Figure 2.15: Pulse sequence of the COSY experiment 
If we consider spin I: 
Iz 
9001 pulse: Ii 
Cos Spin t chemical shift: m11lz 
Ix 
coupling: iJ15  t1 lzSz 
-ly 	2IxSz 	Ix 	 2IySz 
90x pulse: Is & Sx 
Ix 	 -2IzSy 
Spin I chemical shift: col t,Lz 
Spin S chemical shift: 5t.Sz 
Ix 	ly 	-2IzSy 	2IzSx 
cos( \in co/ \sin 	cosj/ \n cos/ \n 	
J" coupling : tj t2 lzSz 
Ix 	2IySz j 	-2IxSz -2IzSy Sx 2IzSx 
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Only the underlined coherences are detectable, thus if we detect the signal on the y axis, we will have 
the following signals coming from spin I: 
ly modulated by: 	 cos it J1s t1 	sin o t1 	cos it J1s t2 	sin (01 t2 
Sy modulated by: 	 sin it Jis t1 	sin w t1 	sin it Jis t2 	sin (o, t2 
Signals coming from spin S generated from Sz in the same way: 
Sy modulated by: 	 cos it jf .Q, ti 	sin w. t1 	cos it .h t 	zin m 
ly modulated by: 	 sin it Jis t1 	sin w t1 	sin it Jis t2 	sin (01 t2 
The ly and Sy signals coming from spin I, and S. respectively, will give rise to the diagonal peaks. In 
each dimension, we have the product of a cosine modulation (J modulation) and a sine modulation 
(precession), which after FT corresponds to their convolution product. The real part of this product 
has the shape of inphase doublets in dispersion (d). 
The ly and Sy signal coming from spin S, and I, respectively, will give rise to the cross-peaks of the 
COSY spectrum. This time we have for each dimension the product of two sine modulations. The 
real part of their convolution product has the shape of antiphase doublets in absorption (a). The final 
result is a two-dimensional spectrum as shown in Figure 2.16. 
/ - -------------- iE7-- v, 
t2 	VI 	 V 
Figure 2.16: Schematic COSY 2D spectrum and its associated signal lineshapes [131] 
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The double quantum filtered COSY sequence uses an extra 90° pulse at the end of the COSY 
sequence and an appropriate phase cycling to select double quantum coherence after the 900  second 
pulse. In this sequence, the diagonal peaks will be antiphase multiplets with absorption lineshape and 
this will avoid the long tails on peaks seen in the COSY experiment that make difficult to observe the 
crosspeaks near the diagonal. 
2.2.8.2 Total correlation spectroscopy (TOCSY) 
90°x 	900-x 	 90°x 
I & S 	H 
ti fi A [P!ck 1 A fi0000 t2  
Figure 2.17: Pulse sequence of the TOCSY experiment. 
The TOCSY experiment [132] is also known as homonuclear Hartmann Hahn experiment 
(HOl-JAHA) [133]. The TOCSY experiment is used in the 1 H-NMR of proteins NMR in conjunction 
with COSY experiment for identification of resonances that are all within one residue or spin-system. 
The key feature of the TOSCY experiment is that it uses a period of spin locking to achieve coherence 
transfer (Figure 2.17). A spin lock pulse is a radio frequency pulse with a duration up to tens of 
milliseconds; more precisely it is a train of non-selective 180°  composite pulses. This means that 
during the spin lock, the only active interactions are the coupling constants, and there will be a 
transfer of magnetisation between two coupled spins when the Hartmann-Hahn condition is satisfied. 
This condition implies that the difference in the magnetic field that they experience is less than the 
magnitude of their J coupling. Usually, if we consider two spins coupled by a spin-spin interaction 
Jis, after creating transverse magnetisation with a 90°x pulse, we have a weak-coupling Hamiltonian, 2 
it J1s IzSz; spin locking of both I and S means that they will evolve under a strong coupling term, 2 it 
Jis (IxSx+IySy+IzSz). 
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The evolution of a coherence Ix, will be as follows: 
Ix 	 No 	Ix (1+cos 27tJist)/2  +Sx (1- cos 2tJ1 'r)/2 + (IySz-IzSy) sin 2101 T 
Strong 
where ,r is the duration of the mixing time. 
There are two different classes of spin-locks: isotropic and anisotropic. Isotropic spin-locks 
(WALTZ-16 or MLEV-16) allow transfer of all magnetisation components, while anisotropic 
spinlocks (MLEV-17) can transfer only one transverse component and the z component. Only 
anisotropic spinlock sequences are employed for TOCSY experiments; the initial anisotropic version 
of the TOCSY experiment was named the homonuclear Hartmann-Hahn (1-IOHAHA) experiment, and 
today the terms TOCSY and HOHAHA are mostly used interchangeably. 
At the end of the t1 period of the TOCSY pulse sequence in Figure2.19, we have: 
-ly cos co, t1 cos irJs t1 + 2IxSz cos w t1 sin itJ15 t1 + Ix sin w t1 cos 701 t1 + 2IySz sin co, t1 sin 701s t1 . 
Before entering the spinlock, we can select the y component by using appropriate phase cycling. Only 
-ly cos co, t1 cos mJis t1 and 2IySz sin (01 t1 sin mJis t1 terms are considered here. Focusing on the first 
term, a 900  —x pulse flips this —ly component back onto the z axis. 
During spin-lock, mixing occurs and the z component gives rise to: 
Iz cos (ol t1 cos 7rJis t1 (l+cos 27rJ1S'r)/2 +Sz cos (Oj t1 cos 701 t1 (1- cos 2itJ1 r)/2 + (IxSy-IySx) cos 1 
t1 cos itJis t1 sin 21J15'r, where t is the duration of the mixing time. 
Finally, the Iz and Sz terms are converted into transverse, observable magnetisation with a 900  x 
pulse, and give rise to diagonal and cross peaks respectively. The multiple quantum terms created 
during the spin-lock are converted into antiphase magnetisation, which during the t2 period evolves 
into observable magnetisation. In the spectra, this gives rise to antiphase multiplets, which in protein 
spectra are strongly diminished by mutual cancellation of their broad lines with opposite phase. 
The mixing period induces an undesirable transfer via dipolar coupling, also called, rotating 
Overhauser effect (ROE). ROE peaks are of opposite sign to those of nuclear Overhauser peaks, thus 
if we allow NOE peaks to build up when the magnetisation is aligned along the z axis before and after 
the spin-lock, NOE peaks will then compensate for ROE peaks. This is achieved by setting the delays 
A to be equal to 'c/4 as the build-up rate of ROE peaks is twice that of NOE peaks. Alternatively one 
can use "clean" isotropic mixing sequences (DIPSI-2rc) [134] that include directly the delays within 




2.2.8.3 Nuclear Overhauser enhancement spectroscopy (NOESY) 
Like the COSY or TOSCY experiments, the NOESY experiment [135] starts with a 900  x 
pulse followed by an indirect evolution time (Figure 2.18), at the end of which the following terms 
exist: 
-ly cos (01 t1 cos tJis t1 + 2IxSz cos (oi t1 sin icJis t1 + Ix sin co, t1 cos 2icJ1 t1 + 2IySz sin co t1 sin 101s t1 . 
A second 90° x pulse leads to: 
-Iz cos (0i t1 cos 7tJis t1 - 2lxSy cos 0)1 t1 sill 7tJ1 t1 + Ix sin (01 tI cos nJIs ti - 2IzSy sin co, t1 sin 7EJjs ti. 
The phase cycling is designed to select only coherence order p=O during the mixing time i.e. the first 
term (-Iz) and the zero quantum part of the second term (I/2[IySx-IxSy]). 
90O 	90° 	 90 
O 
I&s H 
i  fi t2 
Figure 2.18: Pulse sequence of the NOESY experiment 
This first term is a z magnetisation, a non-equilibrium polarisation, modulated with the cosine of the 
chemical shift and coupling, which causes an NOE on neighbouring nuclei: 
-Iz cos 	t1 cos 7tJ15 t1 	__ - Iz (l_Riitm) Cos col  ticos 701S  t1 - Sz (Ris'rm)  cos co, t1 cos 	IS t1 
Mixing(T) 
where Rjs  is the cross-relaxation rate between spin I and 5, R11 is the auto-relaxation rate of spin I, and 
tm is the mixing time. 
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Cross relaxation rate and the duration of 'tm  determine the amount of NOE transfer. After the final 90° 
x pulse, these z components are converted into detectable signals: ly (1 Rij'tm)  cos (ol t1 cos 7tJis t1  + Sy 
(Rj tm) cos o t1 cos 7tJ1 t1 . The first term results in a diagonal peak after 2D FT (at ()l),  the second 
one in a cross-peak at (ol in Fl (t1 ) and at 0)s in F2 (0. The sign of the cross-peak depends on the sign 
of the cross relaxation rate, i.e. the dominance of either W01s  or W21 . 
The second term mentioned above results in the unwanted zero-quantum diagonal and cross peaks that 
are dispersive antiphase signals in both dimension, and some unobservable signal. These peaks can be 
suppressed by recording and co-adding several NOESY spectra with a range of values of r,,. In large 
molecules, they can often be ignored as the zero quantum relaxation rate is very fast, the antiphase 
contributions tend to cancel, and they don't affect the integrated volume of the cross-peaks (antiphases 
don't have a net integral). 
The initial slope of the NOE as a function of 't1  (build-up curve) corresponds to the cross relaxation 
rate, which depends on the internuclear distance. This can be measured in 2D NOESY with a 
sufficiently short 'tm, where NOE cross-peak integrals can be converted into internuclear distances. 
This is usually done with a reference NOE corresponding to a known distance: r1 = rref (Irer1ij)_6, where 
rij  is the distance between two atoms, i and j, and Iij the integral of their NOE cross-peak. 
2.2.8.4 Heteronuclear single quantum spectroscopy (HSQC) 
Heteronuclear correlation spectroscopy is based on the same principles outlined in the COSY 
experiment, but with some important differences. In heteronuclear correlation experiments, the 
coherences from 1H are frequency-labelled during t1 by the heteronucleus ('5N,'3C etc), and both 
frequency dimensions are decoupled to concentrate intensity on singlets at the chemical shift 
frequencies. The sensitivity of this type of experiments is dependent on the gyromagnetic ratio as: 
Signal/Noise . ( )3/2 [113] for two spins, I and S. Thus this equation shows that starting with the 
nucleus with the highest 'y but also detecting that same nucleus achieves the highest sensitivity. There 
are two principle schemes for transferring magnetisation between coupled heteronuclei resulting in the 
creation of single and multiple-quantum coherence transfer, named heteronuclear single-quantum 
spectroscopy (HSQC) [136] and heteronuclear multiple-quantum spectroscopy (HMQC) [137] 
respectively. HMQC requires fewer 1800  pulses and therefore is less sensitive to pulse miscalibration 
and radio-frequency inhomogeneity. Nevertheless single-quantum transfer is generally used because 
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of the favorable relaxation properties of single quantum coherences and singlet structures in the 
spectra. 
The HSQC experiment employs two INEPT (Insensitive Nucleus Enhancement by 
Polarisation Transfer) building blocks (Figure 2.19). The first INEPT is a preparation stage to achieve 
antiphase heteronuclear coherence: 
900x pulse on I 	v .1 2vLzSz 	90°Y pulse on 1 	90y pulse on S 
Iz 	P -ly 	Po 2IxSz 	eo -21zSz 	Po 	-2IzSx 
chemical 	 transfer 
shift Is refocus 
The second INEPT block is described as a reverse INEPT because it converts this coherence back to 
1H magnetisation after labelling under the heteronuclear chemical shift: 
O)St,Sz 	90°x pulse on S 	90°x pulse on 1 	itJ 2rlzSz 
	
-2IzSx 	o -2IzSy 	o, -2IzSz 	01 2IySz 	-Ix 
chemical 	 transfer 	 chemical 
shift labelling shift is refocus 
The delays t, and A are set to 1/4 J,, and 1/8 J1s  respectively so that the transfer of magnetisation from 
Ito S is maximised. A broadband decoupled spectrum is acquired so heteronuclear coupling is again 
supressed, and 'H chemical shift will develop. To select only heteronuclear-bound protons, a phase 
cycling scheme is used on the spin S 90° pulse in the reverse INEPT block. Protons that are not 
directly bound to the heteronucleus will not develop into —2IzSy terms and therefore not be affected 
by phase changes of the spin S 90° pulse. 
90°x 	90°y 	90°x 	90°y 
	
90°x 
nT mm H m nA [fl Ant 	 t2 
I 	II 	III 	(I 	III 	II 	III 
('H) INEPT 	 Rev INEPT 
90°y 	90°x/-x 	90°y 
S 	I 	I 
I t1 	(2) 
(15N or 13C) 
Figure 2.19: Pulse sequence of the SE-HSQC experiment. 
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By subtracting two scans acquired with such phase cycling, signal from non-heteronucleus bound 
protons will cancel. This experiment can be conduced in a sensitivity enhanced (SE) manner [138], 
which yields a phase modulated signal, but with a factor (2)1/2  increase. The SE-HSQC starts like a 
regular HSQC experiment. We have the first [NEPT block to create antiphase coherence, then 
labelling with spin S chemical shift during t1: 
99°x pulse on I 90vt pulse on S 	IV J LMzSz 900y pulse on I&S 	90°x pulse on 
-2IzSy 	o 2IySy 2IySz 	o -Ix 	o 	Li -ly 
chemical 
Shift is refocus 
+ chemical 
shift is refocus 
-2IzSx I 
t_ostlsz I 
90-1 pulse on S 0 	ly 
I (2) 	chemical 
shift labelling 
Cos 	 90x pulse on I 90x pulse on S 	iv J 2ALSz 900y pulse on l&S iv J 2I7Sz 
-2IzSx 	0 2IySx 0 2IySx 	0 	2IySx 	0 -2IySz 0 Ix 
chemical chemical 
shift is refocus shift Is refocus 
90oa pulse on S 
	
Ix 
When recording a SE-HSQC in the TPPI manner, one acquires cosine and sine modulated signal in t1, 
to which both coherence transfer pathways have contributed and which has a factor of (2)1/2  higher 
signal to noise ratio. Phase cycling of the second 900  heteronuclear pulse allows control of the sign of 
ly. These two FIDs are combined to yield pure sine and cosine modulated signals, with twice the 
intensity, which then can be used as input for complex FT. 
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2.2.9 Three dimensional spectroscopy 
The assignment strategy for unlabelled proteins uses a combination of COSY, TOCSY and NOESY 
experiments. However resonance overlap becomes so severe in two-dimensional spectra of proteins 
with more than 80 residues, that it is often impossible to identify adjacent spin system. In three-
dimensional experiments, three frequencies rather than two label each crosspeak. When using '5N 
labelling, it is possible to resolve the resonances of the amide protons with the 15N chemical shift of 
their attached nitrogen. This is used in three dimensional TOCSY-('5N, 'H) HSQC [139] and 
NOESY-('5N, 'H) HSQC [139-141] experiments. Although this facilitates sequential assignment, 
the sequential connectivity between spin-systems still relies on identification of the Ha of each 
residue and therefore has some ambiguities. The limited resolution among Ha resonances is 
overcome in triple resonance experiments used in 15N/ 13C  labelled proteins as they employ 
coherence transfer through the 'J or 2J heteronuclear coupling (large coupling) only rather than the 
3J hornonuclear coupling (small coupling) used in COSY and TOCSY experiments [142]. 
In two-dimensional experiments, the evolution period labels spins with their chemical shifts in the 
indirectly detected dimension, while in the mixing period spins are correlated to each other. In 
three-dimensional experiments, the pulse sequence is constructed by combining two 2D 
experiments without the detection period after the first 2D block. One can think of this initial 2D 
sequence as a preparation period for the second 2D part. Thus two evolution periods are 
incremented independently to give a data matrix with three different acquisition times: t, t2, t3- 
2.2.9.1 3D '5N edited TOCSY-HSQC and 3D 15N edited NOESY-HSQC 
15N edited TOCSY-HSQC and '5N edited NOESY-HSQC are concatenations of a homonuclear 
TOCSY and NOESY, respectively, with a ('5N, 'H) HSQC (Figure 2.20). In these experiments only 
NOESY and TOCSY peaks of amide protons are detected. Here the amide protons are acquired in 
the directly detected dimension 43), while their NOEs are indirectly detected (t,) to discard water 
signal contributions in the NOE peaks [142]. If the order of individual building blocks were 
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Figure 2.20: the '5N edited TOCSY-HSQC and 15N edited NOESY-HSQC pulse sequences. 
Taken from reference [1421. 
2.2.9.2 Triple resonance experiments 
The nomenclature of the triple-resonance experiments reflects the magnetisation transfer pathways 
of the experiments, and the nuclei that are involved form the name of the experiments [143]. 
Nuclei, whose chemical shifts are not labelled during the indirectly detected dimensions, but 
through which magnetisation passes, are put in parentheses. Triple-resonance experiments can be 
divided into two groups: experiments that are used for backbone assignment (HNCO, HN(CA)CO, 
CBCA(CO)NH, I-INCACB, HBHA(CO)NH, HBHANH etc), and experiments that are used for side 
chain assignment (H(C)(CO)NH-TOCSY, (H)C(CO)NH-TOCSY). Backbone experiments are 
usually analysed in pairs (HNCO with HN(CA)CO, CBCA(CO)NH with HNCACB, and 
HBHA(CO)NH with HB}-JANI-I), to provide sequential assignment of spin systems. The 
assignments deduced from the analysis of the triple-resonance experiments are then used in double-
resonance experiments (15N edited NOESY-HSQC, H(C)CH-TOCSY and '3C edited NOESY-
HSQC). For illustration purposes, one triple resonance experiment - the HNCO - is considered 




The HNCO experiment (Figure 2.21) correlates the backbone amide proton and nitrogen 
frequencies of one residue with the carbonyl frequency of the preceding residue in the protein 
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Figure 2.21: the 3D HNCO pulse sequence. Taken from reference [142] 
Only these correlations are observed in the 1-INCO since 1Jc0(,),N(1) = 15 Hz, while 2Jco(1),N() - 0 Hz. 
The magnetisation-transfer pathway is the following: 
Nl-I 	 NCO 	 NCO 	 'TNH 
'H 	lo 15N 	10 "CO (t) 	10 '5N(t)0 'H(t) 
The sequence starts with an INEPT transfer of the magnetisation from the backbone 'H t015  N. 
Next, a delay during which only the one-bond coupling between '5N and 13C0 is allowed, builds up 
antiphase two-spin coherence NxCOz. This is further converted into NzCOy by a selective 13C0 
900 pulse and '5N 90° pulse for 13C0-chemical shift labelling during the evolution time t,. A second 
pair of selective 13C0 90° pulse and '5N 90° pulse converts the magnetisation into NyCOz. This 
coherence then evolves (during the delay 2T) into '5N coherence in antiphase with respect to 
HzNy, which becomes simultaneously labelled by the 15N-chemical shift during the constant-time 
evolution period t2. Finally, a reverse INEPT transfer with sensitivity enhancement converts the 
coherences back to the amide protons for observation. 
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2.2.9.2.2 	Other protein backbone and side chain assignment experiments 
The HN(CA)CO experiment correlates the chemical shifts of the backbone amide proton (i), 
nitrogen (i) and two carbonyl frequencies (i, i-i). Therefore when used along with the HNCO 
experiment, this pair of experiment allows sequential assignment of the spin systems in a '5N/'3C - 
labelled protein. 	Similarly the pair of experiments, CBCA(CO)NH - J-INCACB, and 
HBHA(CO)NH - HBHANH are used for sequential assignment. The H(C)(CO)NH-TOCSY, and 
(H)C(CO)NH-TOCSY experiments are further used to assigned the remainder of the proton and 
carbon side-chain resonances respectively. 
A schematic description of the different frequencies observed in these 3D-experiments along with 
the way they are displayed in the Ansig software package for resonance assignment can be found in 
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Figure 2.22: Experiments for backbone assignments in 15N/13C-labelled proteins 
Experiments are described as they are viewed in the Ansig software package for resonance 
assignments. Note: the so-called "out and back" implementation was used where the magnetisation 
starts and finishes on NH protons, as indicated by the double-headed arrows. 
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Figure 2.23: Experiments for backbone and side-chain assignments in 15N/13C-labelled 
proteins 
Experiments are described as they are viewed in the Ansig software package for resonance 
assignments. Note: the so-called "out and back" implementation was used where the magnetisation 
starts and finishes on NH protons, as indicated by the double-headed arrows in the HBHA(CO)NH, 
and HBT-L&NH experiment. In the TOCSY experiments, magnetisation does not start on NH 
protons. 
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CHAPTER THREE: EXPRESSION AND PURIFICATION OF RECOMBINANT 
PROTEINS 
3.1 	Production systems for recombinant proteins 
Both NMR and X-ray crystallography, require relatively large amounts of pure and 
homogenous material, 10-100 mg for a complete structural study [144]. Sample preparation is a 
"bottle-neck" of structural biology, and in the post-genomic aera this issue has become crucial. 
Structural genomics, i.e. the three-dimensional structure determination of all the protein folds in the 
entire proteome, will require efforts towards more efficient protein expression and purification 
systems, and possibly lead to their automation [145]. Currently obtaining sufficient amounts of pure 
protein can be a long, expensive and relatively complex process. This was emphasised in a recent 
study, which revealed that out of over one thousand proteins, derived from all three biological 
kingdoms, only 15-20% of small (<50 kDa) non-membrane proteins were suitable immediately for 
structural biology [146]. The small number of proteins readily available for structure determination 
was compared to the "low hanging fruit" of structural genomics, and to some extent, this study 
showed also that many proteins cannot be expressed in soluble form in bacteria. Eukaryotic proteins 
often require extensive post-translational modifications or the presence of specific protein chaperones 
in order to fold and/or function correctly, and this renders bacteria unsuitable for their recombinant 
expression. The use of eukaryotic expression systems is therefore a good alternative to bacteria as 
they are likely to possess the correct cellular machinery to process such proteins and allow their 
soluble expression. Currently, these systems are predominantly yeast, insect cells and mammalian 
cells. Yeast is the most commonly used as it has some post-translational capacities, a short doubling 
time when compared to other eukaryotic systems, and is relatively inexpensive. One of yeast's main 
advantages is that metabolic labelling is still possible at reasonable cost, while labelling media for 
insect cells, although commercially available, is relatively expensive, as well as labelling media for 
mammalian cells. The issue of metabolic labelling is crucial to modern protein NMR. Besides the 
technical advantages it offers, isotope incorporation is highly desirable for high resolution NMR 
structures as the accuracy of protein structures determined by NMR is dependent on the extent of the 
data that one can obtain [147]. 
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The time, the resources, the cost of protein production, and of course the level of expression 
achieved by a particular expression system are the parameters that one has to consider when 
undertaking any structural study. This often leads to a "trade-oft" between expression systems. For 
instance, expression of one protein in an insect cells system might be achieved in soluble form but at a 
low level, while bacteria might achieve expression of the same protein in insoluble form, at a high 
level, which subsequently must be refolded. 
This study involved the expression of extracellular proteins of human or rat sources, all of 
which contain established or putative disulphide bonds in various numbers, and which are often 
glycosylated. Thus, the methylotropic yeast Pichia pastoris was employed as an expression system. 
When levels of expression were low or undetectable in yeast, a bacterial system was used as an 
alternative. 
3.1.1 Prokaryotic expression 
Escherichia coli (E. co/i) has long been the primary prokaryotic host for heterologous protein 
expression, therefore there is much available information and technology regarding this system 
involving many different recombinantly expressed proteins. The advantages of E. coil include its 
relatively easy, rapid and inexpensive methods of growth, transformation and maintenance. 
Furthermore, most of the biochemical pathways of E. co/i are understood in great detail, and its entire 
genome has been sequenced. Foreign proteins can potentially be produced in E. co/i in large amounts 
(5-50% of total protein). Nevertheless, prokaryotic cells such as E. coii are unable to perform many 
post-translational modifications, which occur in eukaryotic cells (e.g., glycosylation, phosphorylation 
and disulphide bond formation), and which may be crucial for a foreign protein to adopt an active 
form. The expression and accumulation of a foreign protein in E. co/i may also induce aggregates of 
protein [148, 149]. Sometimes the protein in these inclusion bodies can be refolded in vitro to 
produce functional protein, but this is not always possible and renaturation can be expensive and time 
consuming. 
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3.1.1.1 pET System 
Various E. coli expression systems are commercially available, each system offering different 
benefits for protein expression and purification. All systems are designed to achieve a tightly 
controlled transcription coupled with a strong and rapid induction. Recently, new systems to enhance 
translation have been developed. The pET system is the best-characterised system that is 
commercially available (Novagen), and was employed in this study. pET-based vectors utilise 
bacteriophage T7 transcription signals to achieve very high levels of protein expression (Figure 3.1). 
The power of the pET system is that the T7 RNA polymerase is specific for its own promoter [150, 
151], which is found only on the expression plasmid. Protein expression is achieved in an expression-
E. co/i strain that carries a chromosomal copy of the T7 RNA polymerase gene under the control of 
the lacl gene (DE3 strains). This theoretically enables T7 promoter repression during growth and 
culture expansion that otherwise might adversely affect bacterial growth. Some pET plasmids also 
carry the lacl gene and a lac operator sequence downstream of the T7 promoter (T7lac), to enhance 
repression of any basal expression. Other E. co/i strains (pLysS and pLysE strains) have been 
engineered to contain a compatible plasmid that provides a small amount of T7 lysozyme during 
growth, which binds to T7 RNA polymerase and inhibits transcription. T7 RNA polymerase is 
expressed in the host cell only when induced with IPTG (isopropyl-beta-D-thiogalactopyranoside), a 
non-metabolizable analogue of lactose, allowing transcription from the T7 promoter. Induction is 
usually allowed to continue for a few hours. 
3.1.1.2 Soluble versus insoluble and solubility tags 
In inclusion bodies (see above) only a small fraction of the protein is folded correctly, and the 
rest is in a denatured and non-functional form. In some cases the formation of inclusion bodies 
allows purification of the recombinant protein by washing and pelleting [152]. 
Many vectors are now engineered to contain DNA sequences encoding a specific peptide or protein, 
which will be fused to the gene of interest and can theoretically be used for one-step purification of 
the recombinant protein by affinity binding. One of the first proteins to be exploited as a fusion 
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Figure 3.1: pET system overvi ew-taken from http://www.novagen.com  
partner was glutathione S-transferase (GST) [153]. In vectors containing GST-fusion tag, the 
recombinant protein is fused with GST encoded by the parasite Schistosoma japonicum [151]. This 
allows purification of the fusion protein on a glutathione affinity Sepharose column. The "6xHis" Tag 
is also popular; in this system the recombinant protein is fused to a six-histidine peptide at its N or C-
terminus. This latter is extensively used, especially due to its unique ability to work under denaturing 
conditions. In general, the recombinant fusion protein is engineered so that an endopeptidase 
cleavage site sequence is incorporated between the tag and the protein (e.g. thrombin, factor Xa, 
enterokinase, etc). Many tags have functions beyond purification; for example some of the traditional 
tags are stabilisers of protein folds (GST, Maltose binding protein) [151]. Recently tags with the sole 
purpose of enhancing solubility have been developed such as thioredoxin [154] or nusA tags [155]. 
Although E. coli lacks post-translational capacities, the use of ompl or ompA leader signal 
sequences can direct secretion of recombinant protein into the periplasmic space. This particular 
compartment has an oxidative environment and consequently is the only place where disulphide-
bonded proteins have been observed in E. coil. Therefore targeting recombinant protein to the 
periplasmic space might lead to disulphide bond formation; such a strategy has been successful for the 
production of antibody fragments [151]. Recently, new tags for periplasmic localisation have been 
supplemented with the use of E. coli proteins that catalyse the formation (DsbA) and isomerisation of 
disulphide bonds (DsbC) [156]. 
lao o 
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3.1.2 Eukaryotic expression: the methylotrophic yeast Pichiapastoris 
Mammalian cell expression systems are the best protein expression tools for mammalian 
proteins as they can produce native proteins, but they have extensive drawbacks in term of yield, 
mechanism of induction, and metabolic labelling. Use of non-mammalian hosts such as yeast or 
insect cells have several advantages. These expression systems have much better characterised 
genetics and biochemistry [157, 158], produce near-native glycosylation or at least some 
glycosylation, and have well defined secretory pathways for extracellular expression, and thus 
disulphide bond formation [159]. Yeast based expression systems are particularly attractive. Yeast 
can grow rapidly on minimal media, which enables metabolic labelling at reasonable cost. Expressed 
proteins can be engineered for cytoplasmic or secreted expression. Yeast has the ability to perform 
many eukayotic post-translational modifications. Finally, yeast is well suited for large-scale 
fermentation. 
A highly sucessful system for the production of heterologous proteins is the methylotrophic 
yeast Pichia pastoris (P .pastoris) [160]. The basis of the P. pastoris expression system is methanol 
metabolism. Growth on methanol is mediated by alcohol oxidase, an enzyme whose de novo 
synthesis is tightly regulated by the alcohol oxidase promoter (AOXI). This enzyme has a very low 
specific activity; therefore to conpensate for this, the enzyme is overproduced, accounting for up to 
30% of the total soluble protein of the cell [161]. There is a second alcohol oxidase which is encoded 
by a second AOX gene (AOX2), but has little specific activity and loss of the AOXI gene lead to 
strains that exhibit poor growth on methanol medium, named MutS  strains (Methanol Utilisation 
Slow). Strains with both AOX genes correspond to the wild-type strain and are referred as Mutt 
strains (Methanol Utilisation plus) [161]. Invitrogen has developed plasmids that contain the AOXI 
promoter to induce over-expression of recombinant proteins upon growth on methanol. Vectors 
containing the heterologous protein gene downstream of the AOXI promoter are subsequently 
integrated into the P. pastoris genome by homologous recombination to maximise the stability of 
expression strains. The vector is designed to be linearised with a unique restriction site in either a 
marker gene (histidine gene) or the AOXI promoter. 
After transformation, the free DNA termini of the vector will recombine at the HIS4 locus or 
the AOXI locus (depending on the restriction site employed-Figure 3.2), either by single crossing 
over (insertion) or double crossing over (replacement). Multiple insertions occur spontaneously 
shortly after transformation at a frequency of about 1-10% of the insertion events. Transformant 
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selection is achieved with the HTS4 selection marker, as engineered P. pastoris strains from 
Invitrogen are auxotrophic for histidine. Selection can also be performed using antibiotic resistance 
(zeocin or geneticin). Recombinant proteins are targeted for secretion by use of the ct-factor leader 
sequence. 
3.2 	Materials and methods 
This section describes briefly some of the essential biochemical techniques used in this study. 
3.2.1 Standard molecular biology techniques 
Polymerase chain reaction (PCR), and DNA manipulations were performed according to 
standard protocols [162]. The sequence integrity and the reading frame of all DNA constructs were 
confirmed by cycle sequencing. 
3.2.2 Standard cell culture techniques 
3.2.2.1 E. coil work 
E. Coli strains BL21(DE3) were purchased from Novagen in a chemically competent format 
and used for protein expression. For small-scale expression tests, a single colony from a fresh 
transformation was used to inoculate 5 ml of LB medium with antibiotic (100 jtg ampicillin/ml). 
After growth and induction, 1.5 ml of culture was transferred to an Eppendorf tube, and spun at 
13,000 g for 10 min at room temperature. The supernatant was decanted and the cell pellet was 
resuspended in 1 ml of Phosphate Buffer Saline (PBS) and spun again. For total cell protein extract, 
the cell pellet was resuspended in I ml of PBS, 100 l was then mixed with an equal volume of 2 x 
SDS-PAGE loading buffer, and a sample of 15 .tl was analysed by SDS-PAGE. For soluble fraction 
extract, the cell pellet was resuspended in 300 jtl of Bug Buster reagent (Novagen) supplemented with 
I jil of Benzonase (25 units-Novagen), and incubated for 20 min on a rocking platform at room 
temperature. 
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Figure 3.2: Homologue recombination events of the Fichia pastoris expression vectors at 
different loci 
a) Gene insertion at the HJS4 locus. b) Gene insertion at the AOX1 locus. c) Example of 
multiple gene insertion. Taken from reference [161]. 
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The cell debris was then pelleted by centrifugation (10 mm, 13,000 g, room temperature), the soluble 
fraction decanted into a clean Eppendorf tube and an equal volume of 2 x SDS-PAGE loading buffer 
was added; a 30 pA sample was analysed by SDS-PAGE. For insoluble fraction extract, the cell pellet 
(above) was resuspended in 100 tl 2 x SDS-PAGE loading buffer, and a 15 pA sample was analysed 
by SDS-PAGE. 
For large-scale bacterial cultures, a single colony from an overnight transformation was 
transferred to 100 ml of LB medium containing appropriate antibiotic and incubated at 37°C overnight 
in a shaking incubator (250 rpm). The next day, cells were harvested by centrifugation (2000 g, 5 mm 
at room temperature), the supernatant was decanted and the cell pellet was resuspended in an equal 
volume of fresh medium containing antibiotic. The culture was then diluted 50-100 times (to a 
volume less than 25% of the flask volume), and the expression of recombinant protein was induced 
with 1 mM IPTG at 0D600  0.7-0.9. Growth was continued for 3-4 hours at 37°C, and 250 rpm. 
3.2.2.2 Yeast work 
All yeast constructs were linearised and transformed in Pichia pastoris strain KM71 by the 
electroporation method [161]. Use of Pichia pastoris strain KM71 yields only Muts  transformants 
since this strain is itself exclusively Muts. Transformants were selected using zeocin and selected 
clones were tested for their capacity to secrete relevant fragments (see appendix A). Whenever 
possible, a clone apparently secreting the highest amount of recombinant protein was selected, and 
used for further large-scale growth to allow protein characterisation and authentication. Pichia 
pastoris strain KM71 has a mutation in the histidinol dehydrogenase gene (HIS4) [161], which 
prevents histidine synthesis. The pPICZ alpha plasmid [163] or its modified version used in this 
study does not complement HJS4 and selected transformants were further transformed with linearised 
pPIC9 vector to restore their ability to grow on histidine deficient medium. Alternatively, a pre-
transformed pPIC9 Pichia pastoris strain KM71 was established and used directly in some 
transformations. 
For sample preparation, cultures were grown in shake-flasks or high cell density 
fermentations. In each cases, the starter culture consist of a single colony selected from yeast peptone 
dextrose (YPD) Zeocin agar plates (see appendix A) and inoculated into 10 ml of buffered minimal 
glycerol medium (BMG) in a 50 ml Falcon tube, and incubated for 36 h at 30°C in a shaking 
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incubator (250 rpm). For shake-flasks cultures, this starter culture was used to inoculate I I of BMG, 
and split into four 11 baffled flasks (Nalgene) capped with a BugStopper sterile closure (Whatman). 
Cultures were grown for another 36-48 h at 30°C (250 rpm) before harvest by centrifugation (1850 g 
for 5 minutes at room temperature) under sterile conditions. Cells were resuspended in one-fifth of 
the original culture volume (200 in]) of buffered minimal methanol medium (BMM) for induction. 
Induction periods were typically 5 days at 25-30°C (250 rpm) with daily addition of 100% methanol 
to maintain a final concentration of 0.5% (v/v). 
For 15N-isotope labelling, cultures were also grown in shake-flasks, but 15N BMG and '5N 
BMM were used (see appendix A) which had the same composition as BMG and BMM media except 
that they contain 0.2% of 15N-ammonium sulfate (Goss Scientific-Cambridge Isotope labs) as the sole 
nitrogen source. For 15N/'3C-isotope labelling, three minimal media were used (see appendix A). 
15N/13C buffered minimal dextrose medium (BMD) that contain 0.2% '5N-ammonium sulfate, and 
0.5% '3C-glucose (Goss Scientific-Cambridge Isotope labs) was used instead of BMG medium. Cells 
were then harvested by centrifugation as described above, and resuspended in '5N/'3C BMG that 
contains 0.2% '5N-ammonium sulfate and 0.1% '3C-glycerol for 2h prior to induction. This stage 
allows a smooth switch between glucose and methanol carbon source for the cells, and was found to 
prevent cell death. Induction was carried out using 15N/'3C BMM, which contains 0.2% 15N-
ammonium sulfate and 0.5% '3C-methanol. To minimise protein degradation during production, the 
pH of both BMG and BMM solutions were lowered to 3, using phosphoric acid, as well as 
implementing a daily harvest and medium change. Quantitatively and qualitatively, no difference was 
observed between samples obtained from growth at pH 6 or 3. 
In some cases, the shake-flask method in minimal media was replaced by a fermentation 
method for higher protein production. A starter culture as described above was used to inoculate 200 
ml of BMG in a one-litre flask for 24 h (OD600 -6). This culture was then used to initiate a ferrnentor 
culture containing 2 1 of P. pastoris basal salt medium and 6.7 ml of PMT1 trace metal salts 
(Invitrogen) contained within a 5 1 working volume vessel on a BioFlo 3000 fermentation unit (New 
Brunswick Scientific Co). Dissolved oxygen concentration (DO) was maintained at 40%, the 
temperature at 30°C, the pH at 5 by using ammonium hydroxide, and antifoam (Sigma) was used to 
control excess foaming. After 18-24 h, DO increased to 100% indicating that glycerol was 
completely consumed and the glycerol fed-batch phase could be initiated. Cells were then fed with 
50% w/v glycerol and 12 ml of PMTI trace metal salts over 24 hat a rate of 40 ml per hour (18.15 
ml/h/litre initial fermentation volume). At the end of the glycerol fed-batch step, again DO increased 
81 
Expression and purification of recombinant proteins 
to 100% indicating that glycerol was completely consumed. DO spikes were thus used to make sure 
the glycerol was limiting. Induction was then carried out for 3-4 days at a methanol feed rate of 7.5 
ml per hour with an initial slow ramping to allow the culture to adapt smoothly to methanol. 
3.2.3 Some general biochemical methods 
General reagents were purchased from Sigma or otherwise stated. Buffers were prepared 
using Milli-Q grade water. 
3.2.3.1 Chromatography 
Fast protein liquid chomatography (FPLC) was performed on a Waters 650E Advanced 
Protein Purification system fitted with a Waters 600 controller unit, a Waters 996 photodiode array 
detector and a Waters fraction collector. High-pressure liquid chromatography (HPLC) was carried 
out on a Waters system comprising a Waters 600 controller unit, a Waters 616 pump unit, a Waters 
486 tunable absorbance detector and a Waters fraction collector. Alternatively, a BioCad 700E 
Perfusion chromatography workstation comprising a Scout Column selector and an Advantec SF-
2120 super fraction collector was used for both FPLC and HPLC. 
FPLC media for self-packed columns and pre-packed columns were from Amersham 
Pharmacia Biotech (ion exchange, hydrophobic interaction, gel filtration, and affinity 
chromatography) or from PerSeptive Biosystems (POROS media). HPLC pre-packed columns were 
from Brownlee and media for self-packed columns was from PerSeptive Biosystems (POROS media). 
Self-packed Concanavalin A (Con A) sepharose and metal chelate affinity-chromatography 
columns were prepared with Amersham Pharmacia Biotech media and Novagen media, respectively. 
The media was packed in 20 ml columns from Biorad laboratories (Econo-Pac columns with 10 ml 
reservoir) and operated under gravity flow. 
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3.2.3.2 Denaturing electrophoresis of proteins 
Protein samples were resolved by reducing SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) using a Mini-PROTEAN II or Criterion gel system (Biorad Laboratories) and visualized 
using the Coomassie blue method. SDS-polyacrylamide gels were 15% acrylamide (self-poured). 
8-16% and 10-20% SDS-polyacrylamide gradient gels were purchased in a precast format from 
Biorad Laboratories or Novex. Prestained molecular weight markers were from New England 
Biolabs. 
In most cases, protein samples were precipitated by addition of trichlororacetic acid (TCA) 
solution to a 10% (v/v) final concentration prior to SDS-PAGE analysis. 
3.2.3.3 Western blotting 
Proteins were first resolved using SDS-PAGE before electrotransfer onto a nitrocellulose 
membrane (Amersham Pharmacia Biotech). Electro-transfer was performed in a Mini Trans-Blot cell 
(Biorad Laboratories) at constant voltage (150 mA) for 85 minutes in Towbin buffer (10% Methanol). 
Positive transfer was monitored using prestained molecular weight markers. Blotted membranes were 
blocked for I h with 5% Milk-phosphate buffered saline (PBS). Membranes were then washed over a 
period of 30 min with PBS (three buffer changes). Antibody incubation was performed at room 
temperature for an hour or overnight at +4°C. Detection of polyhistidine tags was carried out with 
anti-His6 monoclonal antibodies that are horseradish peroxidase conjugated (Sigma), and which allow 
detection without the need of a secondary antibody (1:800-1:500 dilution). The DAB (3,3'-
diaminobenzidine) peroxidase substrate from Sigma was employed for staining. 
3.2.3.4 Protein ultra-flifration and dialysis 
Concentration of protein samples was achieved by ultra-filtration. Large volumes (from I I) 
were concentrated to 200 ml using a Millipore Prep/scale-TFF cartridge (regenerated cellulose) linked 
to a peristaltic pump (Millipore). Further concentration was performed with gas (N2) -pressure stirred 
cells (Arnicon, Millipore), which typically allowed concentration of several hundreds of ml to as little 
to 5 ml. Ultrafiltration membranes (Polyether sulfone) used in such stirred cells were purchased from 
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Pall Gelman Laboratory. Each recombinant protein sample was concentrated using an appropriate 
molecular weight cut-off. Final concentration, in the range of several hundreds of microliters, was 
achieved by centrifugal ultra-filtration with centricon concentrators (Millipore) or Vivaspin 
concentrators (Sartorius). Dialysis tubing for buffer exchange or use in refolding protocols was 
purchased from Pierce and Warriner (Spectralpor6). 
3.2.3.5 Estimation of protein concentration 
Protein concentration was calculated using absorbance at 280 nm and a theoretical extinction 
coefficient based on the protein sequence (ProtParam Tool, Expasy Tools —http://www.expasy.ch). 
3.2.3.6 Mass spectrometry analysis 
Ion electrospray mass spectroscopy (atmospheric pressure) was carried out on a Micromass 
Platform IT single quadrupole mass spectrometer. Samples were prepared in 50% acetonitrile-water, 
0.5% formic acid. Positive ionisation was normally used. 
3.2.3.7 N-terminal sequencing 
For protein N-terminal sequencing, protein samples were first resolved using SDS-PAGE and 
electro-blotted on PVDF (Polyvinylidine difluoride) membranes (ProBlott-Applied Biosystems). 
Membranes were stained with 0.1% Coomassie blue (G-250) in methanol and destained with 10% 
acetic acid-50% methanol. Relevant bands were submitted for protein N-terminal sequencing on a 
ABI 477A sequencer at the Welmet protein characterisation facility (University of Edinburgh). 
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3.3 	Results and discussion 
3.3.1 Preliminary remarks 
Successful protein expression for structural biology often requires the testing of different 
systems and hosts. Protein purification can also be problematic and may require modifications of 
the original construct derived from the cDNA to fine tune domain-boundaries or simply to aid the 
purification process by using affinity tags. Such investigations are to some extent based on trial-
and-error, and may be extremely time-consuming. This work illustrates the difficulties in defining 
domain-boundaries when undertaking the structural study of modular proteins. 
Yeast has been the host of choice throughout this study, since all constructs are, or at least 
suspected to be disulphide bond containing as well as N-glycosylated. CPI and FTM2 expressions 
were of particular interest. CPI NMR data exhibited poor 'H chemical shift dispersion and lack of 
crosspeaks in the '5N-HSQC spectrum, indicating that it may be poorly structured, aggregated or in 
dynamic exchange (see chapter four). As mentioned earlier, YTH identified the C-terminus of the 
fibulin protein family as a ligand for the complement module pair in the GABAB receptor Ia. Early 
YTH screens localised the interaction region to the last three epidermal growth factor-like (EGF) 
modules (repeat 8, 9, and 10) and the FTM2. Further screens refined this interaction to the FTM2 on 
one hand, and CPI on the other, which consequently led to a focus on the FTM2 only. Nevertheless 
the array of EGF modules (EGF-8-1 0)were expressed and purified, and subsequently used to raise 
antibodies against fibulin-2. 
3.3.2 Yeast expression 
3.3.2.1 GABAB  Ria complement module pair constructs 
The poor quality of the NMR data of the recombinantly expressed GABAB Ria complement 
module pair, led to an investigation of the influence of the factors that could be important for proper 
folding. Complement module sequences are characterised by the presence of four cysteine residues 
that form the two disulphide-bonds of a module and in general also define the module boundaries. 
The GABAB  Ria N-terminal sequence does contain the consensus sequence for two complement 
modules, but there are seven residues N-terminal to the first cysteine of the first module that include a 
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potential N-glycosylation (Asn23; Figure 3.3-a). This first predicted module also includes a second 
consensus motif for N-glycosylation (Asn83), as well as an extra tryptophan residue in the predicted 
first loop. An overview of the different constructs that have been made and examined by NMR 
spectroscopy is presented in Figure 3.3-b. These constructs are presented, in the following sections, in 
the chronological order in which they were made and follow the investigation of the influence of the 
N-terminal extension in CPI on protein folding. The role of N-glycosylation was investigated also 
through mutagenesis and by means of endoglycosidases. All yeast expression constructs used the 
Pichiapastoris pPICZa A expression vector (Figure 3.3-c). 
3.3.2.1.1 	TR-CP12 
The GABAB  Ria "truncated" complement module pair (TR-CP12) corresponds to residues 24-159 in 
the original GABAB  Ria rat protein sequence (numbering includes the protein signal sequence). This 
protein fragment is of the same sequence as in humans except for two conservative mutations that are 
found in the second predicted complement module: glutamic acid 128, and valine 144 are replaced by 
aspartic acid and isoleucine, respectively. 
A yeast strain, expressing the TR-CP12 was prepared by Dr. Edward Hawrot in our laboratory 
[34]. The yeast clone was shown to produce two forms of the recombinant fragment, as seen by SDS-
PAGE (Figure 3.4-a). The major protein in the sample has a mass of -16 kDa while the minor form 
has a mass of-20 kDa. Mass spectroscopy confirmed a mass of 15628.7 for the major form, which 
corresponds, to the expected mass of the recombinant protein fragment if all eight cysteines are in 
disulphide bonds, as would be expected for two complement modules, and with an EAEF N-terminal 
sequence from cloning, but without an N-glycan. The minor form was found to have the same N-
terminal sequence and to correspond to an N-gy!cosy!ated form of the major protein. This minor 
protein can be treated by endoglycosidase (EndoH) and led to a band shift by SDS-PAGE, consistent 
with molecular weight of the major form [34]. 
Following Dr. Hawrot's work in our laboratory, the current work started with large-scale 
protein preparations for structure determination. Typically, preparations were on a 1 1 BMG-200m1 
BMM scale, as described previously, and yielded up to —10 mg of protein. The 200 ml of culture 
obtained at the end of the induction period (5 days) was harvested, and spun at high speed (10000 g, 
30 mm, 40C), the supernatant was isolated and protease-inhibitors were added (1 mM PMSF/10-20 
mM EDTA). Preparations were kept at 4°C prior purification, alternatively stored at —20°C. Protein 
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concentration was carried out by ultrafiltration using 3 kDa molecular weight cut-off membranes, to a 
volume of 20 ml. Originally, the protein sample was purified according to Dr Hawrot's protocol 
using a I ml reverse phase C18 column equilibrated in 90% H20-10% acetonitrile with 0.1% v/v 
trifluoroacetic acid (TFA). Purification was achieved by an elution gradient from 80% H20 20% 
acetonitrile [0.1% v/v TFA] to 60% H20 40% acetonitrile [0.1% v/v TFA] at a flow rate of 1 ml/min  
over 34 column volumes. This allowed only a partial resolution of the two protein forms; the minor 
(N-gylcosylated) form was shown to elute slightly earlier than the major form. This result was in 
agreement with Dr. Hawrot's findings when he repeated the same experiment in his own laboratory at 
Brown University (RI-USA). 
Subsequently, a new purification strategy was devised. Several ion exchange chromatographic 
conditions were investigated, and both cation and anion exchange were tested. Best conditions were 
found to be as follow: the concentrated protein was first desalted against 50 mM sodium acetate-pH 
5.3 using gel filtration (PD-10 column), and purified by cation exchange chromatography on a 1-ml 
MonoS column, equilibrated in the same buffer. Elution was achieved with a gradient of 0-100% 1 M 
NaCl in buffer (above) at a flow rate of 1 ml/min over 25 column volumes. This allowed a initial 
capture of the two forms, which eluted as a single peak (Figure 3.4-b), as shown by SDS-PAGE. 
Fractions containing protein were pooled and concentrated to 20 ml. The two protein forms were then 
resolved by hydrophobic interaction chromatography as follows: the protein concentrated from cation 
exchange chromatography was first desalted against water and then an equal volume of 0.2 M sodium 
phosphate buffer, pH 7, containing 3.6 M ammonium sulfate was added. The protein was applied to a 
1-ml phenyl superose column equilibrated in 0.1 M sodium phosphate buffer, pH 7 containing 1.8 M 
ammonium sulfate. Elution was achieved with a gradient of 100-0% ammonium sulfate at a flow rate 
of 0.5 ml/min over 25 column volumes (Figure 3.4-c). 
The peak containing the minor form eluted earlier than that of the major form (Figure 3.4-c&d). 
Fractions from between the peaks containing a mixture of the two forms were discarded and each 
form was concentrated separately using Vivaspin6 concentrator (5 kDa cut-off). Buffer-exchange 
against an appropriate NMR buffer, and concentration of protein, were achieved simultaneously by 
several rounds of concentrations and dilutions (typically, 5-6 rounds of 10 times concentration-
dilution) to a final volume of 300-600 p.1. 
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Figure 3.3: Overview of the GABAB Ria complement modules expression in Pichiapastoris 
Protein sequence of the predicted complement control protein (CCP or CP) modules against 
others characterised modules [34]. An alignment of the GABAB Ri a pair of CP-modules with a 
CP-pair found in the CNS (the 3rd and the 4th CPs from the rat SEZ-6 protein), a CP-pair found 
in the VCP viral protein (211d  and 3 d modules), and a well characterised CP-pair found in the 
complement system (the 15th and the 16th CPs from the human factor H protein). 
Summary of the protein constructs used in this study. 
















a 	 so mM sodium acetate / pH 5.3 	 b 
50 mM sodium acetate / pH 5.3 + 1 M NaCI 
Fraction number: 	 123456 









c 	 d 
0.1 M sodium phosphate/pH 7 + 1.8 M ammonium sulfate 
0.1 M sodium phosphate! pH 7 
Figure 3.4: Purification of TR-CP12 
Crude preparation concentrate separated by SDS-15% PAGE under reducing conditions, and 
visualized using the Coomassie blue method. One ml of a 200 ml preparation was TCA precipitated. 
Cation exchange chromatogram (blue: buffer, red: eluent). 
Hydrophobic interaction chromatogram (blue: buffer, red: eluent). 
Hydrophobic interaction chromatogram fractions separated by SDS- 15% PAGE under reducing 
conditions, and visualized using the Coomassie blue method. Lanes 1-3: 250 .d of fractions 1-3, TCA 
precipitated. Lanes 4-6: 50 .tl of fractions 4-6, TCA precipitated. 
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For mass spectroscopy, samples were desalted using a reverse phase C4 column (eluting with 
an acetonitrile gradient identical to that used for the C18 column, mentioned above), freeze-dried, 
dissolved in 50% acetonitrile in aqueous solution containing 0.1% TFA and analysed by electrospray-
ionisation mass spectroscopy. 
Two compounds with masses of 15628.5 Da and 15428.3 Da were found to be contained within the 
major form. These correspond to: the expected molecular weight of TR-CPI2 plus the cloning 
artefacts (EAEF) at the N-terminus for the 15628.5 Da compound (expected mass is 15628.7 Da); and 
the same but with cloning artefacts (EF) only at the N-terminus for the 15428.3 Da compound 
(expected mass is 15428.5 Da). These two products represent alternatively processed products of the 
a-factor leader sequence. Incomplete removal of the EA spacers in a-factor pre-proteins is very 
common in yeast [158]. The measured masses are also consistent with expected molecular weights if 
all eight cysteines are in the disulphide form. The presence of cloning artefacts (EAEF) at the N-
terminus was confirmed by N-terminal sequencing. A third compound of 14892.6 was observed in 
some samples (Figure 3.5) and corresponds to the expected molecular weight of the TR-CPI2 with the 
first five N-terminal residues missing (expected is 14892.95 Da). Missing N-terminal residues in 
recombinant proteins expressed in yeast has been reported and seem also to be the result of incorrect 
cleavage of the pre-protein. A form missing only the first two N-terminal residues (15152.2 Da) has 
also been observed by Dr. Hawrot [34]. 
I 
ass 
Figure 3.5: Mass spectrum of the major form of TR-CP12 
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The minor form mass spectrometric analysis was of poor quality, and not reproducible. Protein purity 
was greater than 95% by SDS-PAGE, but despite extensive desalting, a mixture of compounds 
appeared in the mass spectrum of molecular weights between 17.3 and 18.6 kDa: 17360 Da, 17492 
Da, 17816 Da, 17978 Da, 1 7994Da, 18322 Da. Such molecular weights are consistent with the '20 
kDa band seen by SDS-PAGE, and seem to correspond to heterogeneous N-glycosylation at 
asparagine 83, with glycan chains that differ in their number of mannose units. The 17492 Da 
compound represents the 15628 Da compound found for the major form with nine mannose units and 
two N-acetylglucosamine (GIcNAc) units, similarly the 17816 Da compound represents an adduct of 
11 mannose units and two G1cNAc, and the 17978 Da compound represents an adduct of 12 mannose 
units and two GIcNAc. Such heterogeneity could also explain the lack of reproducibility of mass 
spectrometry measurements between different preparations. 
3.3.2.1.2 	FLM-CP12 
The GABA11  Ria "full-length" complement module pair, with the N-glycosylation site 1 
(Asn-23) mutated out (FLM-CP12) corresponds to residues 17-159 in the original GABA8 Ria rat 
protein sequence. This region encompasses the two predicted complement control modules with the 
native seven-residue N-terminal extension described above. This extension contains a putative N-
glycosylation consensus motif (NAT), which could result in covalent glycan linkage at asparagine 
23. To facilitate downstream purification, this site was engineered (N23A) by PCR to abolish the 
consensus motif. 
The DNA encoding for TR-CP12 was obtained from Dr. Hawrot, and was used as a PCR 
template to amplify FLM-CP12. The 5' primer (see appendix B) contained the sequence encoding 
the seven-residue extension with asparagine 23 changed to an alanine, as well as an EcoRI site. The 
3' primer contained a NotI site. The amplified fragment and the vector pPICZa A (Invitrogen) were 
each double digested with the restriction enzymes EcoRl and NotI (37°C-overnight), agarose-gel 
purified and finally ligated by incubation with T4 ligase (160C-overnight). 
The ligation product was transformed into calcium chloride competent-Top 1 OF E. coli cells 
(Invitrogen), and positive transformants were screened by restriction digest after plasmid DNA 
minipreparation. The 5' and 3'AOXl sequencing primers were both used in separated sequencing 
reactions, to confirm both the authenticity and the frame of the cloned insert in the pPICZa A 
vector. 
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A sample of the DNA construct (50 tg) from a midi-preparation was digested with Sad, to 
generate a linear construct. Linearized DNA was phenol-chloroform extracted once, ethanol 
precipitated and resuspended in sterile distilled water. A sample containing 10 tg of linear DNA 
construct in 10 .tl was used for Pichia pastoris transformation by the electroporation method (KM7 1 
strain). Positive transformants appeared after two days on YPDS zeocin plates (see appendix A), 20 
transformants were screened for protein expression (small-scale protein production test - see 
appendix A for method). One transformant expressing good levels of recombinant fragment, as 
judged by SDS-PAGE analysis, was selected and transformed with the linearized (Sad) pPIC9 
vector (Invitrogen) as described previously, to replace the HIS4 gene lacking in the KM71 strain. 
Transformants were selected on minimal dextrose (MD) plates (see appendix A), and one or two 
positives were further screened using a small-scale test as described above. Large-scale preparations 
and protein purification were as described for the TR-CP12, and yielded similarly up to 10 mg of 
recombinant protein. The FLM-CP12 was also expressed as two forms, a minor N-glycosylated 
form and a major lion N-glycosylated form (Figure 3.6). 
Mass spectrometry analysis of the major form revealed a single compound of 16010 Da, 
which is consistent with the expected molecular weight of the FLM-CP12 plus the cloning artefacts 
(EF) at the N-terminus (expected mass is 16011.12 Da). Such a mass is also consistent with the 
expected molecular mass as if all eight cysteines are in the disulphide form. The presence of the 
cloning artefacts (EF) at the N-terminus was confirmed by N-terminal sequencing. 
3.3.2.1.3 	WT-CP12 
The GABAB  Ria "wild-type" complement module pair (WT-CP12) corresponds to residues 
17-159 in the original GABAB  Ria rat protein sequence. The seven-residue extension as described 
above is included but now has the original protein sequence containing the N-glycosylation consensus 
motif. 
The DNA construct encoding FLM-CP12 obtained above was used to amplify the DNA 
encoding for WT-CP12 by PCR. The 5' primer (see Appendix B) contained the sequence coding for 
the native seven-residue extension with asparagine 23, as well as an EcoRl site. The 3' primer 
contained a NotI site. Cloning procedure and yeast transformation were as described for the FLM-
CP12. Large-scale preparations were also similar to the FLM-CP12. 
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The recombinant WT-CPI2 was expressed as two forms, but the yield was lower than that 
obtained for previous constructs. Following deglycosylation by the endoglycosidase EndoHf, the two 
forms collapsed to a single band by SDS-PAGE, consistent with the expected molecular weight of the 
non N-glycosylated protein form, with intensity now similar to the previous constructs. This evidence 
for hyper- and heterogeneous N-glycosylation at asparagine 23 and is consistent with observations of 
other N-glycosylated proteins overexpressed in this study (see EGF8-10 expression, section 
3.3.2.3.2). Hyper N-glycosylation in yeast has been described in many published studies [158], and 
has been observed by many other researchers in our laboratory (Andrew Herbert - unpublished, Dr. 
Joanne O'Leary - PhD Thesis). 	Subsequently, all WT-CP12 samples were exhaustively 
deglycosylated by use of endoglycosidase Endo Hf. 
Protein purification was achieved by cation exchange chromatography approximately as 
described for the previous fragments, although cation exchange condition varied slightly: binding 
buffer and elution buffer were 12.5 mM sodium acetate, pH 5.3 instead of 50 mM sodium acetate, pH 
5.3. After cation exchange, samples were concentrated, and again buffer-exchanged against the cation 
exchange binding buffer prior to deglycosylation with 2500 units of endoglycosidase EndoHf (4 h, 
37°C) per mg of recombinant protein. Endoglycosidase Endo Hf was subsequently removed by 
reloading the cleavage mixture on cation exchange column, and further purification was achieved by 
reverse phase chromatography (C8 column, same gradient as described previously). SDS-PAGE 
analysis and NMR spectroscopy confirmed removal of the N-glycans, although in some cases the 
recombinant protein was further purified on a Concavalin A (Con A) sepharose column to remove 
uncleaved N-glycosylated forms prior to reload on the cation exchange column. For Con A sepharose 
chromatography, the protein sample was desalted by gel filtration (Hiprep_Desalting column) against 
water, an equal volume of 2x stock Con A binding buffer (40 mM Tris-HC1, pH 7.4, 1 M NaCl) was 
added, and the protein sample was applied to a 5 ml Con A sepharose column (gravity flow) 
equilibrated in the same buffer (lx: 20 mM Tris-HCI, pH 7.4, 0.5 M NaCl). The protein sample was 
loaded, 2 ml at a time, to allow binding of uncleaved N-gylcosylated forms, the column was then 
washed with five column volumes of binding buffer, and absorbance at 280 nm was used to monitor 
the protein content of each 2-ml fraction. Protein yields were in the order of 8 mg per preparation. 
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Figure 3.6: SDS-(10-20%) PAGE analysis of the GABAB Ria complement module pair 
fragments under reducing conditions 
Each lane corresponds to 20 .tg; visualised using the EZ blue stain (Sigma- Coomassie blue 
method). 
Lane 1: FLM-CP12 glycosylated 
- 	Lane 2: FLM-CP12 non glycosylated 
Lane 3: TR-CP12 glycosylated 
Lane 4: TR-CP12 non glycosylated 
Lane 5: WT-CP12 deglycosylated. 
Mass spectrometry analysis revealed four compounds with molecular weight of 16056.6 Da, 
16072.6 Da, 16259.3 Da and 16275.6 Da. The first mass corresponds to the expected mass of the 
WT-CP 12 plus the cloning artefacts (EF) at the N-terminus (expected mass is 16054.14 Da) plus 2.5 
Da. The second compound corresponds to the first one plus an unknown adduct of 16 Da. The third 
compound corresponds to the first one with an adduct of 202.7 Da, which probably corresponds to one 
G1cNAc unit (average mass is 203.2 Da). The last compound corresponds to the second one with an 
adduct of 203 Da, corresponding to one G1cNAc unit. The presence of the cloning artefacts (EF) at 
the N-terminus was confirmed by N-terminal sequencing. 
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The molecular weight found for the first compound is therefore 2.5 Da out when compare to 
the expected weight for the WT-CP12. Although such a difference could account for breakage of one 
disulphide bond, this seems unlikely as in the other fragments the mass analysis indicates all cysteines 
are disulphide bonded. This discrepancy could be the result of protein modification(s) that occur on 
some unidentified residues; one possibilty is deamination of asparagine or glutamine to aspartate or 
glutamate, which in both case account for the again of one Da. The adduct of 16 Da could be 
explained by hydroxylation (of lysine or tryptophan), or more likely by oxidation of methionine. A 
discrepancy of +14-16 Da was also found in the module 1 constructs, where it will be shown that such 
modification is not related to disuphide bond formation (see below). 
3.3.2.2 GABAB  Ria CP single module constructs 
3.3.2.2.1 	CP2 
The GABAB  Ria complement module2 (CP2) corresponds to residues 96-159 in the original 
GABAB  Ria rat protein sequence. The putative "linker" sequence (residue 96-residue 98) was 
included at its N-terminus. The DNA encoding for CP2 was amplified from the truncated module pair 
DNA construct (see Appendix B) and cloned with a similar directional cloning strategy. Yeast 
transformation and large-scale preparations were as described previously. 
CP2 was also purified by cation exchange chromatography. The concentrated protein 
was first desalted against 50 mM sodium acetate, pH 4.6 using gel filtration (PD-10 column), and 
purified by cation exchange chromatography on a 1-ml MonoS column equilibrated in the same 
buffer. Elution was achieved with a gradient of 0-100% 1 M NaC1 in buffer at a low rate of 1 mI/mm 
over 25 column volumes. Protein samples were buffer-exchanged, and concentrated as described 
previously but membranes with a 1 kDa molecular weight cut-off were used for the concentrators. 
Sample was of great purity according to SDS-PAGE analysis (Figure 3.7-a) and mass spectrometry 
(Figure 3.8). 
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Figure 3.7: SDS410-20%) PAGE analysis of GABAB Ria complement module fragments 
under reducing conditions, visualised using the EZ blue stain (Sigma- Coomassie blue 
method) 
:il Lane 1:CP2--15g 
Lane 2: WT-CPI deglycosylated 20 .tg 
Lane 3: WT-CP12 deglycosylated - 2 p.g 
b) 
	
IWIF + 	Lane 1: TR-CP1 glycosylated + non glycosylated forms —40 .tg 
+ 	Lane 2: TR-CPI deglycosylated -- non glycosylated forms - 40 .tg 
96 
stan 1 
ss0225b I (4 220) San (05, 2x1000), TI (500:30000I3Low) 




Expression and purification of recombinant proteins 
Mass spectrometry analysis of some samples revealed a single compound of 7482 Da, a 
molecular weight consistent with the expected molecular weight of CP2 fragment plus the cloning 
artefacts (EAEF) at the N-terminus (expected mass is 7481.42 Da) with all cysteines disulphide 
bonded. In some samples, two additional compounds of 7152 Da and 7005 Da were observed (Figure 
3.8), which correspond to species missing N-terminal residues. The 7152 Da compound is missing 
the three N-terminal residues (expected mass is 7152.11 Da), while the 7005 Da compound is missing 
four N-terminal residues (expected mass is 7004.93). The presence of the cloning artefacts (EAEF) at 
the N-terminus was confirmed by N-terminal sequencing. 
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3.3.2.2.2 	TR-CPI 
The GABAB  RIa "truncated" complement modulel (TR-CPI) corresponds to residues 24-98 
in the original GABAB  Ria rat protein sequence. As for the TR-CP12, the N-terminal seven-residue 
extension is absent but "linker" sequence (residue 96-residue 98) between the two putative CPs is 
included. 
The DNA encoding for the TR-CPI was amplified from the TR-CPI2 DNA construct (see 
Appendix B) and cloned with a similar directional cloning strategy. Yeast transformation and large-
scale preparations were as described previously. Protein purification was similar to the WT-CPI2 
(including deglycosylation), except cation exchange buffers were 25 mM sodium acetate, pH 5.3. 
Membranes with a 3 kDa molecular weight cut-off were used for the concentrators. Sample gave a 
single band by SDS-PAGE analysis (Figure 37-b). 
Three species with masses of 8809 Da, 9011 Da, and 9026 Da were found for the major form. 
These correspond to the expected molecular weight of the truncated modulel plus the cloning 
artefacts (EF) at the N-terminus for the 8809 Da compound (expected mass is 8810.06 Da - cysteines 
oxidised), and the cloning artefacts (EAEF) at the N-terminus for the 9011 Da compound (expected 
mass is 9010.26 Da - cysteines oxidised). These two compounds represent alternatively processed 
products of the a-factor leader sequence. The third compound corresponds to the 9011 Da compound 
with an adduct of 15 Da. The presence of the cloning artefacts (EAEF) at the N-terminus was 
confirmed by N-terminal sequencing. 
3.3.2.2.3 	WT-CP1 
The GABAB  Ria "wild-type" Complement modulel (WT-CPI) corresponds to residues 17-
98 in the original GABAB RI  rat protein sequence. As in the WT-CP12, the seven-residue extension 
with the N-glycosylation consensus motif was included. This construct also contains the entire 
putative "linker" sequence (residue 96 residue 98) between the two predicted modules. 
The DNA encoding WT-CPI was amplified from the WT-CP12 DNA construct (see 
Appendix B) and cloned with a similar directional cloning strategy. Yeast transformation was as 
described previously but the Pichia pastoris KM71 strain was transformed with pPIC9 linearised 
vector before use to avoid the necessity of retransformation for histidine complementation. Methods 
for large-scale preparation and protein purification were similar to those used for the GABAB Ria 
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WT-CPI2. Protein samples were buffer-exchanged against appropriate NMR buffer by several 
rounds of concentrations and dilutions as described previously with 3 kDa molecular weight cut-off 
membranes. The sample gave a single band by SDS-PAGE analysis (Figure 3.7-a). 
Analysis by mass spectrometry revealed three major compounds with molecular weights of 
9453 Da, 9657 Da, and 9860 Da (Figure 3.9). The first species corresponds to the expected molecular 
weight of the WT-CPI (cysteines oxidised) plus the cloning artefacts (EF) at the N-terminus 
(expected mass is 9435.7 Da), and an adduct of 17.3 Da. The second compound correspond to the 
first one plus an adduct of 204 Da, which corresponds to one GIcNAc unit (average mass is 203.2 
Da). The last compound correspond to the second one with an adduct of 203 Da, corresponding to a 
second G!cNAc unit.The discrepancy of 17.3 Da in the first species is close to 18 Da, and could 
correspond to hydrolysis of a peptide bond with the resulting fragments held together by a disulphide 
bond, for example. This hypothesis can be ruled out from experiments shown in section 3.3.2.2.4, 
and it is more likely to correspond to an adduct of 16 Da as seen in the module pair constructs, since 
mass spectrometer calibration can be out by 1 Da. The presence of the cloning artefacts (EF) at the 
N-terminus was confirmed by N-terminal sequencing. 
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Figure 3.9: Mass spectrum of WT-CP1 
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3.3.2.2.4 	Disulphide bond pattern in the GABAB Ria CP1 constructs 
3.3.2.2.4.1 	Deduction of the number of disulphide bonds by reduction and 
carboxymethylation 
The discrepancies in the mass analysis of the CPI constructs raise the question of proper 
disulphide bond formation, and correct chain length. Reduction of disulphide bonds using DTT and 
subsequent carboxymethylation of free cysteines by neutralised iodoacetic acid allows deduction of 
disulphide bonds in protein, and identification disulphide bonded proteolytic fragments. 
A sample of WT-CPI (100 p.g in 100 j.il of 0.5 M Tris-HCI, pH 8.6, 5 mM EDTA, and 8 M 
urea), was reduced with 10 mM DTT for 2 h at 40°C under N2. A second sample of WT-CPI that has 
been denatured and reduced as above was further carboxymethylated with neutralised-iodoacetic acid 
(1.44 M stock in 1 M NaOH solution-final concentration was 40 mM) for 15-30 min at room 
temperature in the dark. In parallel, a third sample of WT-CPI (100 jig in 100 jtl of sterile distilled 
water) was carboxymethylated with neutralised iodoacetic acid under the same conditions as above 
but without prior denaturation or reduction. Finally, a fourth sample, in water, was reduced with DTT 
as above. 
All four samples: denatured-reduced, denatured-reduced-carboxymethylated, carboxymethylated only, 
and reduced only were analysed by liquid chromatography mass spectrometry (LCMS). The resulting 
mass spectra are shown in Figure 3.10 and Figure 3.11. 
Figure 3.10-a shows the mass spectrum of the reduced only form - some mass changes can be 
observed when compared to the original mass spectrum shown in section 3.3.2.2.3. The three species 
previously observed were 9453 Da, 9657 Da, and 9860 Da. After reduction with DTT, masses for the 
same sample are 9452 Da, 9655 Da, and 9858 Da. The apparent decrease of 1-2 Da observed for each 
species must correspond to the reduction of at least one disulphide bond, although the expected mass 
difference for complete reduction is 4 Da. Once "denatured and reduced" (Figure 3.10-b), all three 
species showed an adduct of 3-4 Da when compared to the reduced-only species (9455 Da, 9659 Da, 
and 9862 Da), which is consistent with the reduction of one or both disulphide bonds. It seems 
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Figure 3.10: LCMS of WT-CP1 
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Interestingly a discrepancy of 4-5 Da is observed between the species from the carboxymethylated-
only control sample (9451 Da, 9654 Da, and 9858 Da; Figure 3.1 1-A) and the respective species from 
the "denatured and reduced" sample. This is consistent with the complete reduction of both 
disulphide bonds under the latter conditions. No smaller fragments were observed following 
disulphide reduction, which implies that the peptide chain of the WT-CPI is intact. 
Figure 3.1 1-a show the mass spectrum of the carboxyrnethylated-only form; no significant 
mass changes can be observed when compared to the original mass spectrum shown in section 
3.3.2.2.3. Following carboxymethylation, but without disulphide reduction, peaks at 9451 Da, 9654 
Da, and 9858 Da are obtained. The apparent decrease of 2-3 Da observed for each species is of 
unknown origin but may well arise from calibration error between the two experiments; but 
interestingly, this time, lead to an adduct of 15.3 Da instead of 17.3 Da when comparing the first 
species of the carboxyrnethylated-only to the expected mass (9435.7 Da - cysteines oxidised). 
Carboxymethylation by iodoacetic acid is expected to occur specifically on free thiol groups, although 
side-reactions involving tyrosine, tryptophan and histidine have been reported . This type of 
modification introduces a CI-I2COOH group on free thiol, which would result in an adduct of 58 Da. 
No adduct of 58 Da can be detected on any of the three species and therefore it can be deduced that no 
free thiol groups are exposed in the native WT-CPI. Once denatured-reduced, and carboxymethylated 
(Figure 3.11-b), each of the three species originally observed in the carboxymethylated-only sample 
showed an adduct of 237-235 Da. Such adducts correspond closely to four times the expected 58 Da 
adduct. It can therefore be deduced from this last experiment and from the previous one that both 
disulphide bonds are formed in native WT-CPI, and the polypeptide chain is intact. This implies that 
the adduct of 15-17 Da observed in the WT-CPI is not due to peptide cleavage, which, anyway, 
would add 18 Da. The adduct is most likely a result of methionine oxidation (only one methionine in 
the CP1 amino-acid sequence), or lysine hydroxylation. 
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3.3.2.2.4.2 	Endoproteases digestions and their fragments analysis by Q-TOF Mass 
spectroscopy 
Two types of endoproteases were used: Trypsin and S. aureus V8 Protease. Digestions and 
mass spectrometry analysis on Q-TOF (Quadrupole Time Of Flight) mass spectrometer were 
performed by Dr. Adam Gouldsworthy (Edinburgh University). Digests were performed on the TR-
CPI construct. Only trypsin digestion was successful, and this clearly identified the presence of the 
disulphide bond involving cysteine II (Cys130) and IV (Cys156). Most of the fragments were from 
non-specific cleavage reactions and were identified by their amino acids sequences. Some of these 
fragments are shown in Table 3.1. 
Table 3.1 
Fragment mass (Da) from Trypsin Corresponding amino acid sequence & observed sequence 
digest (cut after R&K) (underlined) 
1159.63 (IM+2H12 ) (K)AINFLPVDYEIEYVCR(G) + (R)CVR(I) 
674.01 (IM+3H13) (N)FLPVDYEIEYVCR(G) + (R)CVR(I) 
643.31 (IM+2H12 ) (Y)EIEYVCR(G) + (R)CVR(I) 
Taken together, denaturation/reduction - carboxymethylation experiments and endoprotease 
digestions strongly suggest the presence two disulphide bonds for the GABAB Ria CPI. Cysteines II 
and IV are paired as expected, which obviously implies a cysteine I and III pairing. Consequently, it 
can be concluded that the disulphide bond found in the CPI constructs are as expected for a CP 
module. Carboxymethylation experiments were also performed on WT-CP12, and confirmed the 
absence of free cysteines, the presence of four disulphide bonds and an adduct of 16 Da (data not 
shown). 
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3.3.2.3 Fibulin-2 constructs 
The recombinant expression of flbulin-2 fragments identified from yeast-two-hybrid (YTH) screens 
(see chapter one) was undertaken to provide material for both structural and binding studies. DNA 
coding for different the fibulin-2 constructs were designed on the basis YTH results and their 
subsequent cloning in a Pichia pastoris expression vector was performed by Dr. Julia White 
(GlaxoSmithKline - Stevenage - UK). All DNA constructs (Figure 3.12) were cloned in a modified 
version of the commercially available vector pPICZc A vector from Invitrogen. It allows fusion of 
the targeted protein fragment with a c-myc epitope tag and a hexahistine tag, but was engineered in 
our laboratory (Dr. Nick Mullin and Andrew Herbert - unpublished) to include a thrombin-specific 
cleavage site to allow their subsequent removal. 
EGFs—FTM2: 27.6 kDa 
b0c, 	
MW=31 kDa 
EGF-8-10: 14.8 kDa 
4 
MW=18.2 kDa 
FTM2: 13.3 kDa 
IIIIIIIII " 	
MW= 16.7 kDa 
3.4 kDa 
Keys: 
E 	fibulin-type domain 
o EGF like module 	his tag 
thrombin cleavage site 
' 	N-Glycosylation site - c-myc epitope 
Figure 3.12: Fibulin-2 constructs in Pichia pasloris 
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3.3.2.3.1 	Fibulin-2 EGF like repeats 8-10 and fibulin type module 
The fibulin-2 epidermal growth factor like repeats 8-10 and fibulin-type module 
(EGFsFTM2) construct correspond to the C-terminal end of fibulin-2 (Swiss Prot accession number 
P98095), and more specifically to residues 942-1184 in the original fibulin-2 human protein 
sequence (numbering includes the protein signal sequence). This fragment of fibulin-2 contains three 
consensus sequences for epidermal growth factor like modules (residues 942-1072) and the recently 
identified fibulin-type module (residues 1069-1184) shared with fibrillins. One N-glycosylation site 
is found at position Asn 1035 in the third putative EGF like module. 
The DNA encoding for EGFs'FTM2 was cloned in the modified pPICZa A vector. The 
resulting plasmid was then linearised (Sad) and yeast was transformed as described for the GABAB  
Rla fragments. Transformation yielded to a large number of transformants, and -30 were screened in 
induction tests with Endo Hf  treatment prior to SDS-PAGE analysis. All failed to show any 
expression of the recombinant fragment. Subsequently, some transformants were grown and induced 
on a larger scale (100 ml BMG, 20 ml BMM); then their supernatant was concentrated, and treated 
with Endo Hf. Again no expression could by detected by SDS-PAGE (Figure 3.13), or by Western 
blot (anti-His6 antibodies, not shown). 
The reason for the lack or the very low expression of EGFsFTM2 is unknown. A large 
number of transformants were present, and other protein constructs (that later were found to express 
protein) were transformed using the same P. pastoris preparation, thus providing a control for the 
transformation. Cell pellets were also assayed by Western blotting (anti-His6 antibodies-not shown), 
but also failed to show any expression. Interestingly a faint band at 25 kDa is present in the SDS-
PAGE analysis from the larger scale preparation mentioned above, and could represent either a host 
protein or alternatively EGFsFTM2 free from the c-myc epitope and His6 tag; which therefore could 
account for the lack of detection by Western blotting. Time didn't allow further investigation of such 
a possibility, nor further characterisation of the EGFsFTM2 yeast clone(s). Western blotting with 
anti c-myc antibodies as well as PCR analysis to check construct integration into P. pastoris genome 
could be the focus of future work. However, expression in P. pastoris is not always successful, and 
there is 50-75% chance of expressing a protein in P. pastoris [161]. One explaination for no 
expression in P. pastoris is premature transcriptional termination - AT base repeats present in the 
DNA construct might ressemble the consensus sequence for such a transcriptional termination [161]. 
However, no such a sequence can be readily identify in the DNA coding for EGFsFTM2. 
106 
Expression and pur?flcation  of recombinant proteins 
EGFs-FTM2: 27.6 kDa 	




62 pow bo( - -4 End oH1  E 
32.5 




Figure 3.13: Expression tests of the EGFs-FTM2 construct 
Two clones were grown (100 ml BMG) for two days, then harvested and induced for 5 days (20 ml 
BMM, 0.5% methanol daily). Supernatants were concentrated to a final volume of 2 ml using 5 kDa 
molecular cut-off concentrators. For each clone, one ml of supernatant was treated with Endo Hf, 
analysed by SDS- 15% PAGE under reducing conditions, and visualized using the Coomassie blue 
method. Lane I is clone #10, and lane 2 is clone #12. 
Note: cartoons legend as in Figure 3.12 
3.3.2.3.2 	Fibulin-2 epidermal growth factor like repeats 8-10 
The fibulin-2 epidermal growth factor like repeats 8-10 (EGF-8- 10) construct (residues 942-
1072) was transformed as described in the case of the GABAB RI  fragments. All transformants were 
shown to express the fragment at a good yield (Figure 3.14-a). The fragment was heavily 
glycosylated, and couldn't been detected without prior Endo Hf treatment. This could be the result of 
heterogeneous hyper-glycosylation combined with the low susceptibility of glycosylated protein to 
TCA precipitation. Figure 3.14-a also illustrates clonal variation, i.e. how the level of recombinant 
protein production differs from one clone to another. Such variation arises from multiple insertion of 
the DNA construct encoding for EGF-8- 10. Large-scale preparation of the EGF-8-1 0 construct was 
as described in the case of the GABAB Rla fragments. After induction, the culture supernatant was 
concentrated to 20 ml by ultra-filtration using 3-5 kDa molecular weight cut-off membranes, and 
Endo H1  treated (6h, 37Q. 
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The protein concentrate was then desalted against 20 mM sodium phosphate, pH 7.4, 0.5 M 
NaCl using gel filtration (PD- 10column), and purified by immobilized metal affinity chromatography 
(Figure 3.14-b) on a HiTrap metal chelating column (I ml) charged with nickel and equilibrated in the 
same buffer. Elution was achieved with a 0-100% 0.5 M imidazole gradient in buffer over 25 column 
volumes. Sample was of good purity according to SDS-PAGE analysis, and 8 mg were buffer-
exchanged against IxPBS buffer, concentrated with concentrators of a 5 kDa molecular weight cut-off 
membrane, and submitted for antibody-production to our collaborator, Dr. Jeffrey Mcllhinney (Oxford 
University-MRC Neuro-anatomy Unit). However protein characterisation was proven difficult, as the 
EGF-8-10 construct failed to be seen by mass spectrometry despite repeated attempts. Finally N-
terminal sequencing reveal the expected N-terminal sequence (first eight residues with the cloning 
artefacts EF). 
3.3.2.3.3 	Fibulin-type module from fibulin-2 
The fibulin-type module from fibulin-2 (FTM2), residues 1069-1184, was transformed as described 
for the EGFs--FTM2 construct. Induction tests failed to show any recombinant expression, and larger 
scale growths also failed. Nevertheless, tags used for protein detection are putatively removable and it 
was hypothesised that a combination of proteolytic degradation and low expression level might 
account for the lack of detection by Western blot. Consequently, a fermentor was used to provide 
larger quantities of material. 
A positive yeast transformant for the FTM2 was grown in a benchtop fermentor (BIOFLO 3000- New 
Brunswick scientific). The fermentation followed a standard protocol (2 1), including a glycerol batch 
feed (11 of 50% glycerol) and a methanol batch feed for induction (100 h). Fermentation samples 
were taken every 24 h. None of these sample contained material for a direct visualisation of FTM2 
overexpression. After completion, the fermentation supernatant (3 1) was concentrated to 20 ml. 
Overexpression was still undetectable. In an attempt to isolate any small amount of protein that could 
have been produced, the concentrated supernatant was fractionated using a different type of 
chromatography (not shown). The FTM2 construct includes a fused hexa-histidine tag, therefore 
nickel affinity chromatography was used to try to isolate some protein, but only host proteins were 
found in the bound fraction. Cation exchange chromatography allowed isolation of a protein that 
could correspond to the fibulin type module construct free of tags but N-terminal sequencing revealed 
the sequence of a host protein. 
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Figure 3.14: Expression of the EGFs-'FTM2 construct and EGF-8-10 
Expression tests of the EGF-8-10 construct: three clones (I-Ill) were analysed by SDS-15% 
PAGE under reducing conditions, and visualized using the Coomassie blue method. For each 
clone, lane 1 corresponds to the crude supernatant and lane 2 corresponds to the same crude 
supernatant pre-treated with Endo Hf. Each lane is one ml of the expression test supernatant 
TCA-precipitated. 
Nickel-affinity chromatogram of the large-scale preparation of the EFG-8- 10 construct (red: 
buffer, blue: eluent). Also shown is the SDS-15% PAGE analysis under reducing conditions of 
the major peak from the nickel-affinity chromatography (fraction 23 mm, one ml fraction were 
collected every minute). 100 .d of fraction 23 was TCA-precipitated. Gel was SDS-15%, and 
visualised using the Coomassie blue method. 
Note: cartoons legend as in Figure 3.12 
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3.3.3 Bacterial expression 
The lack of expression of the FTM2 in yeast led to the investigation of alternative hosts. The 
FTM2 (residues 1069-1184) was therefore cloned into prokaryotic expression vectors to allow 
recombinant expression in E. coli. As mentioned above, successful recombinant protein expression in 
E. coli is frequently achieved in the case of cytosolic proteins. However, extracellular proteins often 
accumulate as inclusion bodies. The FTM2 was expressed in various pET systems; only when fused to 
a thioredoxin solubility tag was the protein fragment recovered in a soluble form. 
3.3.3.1 Fibulin-type module from tibulin-2 as inclusion bodies 
Cloning of the FTM2 in pET15b (Novagen; Figure 3.15) results in fusion with a hexa-N- 
terminal histidine tag (Figure 3.16). 	This allows the use of immobilized-metal affinity 
chromatography for downstream purification of the recombinant protein. This tag is cleavable by use 
of a specific protease, thrombin. The DNA construct encoding for the FTM2 in the pPICZcx A-
derived vector mentioned above was used as a PCR template. The 5' primer (see appendix B) 
contained an NdeI site. The 3' primer contained an XhoI site. Cloning of the PCR product in pETl5b 
was performed as described previously, in a non-inducible E. coli strain (TOPIO). For protein 
production, BL2I(DE3) chemically competent cells were transformed with the FTM2-pET15b 
according to Novagen's protocol. Small-scale expression tests and large-scale growth for protein 
production were as described previously. 
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Figure 3.15: pETlSb vector from Novagen 
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Figure 3.16: Overview of the E. coil expression 
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After 4 h of induction (1 mM IPTG), cells were harvested by centrifugation (6500 g, 4°C, 15 
mm), washed in PBS, and centrifuged again. The cell pellet was typically 3.6 g per litre of growth 
medium. Cell extract was prepared by use of the Bug Buster reagent (28 ml, Bug Buster is a mild 
detergent from Novagen) and benzonase (700 units), incubated for 20 min on a rocking platform at 
room temperature with protease-inhibitors ("Complete Protease inhibitor cocktail tablets without 
EDTA" from Roche), and centrifuged at 16,000 g for 20 min at 4°C. Inclusion bodies were prepared 
by resuspending the cell pellet in Bug Buster reagent (28 ml) supplemented with lysozyme (200 
tg/ml), incubated at room temperature for 5 min with proteases inhibitors, and centrifuged at 16,000 g 
for 20 min at 4°C. The cell pellet was further washed with 120 ml of 1:10 diluted Bug Buster reagent 
with protease-inhibitors (in deionized water), vortexed for 1 mm, and centrifuged at 16,000 g for 20 
min at 4°C. This step was repeated a second time with only 40 ml of 1:10 diluted Bug Buster reagent. 
Inclusion bodies were solubilized in 20 ml of 20 mM sodium phosphate (pH 7.4), 0.5 M NaCI, 6 M 
guanidine hydrocloride (GdnHCI), and 5 mM 3-mercaptoethanol (I3ME). Finally, the preparation of 
the inclusion bodies was clarified by centrifugation at 20,000 g for 20 mm (4°C) and the supernatant 
was filtered through a 0.2 gm syringe filter. 
The His-tagged protein solubilised from inclusion bodies was purified on a self-packed 2 ml 
immobilized-metal affinity column charged with nickel (Novagen) and equilibrated in 20 mM sodium 
phosphate-pH 7.4, 0.5 M NaCl, 6 M GdnHCI, and 5 mM 13MB (equilibration buffer). The column 
was operated under gravity flow at 4°C. The preparation of inclusion bodies was loaded in 10 ml 
aliquots, and the column was washed with 20 ml of equilibration buffer applied in 4 batches of 5 ml. 
Elution was achieved by an imidazole concentration step-gradient. Each step was 5 ml of 
equilibration buffer supplemented with increasing concentration of imidazole, as follows: 10, 20, 30, 
50, 80, 90, 100, 500 mM and 1 M. Most of the protein was recovered in the 30-90 mM imidazole 
fractions (Figure 3.17). These fractions were enriched in FTM2 when analysed by SDS-PAGE, 
although all showed contamination, with smaller fragments and a higher molecular weight host 
protein (-30 kDa). Further analysis by Western blotting using anti-His6 antibodies suggested that 
some of the smaller fragments came from proteolytic degradation of the FTM2 at its C-terminus. 
Interestingly, the amount of recombinant protein recovered from large-scale growths was far 
smaller than expected from the amount observed in small-scale expression tests. The use of 
denaturing conditions, along with the use of proteases inhibitors throughout purification (although 
EDTA was not employed), led to speculation that degradation might have occurred during cell 
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growth. Thus, this construct was not pursed, and use of the thioredoxin solubility tag was 
investigated. 
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Figure 3.17: FTM2-pET15b purification by immobffised-Ni2 affinity chromatography 
Lane 1: inclusion bodies extract (10 l from a 10 ml fraction). Lane 2: unbound fraction (10 .d from a 
10 ml fraction). Lane 3: as lane 1. Lane 4: as lane 2. Lane 5-8: buffer wash fraction, 50 i.tl were TCA 
precipitated from a 5 ml fraction. Lane 9-17: imidazole step gradient in buffer-10, 20, 30, 50, 80, 90, 
100, 500 mM and I M imidazole-each lane, each lane is 50 tl TCA precipitated from a 5 ml fraction. 
Gel is 10-20% SDS Tris-HC1 (reducing conditions), and visualized using the Coomassie blue method. 
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3.3.3.2 Fibulin-type module from fibulin-2 expressed as fusion proteins to enhance 
solubility 
3.3.3.2.1 	pET32a(+) construct 
The DNA insert encoding for FTM2 with a 5' NcoI and a 3' Xhol restriction site was excised 
from the YTH vector (pACT2-Clontech) provided by Dr. Julia White. The insert was further ligated 
in the pET32a(+) vector (Novagen; Figure 3.18) previously digested by the same restriction enzymes. 
The resulting construct was named FTM2-pET32a(+). 
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Figure 3.18: pET32a(+) vector from Novagen 
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Figure 3.19: FTM2-pET32a induction test 
Lane 1: E. co/i BL2 1 (DE3) -control-insoluble fraction. Lane 2: same as lane 1-soluble fraction. Lane 
E. co/i BL2 1 (DE3)-transformed with the FTM2-pET32a(+) non induced- insoluble fraction. Lane 
same as lane 3 but induced- insoluble fraction. Lane 5: same as lane 3 but non induced- soluble 
fraction. Lane 6: same as lane 3 but induced- soluble fraction. Gel is 10-20% SDS Tris-HCl 
(reducing conditions), and visualized using the Coomassie blue method. Test and sample load 
according to section 3.2.2.1 
Induction tests and large-scale growth were as described for the pET1 5b construct. When fused to 
thioredoxin (Tdx), the FTM2 is expressed as a soluble protein, and to a high level (Figure 3.19). The 
FTM2 fused to thioredoxin (FTM2-pET32a(+) is 30 kDa) was purified by immobilized Ni2taffinity 
chromatography. Several large-scale preparations were made with 4 h of induction (1 mM IPTG), and 
cell pellets were between 3-4 g. Soluble extracts were prepared by use of the Bug Buster reagent as 
described previously. Elution was achieved by imidazole step gradient: 10, 20, 30, 40, 50, 80, 90, 
100, 150, 200, 300, 500 mM and 1 M imidazole in equilibration buffer, as in purification of the 
pET1 Sb construct. Most of the fusion protein was recovered in the 50-90 mM imidazole fractions, 
and gave a single band by SDS-PAGE analysis (Figure 3.20-a). 
These fractions were pooled and desalted against different buffers by dialysis or ultrafiltration 
(pressure cell). Desalting against enterokinase cleavage buffer (20 mM Tris-HCl - pH 7.4, 50 mM 
NaCl, 2 mM CaC12) and thrombin buffer (20 mM Tris-HCl - pH 8.4, 150 mM NaCl, 2.5 mM CaC12) 
is necessary to release the FTM2 from Tdx. In both cases, however, desalting against these buffers 
resulted in protein precipitation, with only a small proportion of the protein preparation recoverable. 
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Cleavage with enterokinase (25 units in 5 ml-24 h at 20°C) led to further protein precipitation during 
incubation, and to non-specific digestion products. Thrombin cleavage (12 units in 5 ml - 24 h at 
20°C) led to the expected products: the total fusion protein has a predicted molecular weight of 30.8 
kDa, which after cleavage lead to two distinct fragments of 14 kDa and -16.5 kDa. The smallest 
corresponds to the Tdx with a His6 tag, while the largest corresponds to the FTM2 with an extra 
streptavidin-affinity tag (S-tag) and an enterokinase cleavage site (Figure 3.20-b). 
After cleavage, the mixture was diluted in the immobilized-Ni2 affinity 
chromatography equilibration buffer (20 ml) and re-loaded on a Ni -column that had been pre-
equilibrated in the same buffer. The column was then washed with 5 ml of buffer, and elution of the 
bound protein was achieved with a five-step imidazole gradient (10, 20, 30, 50, 100 mM - each time 5 
ml). Fractions were analysed by SDS-PAGE. The FTM2 was found in the unbound and wash 
fractions, while Tdx was found mainly in the 30-100 mM fractions (Figure 3.20-c). Both unbound 
and bound fractions eluting at 50 mM imidazole were analysed by Western blotting with anti-His6 
antibodies (Figure 3.20-d) 
Overall only a small quantity of FTM2 was recovered, and subsequent investigations such as 
refolding or biophysical characterisation were impossible. Moreover, cleavage of the fusion protein 
with thrombin results in the FTM2 still fused to an S-tag, an affinity tag that would certainly interfere 
with antibody-production and possibly with refolding. 
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Figure 3.20: Purification of the FTM2-pET32a(+) construct 
SDS-15% PAGE analysis under reducing conditions of the FTM2-pET32a(+) construct (30.8 
kDa) before thrombin cleavage - 100 0 were TCA precipitated from a 5 ml fraction. Gel 
visualized using the Coomassie blue method. 
SDS-1 5% PAGE analysis under reducing conditions of the FTM2 (16.7 kDa with tags) and 
Tdx (14.1 kDa) free products from thrombin cleavage - 300 41 were TCA precipitated from a 
5 ml fraction. Gel visualized using the Coomassie blue method. 
C) 	SDS-15% PAGE analysis under reducing conditions of the cleavage products after reload of 
(b) on nickel-affinity resin. Lane 1 is the unbound fraction, and lane 2 is the bound fraction 
eluted with 50 mM imidazole; each time, 1 ml was TCA precipitated from a 20 ml fraction 
(lane 1) and from a 5 ml fraction (lane 2). Gel visualized using the Coomassie blue method. 
d) 	Western blot of (c) using anti-His6 antibodies (membrane staining as described in section 
3.2.3.3). 
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3.3.3.2.2 	pET1532 construct 
Complete removal of affinity tags was thought to be achieved by enterokinase cleavage in the 
pET32 construct, as such cleavage was found to be non-specific (above), a strategy based on 
compatible restriction sites between the FTM-pETl5b and pET32a(+) vectors (Figure 3.15 and 3.18) 
was used to introduce a thrombin site prior to the FTM2 sequence (Figure 3.16). This approach was 
developed to avoid further PCR engineering of the FTM2 DNA coding sequence; also the presence of 
an extra His6 tag was found to improve one-step purification of the fusion protein. 
The DNA encoding for the FTM2 fused (at its N-terminus) to a thrombin cleavage sequence 
and a His6 tag was obtained by digesting the FTM2-pET5b plasmid using NcoI and XhoI restriction 
sites. This insert was then ligated in the pET32a(+) vector previously digested with same restriction 
enzymes. The resulting construct was named FTM2-pET1 532. 
Large-scale preparations and one step purification of the fusion protein by immobilised-
nickel affinity chromatography were as described for the FTM2-pET32a(+) construct. Fusion protein 
eluted at 100-250 mM imidazole, but mainly between 150 and 200 mM. This increase in binding 
illustrates the utility of the second His6 tag. The fusion protein was processed as described above. 
Despite extensive protein precipitation during desalting and concentration; some protein was 
recovered (Figure 3.21). Use of biotinylated thrombin allowed its removal after cleavage by 
streptavidin agarose (Thrombin cleavage/capture kit, Novagen). Fractions seen in Lane 3, 4 and 5 in 
Figure 3.21 were pooled, concentrated and submitted for antibody-production to Dr. Jeffrey 
Mcllhinney. 
Diverse approaches were tested to minimise or recover some of the precipitate. One 
approach was to concentrate the fusion protein against a weak denaturing buffer to prevent protein 
precipitation. Fractions from Ni2taffinity chromatography were concentrated and desalted with 10 
mM Tris-HC1, pH 8, 3 M urea, to a volume of 4.5 ml. The protein was then diluted once with 10 
mM Tris-HC1, pH 8, to give a final concentration of 1.5 M urea. One ml of lOx thrombin cleavage 
buffer was added to the 9 ml, and cleavage was performed as described previously but with 50 
thrombin units. After cleavage the protein was diluted to 20 ml of equilibration buffer containing 6 
M urea and 10 mM reduced glutathione (GSH), and Ni2 -affinity chromatography was performed 
under the same denaturing and reducing conditions (Figure 3.22). 
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Figure 3.21: Purification of the FTM2-pET1532 construct under native conditions 
Lane 1: unbound fraction - 200 .tl were TCA precipitated from a 10 ml fraction. Lane 2: 
buffer wash fraction - 200 Ml  were TCA precipitated from a 5 ml fraction. Lane 3-8: 
imidazole step gradient in buffer-10, 20, 30, 50, 100, 500 mM imidazole- each lane is 200 .tl 
TCA precipitated from a 5 ml fraction. Gel is 10-20% SDS Tris-HC1 (reducing conditions), 
and visualized using the Coomassie blue method. 
Western blot of lanes 3-7 from (a) using anti-His6 antibodies (membrane staining as described 
in section 3.2.3.3). 
Surprisingly, some unc leaved fusion protein was found in the unbound fraction, wash and early 
gradient fractions along with the FTM2; while Tdx bound to the column and eluted later in the 
gradient as shown by Western blotting (anti-His6 antibodies; Figure 3.22). One explanation is that 
thrombin cleavage under denaturing conditions is less efficient, thus leading to a significant amount of 
uncleaved fusion protein, which in this preparation did not totally bind onto the Ni2 affinity resin. 
However, it will be possible to isolate 2-3 mg of FTM2 by adding a gel-filtration step to this last 
approach. This could then enable antibody-production. 
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Figure 3.22: Purification of FTM2-pET1532 construct under denaturing conditions 
Lane 1: unbound fraction -100 .t1 were TCA precipitated from a 10 ml fraction. Lane 2-9: 
imidazole step gradient in buffer-20, 40, 60, 80, 100, 150, 200, 500 mM imidazole- 6 M urea, 
10 mM GSH- each lane is 501.tl TCA precipitated from a one ml fraction. Gel is 10-20% SDS 
Tris-HC1 (reducing conditions), and visualized using the Coomassie blue method. 




CHAPTER FOUR: BIOPHYSICAL STUDIES OF RECOMBINANT PROTEINS 
4.1 	Nuclear Magnetic Resonance spectroscopy studies 
The GABAB  Ria CP fragments investigated in the current study were presented in chapter 
three, and their order of appearance was related chronologically to the iterative process that took place 
between the protein production phase of this work and its goal -NMR spectroscopy. This chapter 
presents the NMR characterization of these fragments along with the hypotheses regarding the folding 
of the CP modules formulated during the course of this study. 
'H-15N HSQC spectra provide a powerful tool with which to investigate protein folding. In 
such spectra, resonances arise from correlations between nitrogen nuclei and their attached protons. 
Therefore these spectra constitute "protein fingerprints" with one cross-peak for each non-proline 
residue in the molecule. Good chemical shift dispersion is characteristic of well-folded proteins. 
Figure 4.1 shows the 1 H-15N HSQC spectrum ofTR-CP12. The spectrum displays 114 cross-peaks of 
different intensities (count exclude side chain NH2  from On or Asn residues, and NHe1 from Trp 
residues). TR-CPI2 contains 136 residues plus four extra residues, which are cloning artifacts. TR-
CPI is predicted to contain 72 residues, while CP2 is predicted to consist of 61 amino acids, and there 
is a three-residue linker between the two modules; there are also 9 proline residues. Thus, the number 
of cross-peaks found in the 'H-'5N HSQC spectrum of TR-CPI2 is close to the number of cross-peaks 
that one would expect for two folded modules. However in 2D-1H and 313-15N edited TOCSY 
experiments only few cross-peaks were detected (Figure 4.2). 
Missing cross-peaks in protein TOCSY spectra can arise from severe line broadening and this 
may be due to several factors: aggregation leads to multimers that have shorter T2 values than the 
monomeric form and in general result in line broadening; conformational fluctuations on an 
intermediate time scale results in line broadening; amides in intermediate exchange with water can 
also be a cause of line broadening. Aggregation is often a problem in protein NMR because samples 
must be at 0.5 - 1.5 mM concentration (in standard probes) to achieve adequate signal-to-noise ratios. 
The correct choice of temperature, pH, buffer type, and ionic strength may help to reduce some of the 
factors that contribute to line broadening. 
Several samples of the TR-CP12 were produced and tested in various conditions of 
temperature (12-37°C), pH (Figure 4.3), and buffers (Tris buffer, acetate buffer, phosphate buffer). 
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Two types of detergents, 3-[(3 -Cholamidopropyl)dimethylammonio]- 1 -propanesulfonate (CHAPS) 
(5-25 mM) and 8,octyl-J3-D-gluco-pyranosicle (5-20 mM) were used. Additions of glycerol (5-10%) 
or increasing concentrations of sodium chloride (up to 500 mM), and addition of GABA (up to 6 
mM), or Ca 2+  (up to 20 mM) were also tested. In addition to inspection of TOCSY experiments, one-
dimensional '5N T2  measurements [164] were used to monitor the effects of these conditions. 15N T2 
values were estimated from ID 'H-'5N HSQC spectra recorded with different relaxation delays, and 
enabled an estimate of the mean '5N T2  value for the ensemble of residues (Figure 4.4). Best 
conditions for the TR-CP12 were established as 20 mM sodium actetate, pH 4, at 37°C, which yielded 
a mean '5N T2  of 78 ms (0.6 mM). This value is shorter than the one observed for another CP module 
pair; the '5N T2  of VCP23 were approximately 100-110 ms. On the other hand the TR-CP12 mean T2 
value was not much lower than that of the CRI-15-16 pair, which exhibited values of around 85-90 
ms. A doubling of the protein concentration (1.2 mM) resulted in a 10 ms decrease of the mean '5N T2 
value, suggesting that the protein is prone to aggregation (not shown). Nevertheless, the quality of the 
2D-'H and 3D-'5N edited TOCSY experiments ofTR-CPI2 did not improve and it was concluded that 
beside a possible aggregation problem, a protein folding issue could be responsible for the 
shortcomings of the TOCSY spectra. 
N-glycosylation can have a profound effect on protein folding. Some proteins have been 
found to fold properly only when correct glycans were attached onto the polypeptide chain [165, 166]. 
An NMR study of the adhesion domain of the human CD2 [167], a cell surface glycoprotein found 
lymphocytes, revealed that interactions between specific residues and the N-glycan were essential for 
proper folding of the molecule. Strikingly, only the first two GlcNac units from the sugar moiety 
were involved in these contacts. In our laboratory, Dr Joanne O'Leary reported that mutation of the 
N-glycosylation consensus sequence in the membrane cofactor protein CP module 1 altered its folding 
(Dr Joanne O'Leary- PhD thesis). Consequently a sample of the glycoform of TR-CP12 was prepared 
(see chapter three) and investigated by NMR. Some differences can be observed from a direct 
comparison of the two 1 H-15N HSQC spectra (Figure 4.6). Six to eight extra cross-peaks can be 
observed, some cross-peaks observed in the non-glycoform are shifted or became more intense, and 
two other cross-peaks disappeared (in the region 117 ppm in '5N and-7.5 ppm in 'H). These 
differences are, however, difficult to interpret. Some cross-peaks might be shifted simply because of 
the presence of the N-glycan rather than because of a change in folding, also it worth noting that this 
sample is slightly more concentrated. However the mean '5N T2  value of the glycosylated form was 
similar to the non-glycosylated form of TR-CP 12 (83 ms) and the quality of TOCSY experiments did 
not significally improved. 
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The presence of the seven-residue extension at the beginning of CP 1 might be of importance 
in terms of protein folding. In the case of the immunoglobulin-type domains of titin, a large multiple 
modular muscle protein, the amino-terminal extension (six residues) was found to have a profound 
effect on protein stability [168, 169]. The 'H-'5N HSQC spectrum of the GABAB R1a-"full-length 
and mutated to remove N-glycosylation site 1" CP12 (FLM-CP12) construct did not, however, 
support this hypothesis; only a few extra sharp cross-peaks can be observed when compared to the 
truncated version (Figure 4.6), and no significant improvement in the quality of the TOCSY 
experiments was observed from this construct. Unfolded residues are characterised by sharp 
resonances, and from this observation it can be speculated that the N-terminal extension is unfolded. 
At this stage of the study, the choice could have been to attempt assignment of TR-
CPI2 using triple resonance experiments. An important motivation for working with the module pair 
rather than the single modules was to elucidate details of the intermodular orientation. This depends 
upon a full assignment of residues near the junction between modules, and the observation of critical 
intermodular NOEs. However, on the basis of the overall quality of the HSQC, and the lack of signals 
in 2D-'H and 3D-'5N TOCSY spectra, it was judged unlikely that this sample would yield sufficient 
NMR data for a useful structure determination. It was therefore decided that investigation of 
individual modules should be the next step, with the possibility of returning to the double module at a 
future date. Single module constructs were therefore produced to investigate the folding of individual 
modules (Figure 4.7). 
The 'H-'5N HSQC spectrum of the CP2 (Figure 4.7) exhibits a good chemical shift dispersion 
characteristic of a well-folded domain. Surprisingly, there are more cross-peaks in the spectrum than 
expected - 86 peaks (count excludes the region containing side-chain resonances of Asn, Gin, and 
Trp) can be found instead of the 64 expected. It was concluded that CP2 has more than one 
conformation in solution, with the extra cross-peaks arising from the existence of additional slowly-
or non-exchanging conformation(s) possibly in a localized region of the polypeptide chain, later 
attributed to a cis/trans proline isomerisation (see chapter five). 
Subsequently, the 'H-'5N HSQC spectrum of CP1 expressed as an isolated module was found 
to have fewer dispersed cross-peaks than expected, with little chemical shift dispersion and a 
significant number of random-coil position peaks, indicating that it does not have a clearly defined 
structure (Figure 4.7). It may be largely unfolded, or may exist as multiple conformations in 
intermediate exchange. Further investigations of TR-CPI included changing temperature (8-37°C) 
and pH titration (3.5-8) were undertaken without success (Figure 4.8). Also investigated were 
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comparisons of TR-CPI with GABAB  Rla—"wild-type" (WT-CPI) (Figure 4.9), and of the fully 
glycosylated WT-CPI with its deglycosylated form (Figure 4.10). Finally the WT-CP12 glycosylated 
(Figure 4.11) and the WT-CPI2 non-glycosylated were also compared (not shown). None of these 
constructs yielded NMR spectra that showed any significant improvements, although some resonances 
seem to get sharper in the "wild-type" versions when compare to the "truncated" ones. 
Superposition of the 'H-'5N HSQC spectra, and of the 'H 2D-NOESY spectra, collected on 
CPI2 and CP2 (Figure 4.12, 4.14, and 4.15), show that some of the well-resolved cross-peaks 
corresponding to CP2 are shifted in the context of the pair, and therefore some interaction might exist 
between the two modules. Interestingly, the ratio of trans to cis conformer population of CP2 in the 
context of the pair appears to differ from isolated CP2 (Figure 4.12). This could be assess through 
well resolved cross-peaks from CP2 inside the module pair, and will be the focus of future work. 
CP 1 appears to be more structured in the context of the module pair than on its own (Figure 
4.14, and 4.15). Interestingly, '--11 resonances in the TR-CPI 'H-'5N HSQC spectrum ('-108-113 ppm 
in '5N, and - 8.25-8.7 ppm in 'H) have shifts that are characteristic of the glycine/theronine residues 
in unstructured peptides [170], and therefore could account for the seven glycine and four threonine 
residues found in its primary sequence (Figure 4.7). The 'H-'5N HSQC spectrum of CPI has 
similarities with the 'H-'5N HSQC spectrum of the human a-lactalbumin (a-LA) molten globule 
formed at pH 2, where only three of the 122 backbone resonances can be observed due to extensive 
conformational fluctuations throughout the protein on a millisecond time scale [171]. Upon full 
denaturation of the a-LA molten globule, additional resonances appeared. Because the resonances of 
the denatured a-LA had been characterised, these additional peaks were assigned, and it was possible 
to identify the region of the a-LA molten globule that unfolds. Interestingly, some cross-peaks 
observed in the denatured cc-LA never appeared in the denatured a-LA molten globule. These peaks 
were thought to exhibit extensive broadening, and it was speculated that they may correspond to 
regions of the molecule that remain in a partly-folded, collapsed state, with some residual structure. It 
is difficult to draw conclusions about the extent to which CP1 is folded or in the molten globule form. 
Some resonances have chemical shifts characteristic of unstructured peptides, others are consistent 
with folded structure. On the other hand, the broadening of some resonances evident in the 'H-15N 
HSQC spectrum of the CPI (Figure 4.7) seems consistent with slow fluctuations of the polypeptide 
chain, as seen in molten globules, which arise from residual structure restricting the conformational 
freedom of the polypeptide chain. 
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Studies on protein folding suggest that molten globules retain native-like secondary structure 
[172] and correct folding topology even in the absence of cooperative interactions between side-
chains [173]. The classic molten globule, therefore, lacks the side-chain interactions that characterize 
the tertiary structure of the native protein [174]. A few examples in the literature, however, emphasise 
the persistence of tertiary structure in some molten globules [173, 175], which may be either native-
like or not, and the term "highly-ordered" [174] molten globule has been used to describe such 
intermediates between native and molten globule states. In 1 H 2D-NOESY experiments, resonances 
arise from dipole-dipole interactions between protons through space, and in the range of 5 A. Cross-
peaks that correlate protons from different side-chains are therefore indicative of protein folding. 
Analysis of the 'H 2D-NOESY spectrum for the TR-CPI suggests the retention of tertiary interactions 
as some NOEs between the aromatic and the aliphatic side-chains can be observed (see Figure 4.13). 
Evidence for proper disulphide bond formation in CP1 was presented in chapter three; such an 
observation suggests the retention of some tertiary structure. 
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Figure 4.1: 1H-15N HSQC-spectra of TR-CP12 -non glycosylated 
Sample was 0.6 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. 
Spectrum was acquired at 600 MHz, and 37°C. Sweep width is 5000 Hz in the 'H 
dimension and 2212.6 Hz in the 15N dimension. Spectrum was recorded with 10 scans, 
1024 complex points in the 'H dimension, and 160 complex points in the '5N dimension. 
After processing, data matrix was 1024 points in 1H, and 256 points in 15N. A sine function 
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Figure 4.2: 3D 'H-'5N edited-TOCSY-spectrum of TR-CP12 recorded with only one 
increment in the 15N dimension 
Sample was 0.6 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 37°C. Mixing time was 0.035 s. 
Sweep width is 5000 Hz in the directly detected 'H dimension, 7400 Hz in the indirectly 
detected 'H dimension. Spectrum was recorded with 40 scans, 1024 complex points in the 
acquisition dimension, and 256 complex points in the indirectly detected 'H dimension. 
After processing, data matrix was 1024 points in the acquisition dimension, 512 points in 
the indirectly 'H dimension. A sine function squared (with an angle of 90°) was applied in 
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Figure 4.3: pH titration of TR-CP12 
a) TR-CP12 -non glycosylated at pH 4 
Sample was 1.1 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 37°C. Sweep width is 5000 Hz in the 1 H dimension and 
2000 Hz in the 15N dimension. Spectrum was recorded with 16 scans, 1024 complex points 
in the 1j  dimension, and 96 complex points in the 15N dimension. After processing, data 
matrix was 1024 points in 'H, and 128 points in '5N. A sine function squared (with an angle 
of 90°) was applied in both dimensions. 
TR-CP12 -non glycosylated at pH 5.5 
Same experimental conditions as in (a), pH was adjusted with NaOH. 
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Figure 4.3 continued: pH titration of TR-CP12 
TR-CP12 -non glycosylated at pH 7.3 
Same experimental conditions as in (a), pH was adjusted with NaOH. 
TR-CP12 -non glycosylated at pH 8.5 
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Figure 4.4: 15N T2 measurement for WT-CP12-deglycosylated 
Sample was 0.4 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 37°C. 
15N T2 -1D trace from 'H- 'N HSQC recorded with different relaxation delays: 16 iiis 
(black), 32 ms (red), 48 ms (blue), and 64 ms (green). 
Spectra were processed in the AZARA software package, and the relative intensity ratio 
between two spectra was used to calculate 15N T2 from the following: '5N T2 = (time delay 
spectrum #2 - time delay spectrum #1) / in (intensity ratio). Sweep width is 5000 Hz in the 
'H dimension (1024 complex points), and 2212.6 Hz in '5N. A sine function squared (with 
an angle of 900) was applied. 128 scans per delay were collected. 
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Figure 4.5: 1 11-15N HSQC-spectra of GABAB Ria CP-fragments 
TR-CP12 - glycosylated 
Sample was 0.8 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. 
Spectrum was acquired at 600 MHz, and 37T. Sweep width is 5000 Hz in the 'H 
dimension and 2212.6 Hz in the '5N dimension. Spectrum was recorded with 10 scans, 
1024 complex points in the 'H dimension, and 160 complex points in the 15N dimension. 
After processing, data matrix was 1024 points in 'H, and 256 points in 15N. A sine function 
squared (with an angle of 90°) was applied in both dimensions. 
TR-CP12 -non glycosylated (black) and TR-CP12 - glycosylated (red) overlaid 
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Figure 4.6: 'H-'5N HSQC-spectra of GABAB Ria CP-fragments 
FLM-CP12 -non glycosylated 
Sample was 0.7 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. 
Spectrum was acquired at 600 MHz, and 37T. Sweep width is 5000 Hz in the 'H 
dimension and 2212.6 Hz in the 15N dimension. Spectrum was recorded with 10 scans, 
1024 complex points in the 'H dimension, and 128 complex points in the '5N dimension. 
After processing, data matrix was 1024 points in 'H, and 128 points in uN.  A sine function 
squared (with an angle of 90°) was applied in both dimensions. 














L'HlPP- 	 a 	
L'HlPP- 	
b 
Figure 4.7: 1H-'5N HSQC-spectra of GABAB Ria CP-fragments 
a) TR-CP1 -non glycosylated 
Sample was 0.7 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 25°C. Sweep width is 5000 Hz in the 'H dimension and 
2000 Hz in the '5N dimension. Spectrum was recorded with 8 scans, 1024 complex points 
in the 'H dimension, and 192 complex points in the '5N dimension. After processing, data 
matrix was 1024 points in 'H, and 256 points in 15N. A sine function squared (with an angle 
of 90°) was applied in both dimensions. 
CP2 
Sample was 0.7 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 25°C. Sweep width is 5000 Hz in the 'H dimension and 2000 
Hz in the 'N dimension. Spectrum was recorded with 8 scans, 1024 complex points in the 
1H dimension, and 128 complex points in the 15N dimension. After processing, data matrix 
was 1024 points in 'H, and 128 points in 'N. A sine function squared (with an angle of 
90°) was applied in both dimensions. 
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Figure 4.8: 'H-15N HSQC-spectra of GABAB Ria CP-fragments 
TR-CP1 -non glycosylated at pH 4 
Sample was 0.8 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 25°C. Sweep width is 5000 Hz in the 'H dimension and 
2216.6 Hz in the '5N dimension. Spectrum was recorded with 8 scans, 1024 complex points 
in the 'H dimension, and 96 complex points in the '5N dimension. After processing, data 
matrix was 1024 points in 'H, and 128 points in '5N. A sine function squared (with an angle 
of 90°) was applied in both dimensions. 
TR-CP1 -non glycosylated at pH 6 
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Figure 4.8 continued: 'H- 'N HSQC-spectra of GABAB Ria CP-fragments 
TR-CP1 -non glycosylated at pH 7.5 
Same experimental conditions as in (a), pH was adjusted with few ml of 0.2 M NaOH. 
TR-CP1 -non glycosylated at pH 8.5 
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Figure 4.9: 'H-15N HSQC-spectra of GABAR Ria CP-fragments 
a) WT-CP1-deglycosylated 
Sample was 0.6 mM in 20 mlvi deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 25°C. Sweep width is 5000 Hz in the 'H dimension and 
2000 Hz in the 15N dimension. Spectrum was recorded with 64 scans, 1024 complex points 
in the 'H dimension, and 160 complex points in the 15N dimension. After processing, data 
matrix was 1024 points in 'H, and 256 points in 15N. A sine function squared (with an angle 
of 90°) was applied in both dimensions. 
WT-CPI-deglycosylated (black) and TR-CPI -non glycosylated (red) overlaid 
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Figure 4.10: 'H-'5N HSQC-spectra of GABAB Ria C P-fragments 
WT-CP1 -glycosylated 
Sample was 0.7 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 25°C. Sweep width is 5000 Hz in the 'H dimension and 
2000 Hz in the 15N dimension. Spectrum was recorded with 16 scans, 1024 complex points 
in the 'H dimension, and 96 complex points in the '5N dimension. After processing, data 
matrix was 1024 points in 'H, and 128 points in 15N. A sine function squared (with an angle 
of 90°) was applied in both dimensions. 
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Figure 4.11: 'H-15N HSQC-spectra of GABAB Ria CP-fragments 
WT-CP12 -deglycosylated 
Sample was 0,7 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 25°C. Sweep width is 5000 Hz in the 'H dimension and 
2000 Hz in the 15N dimension. Spectrum was recorded with 16 scans, 1024 complex points 
in the 'H dimension, and 96 complex points in the 15N dimension. After processing, data 
matrix was 1024 points in 'H, and 128 points in 15N. A sine function squared (with an angle 
of 90°) was applied in both dimensions. 
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Figure 4.12: 'H-'5N HSQC-spectra of GABAB Ria CP-fragments 
WT-CP12 -deglycosylated (blue) and CP2 (black) overlaid 













Figure 4.13: 'H-2D NOESY-spectra of GABAB Ria CP-fragments 
a) TR-CP1-non glycosylated 
Sample was 0.7 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 37°C. Sweep width is 8000 Hz in the acquisition dimension 
and 7000.35 Hz in the indirectly detected dimension. Mixing time was 0.1 s. Spectrum was 
recorded with 32 scans, 2048 complex points and 1024 complex points in the indirectly 
detected dimension. After processing, data matrix was 2048 points in the acquisition 
dimension and 1024 points in the indirectly detected dimension. A sine function squared 
(with an angle of 90°) was applied in both dimensions. 
TR-CP1-non glycosylated at 37°C (black) and TR-CPI-non glycosylated at 25°C 
(red) 
Spectrum recorded at 25°C was acquired at 600 MHz. Sample conditions, spectrum 
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Figure 4.14: 'H-2D NOESY-spectra of GABAB Ria CP-fragments 
a)CP2 
Sample was 0.7 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 37C. Sweep width is 8000 Hz in the acquisition dimension 
and 7000.35 Hz in the indirectly detected dimension. Mixing time was 0.1 s. Spectrum 
was recorded with 92 scans, 2048 complex points and 1024 complex points in the indirectly 
detected dimension. After processing, data matrix was 2048 points in the acquisition 
dimension, and 1024 points the indirectly detected dimension. A sine function squared was 
applied in both dimensions. 
b) TR-CP12-non glycosylated 
Sample was 0.6 mM in 20 mM deuterated sodium acetate, pH 4, and 10% D20. Spectrum 
was acquired at 600 MHz, and 37°C. Sweep width is 10000Hz in the acquisition dimension 
and 7199.42 Hz in the indirectly detected dimension. Mixing time was 0.1 s. Spectrum 
was recorded with 80 scans, 2048 complex points and 1024 complex points in the indirectly 
detected dimension-After processing, data matrix was 2048 points in the acquisition 
dimension, and 1024 points the indirectly detected dimension. A sine function squared was 
applied in both dimensions. 
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Figure 4.15: 'H-2D NOESY-spectra of GABAB Ria CP-fragments overlays 
Left: TR-CPI at 25°C (red) & TR-CP12 at 37°C (blue) 




4.2 	Circular dichroism studies 
Far-UV (180-250 nm) circular dichroism (CD) spectra of proteins are dominated by peptide 
bond dichroism, and therefore are used to estimate their secondary structure content [176-178]. The 
spectrum of a protein is basically the sum of the spectra of its conformational elements. cc-helices 
display large CD bands with negative ellipticity at 208-222 nm, and positive ellipticity at 193 nm. 
13-sheets exhibit a broad negative band near 218 nm and a large positive band near 195 nm. Finally, 
random coils have a weak positive broad band at 217 nm and a large negative band near 200 nm. 
Far-UV CD spectra of different constructs of the GABAB RI  CP modules were obtained at various 
temperatures. These CD data were collected during the course of testing different pH and buffer 
conditions for NMR spectroscopy; hence, the CD data of each construct was recorded with different 
sample conditions, and a direct comparison of these results is difficult. Nevertheless these CD data 
are indicative of the secondary structure content, and complement the NMR data shown in section 
4.1. 
Far-UV CD spectra of CP modules are characterised by a highly unusual large positive 
ellipticity in the 220-260 nm region (Figure 4.16 a-d) [34, 179], which could arise from the 
conserved tryptophan residue being in a 13-sheet environment [179]. All GABAB Rla complement 
module pairs or single module constructs display this unusual characteristic, which is therefore 
consistent with a CP module fold for both modules in the GABAB Ria. Changes in ellipticity of a 
protein as a function of temperature are a convenient way of probing the thermodynamics of folding 
[176]. Thermal denaturation as monitored by CD was therefore used to probe folding and stability 
of the various constructs. Similar experiments on well characterised CP module pairs or single 
modules have shown that they unfold in a cooperative manner [179], i.e. with a concerted loss of 
the interactions stabilising the native structure, which can be described by a "two state" model. 
Figure 4.17 a shows the thermal unfolding of the different constructs of the GABAB Ria CP module 
pair and single modules along with a well characterised single CP module (16th  module of CR1), 
and a CP-module pair (from the viral protein VCP: VCP-2 and 3   module (VCP23)). CP2, and 
VCP23 show clear sigmoidal transitions, consistent with cooperative unfolding, and the CR116th 
transition is also sigmoidal. On the other hand WT-CPI and FL-CP12 have less well defined 
transitions which seem be consistent with little or no cooperativity in the unfolding process. The 
latter has a profile close to the sum of its component GABAB RI a single module-profiles. 
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Figure 4.16: Thermally induced denaturation of the GABAB Ria CP fragments as monitored 
by far-UV CD. CD spectra were obtained on a Jasco-600 spectropolarimeter (Japan Spectroscopic 
Co, Tokyo, Japan), using a cylindrical quartz cell with a path length of 0.5 cm for (a), and (b) 
measurements. Temperature is indicated along individual spectrum, and is given in T. 
FLM-CIP12, 50 iM in 20 mM sodium phosphate pH 6 
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Figure 4.16 continued: Thermally induced denaturation of the GABAB Ria CP fragments as 
monitored by far-UV CD. CD spectra were obtained on a Jasco-600 spectropolarimeter (Japan 
Spectroscopic Co, Tokyo, Japan), using a cylindrical quartz cell with a path length of 0.5 cm for (c) 
measurement, and of 0.02 cm for the (d) measurement. Temperature is indicated along individual 
spectrum, and is given in °C. 
CP2, 80 M in 20 mM sodium phosphate pH 6 
WT-CP1-deglycosylated, 50 j.tM in 20 mM deuterated sodium acetate pH 4 (N1'ffl buffer)-
Note: these measurements are uncorrected for cell path length and protein concentration. 
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Aggregation was suspected from 15N T2 experiments, and could explain the poor cooperativity in 
unfolding observed for WT-CPI and FLM-CPI2. However it worth noting that protein 
concentration in these experiments is relatively low (0.05 mM). 
The near-UV (260-320 nm) CD of proteins arises from the environment of each aromatic 
amino acid side-chain. In the case of structured proteins in their native states, the side-chains of 
such amino acids are placed in an asymmetric environment that is characteristic of the tertiary 
structure of the protein. The tryptophan contribution gives rise to a peak close to 290 nm with a 
fine structure between 290 and 305 nm. Tyrosine's contribution is a peak between 275 and 282 nm, 
and phenylalanine gives sharp peaks between 255 and 270 nm. Disulphide bond contributions are 
normally seen at around 260 nm, although their CD bands are usually much broader than those of 
aromatic amino acids and in general it is difficult to evaluate their contribution to the overall 
spectrum (Dr. Sharon Kelly - Glasgow University - personal communication). Disulphide bond can 
also contribute to the far-UV CD at 225 nm. 
For the WT-CP I, the near-UV spectrum shows a "u-shaped" band with negative ellipticity between 
260-3 10 nm, and a minimum around 280 nm (Figure 4.17 b). A similar profile was observed in the 
case of CR1-15-17 fragment (Figure 4.17 c). Despite the fact that in the latter, three modules 
contributed to the spectra; it is still possible to speculate that such a profile is characteristic of CP 
modules in the near-UV CD. A fine structured "shoulder" is also observed at 295 nm for both WT-
CP1 and CR1-15-17, which might represent the contribution from the conserved tryptophan. 
Denaturation monitored by near-UV CD will be needed to further characterise the extent of these 
tertiary interactions. It also will be of interest to repeat near-UV CD measurement on reduced and 
carboxymethylated CPI, to further characterise disulphide bonds contributions to the spectra. 
Far-UV CD data for WT-CP1 are consistent with an unstable protein, which exhibits little if any 
cooperativity in unfolding, a feature generally found in molten globules. Data from near-UV CD 
are consistent with the presence of some native or native-like tertiary structure. Interestingly, 
reduction of the disulphide bonds was shown to abolish the characteristic far-UV positive ellipticity 
of the TR-CP12 construct [34]. This result implies an important disulphide bond contribution to the 
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Figure 4.17: CD analysis of the GABAR Ria CP fragments. CD spectra were obtained on a 
Jasco-600 spectropolarimeter (Japan Spectroscopic Co, Tokyo, Japan). 
a) Thermally induced denaturation of the GABAB Ria fragments and others CP fragments 
from human complement or Vaccina virus complement control protein monitored by far-UV 
CD. Plots of the percentage total change versus temperature were derived from measurements 
shown in figure 4.16 by taking the maximum ellipticity. CRI-46 [179] and VCP23 values were 
extracted from reference [180]. The observed change from the native protein (0 M GdnHCI) at each 
concentration was expressed as a percentage of the total change induced by 6 M GdnHCl, and 
plotted against the concentration of GdnHC1. The maximum ellipticity and readings at ±1.0 and 
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Figure 4.17 continued: CD analysis of the GABAB Ria CP fragments. CD spectra were 
obtained on a Jasco-600 spectropolarimeter (Japan Spectroscopic Co, Tokyo, Japan). 
Near-UV CD spectrum of WT-CP1 - deglycosylated - 51 VM in 20 mM deuterated sodium 
acetate pH 4 (NMR buffer) - cell path-length was 0.02 cm. 
Near-UV CD spectra for CR1 45-17 over a range of temperature, as indicated by the 
numbers. Takenfrom reference f1791 
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4.3 	Differential scanning calorimetry studies 
The temperature-induced denaturation of a protein enables assessment of stability. 
Differential scanning calorimetry (DSC) can be used to analyse the thermodynamics of protein 
unfolding. With this technique one measures, as a function of temperature, the excess heat capacity 
(Cr) of a protein-containing solution, relative to the same volume of a buffer solution [181]. After 
concentration and baseline correction, the DSC data are fitted to a model of unfolding to yield the 
apparent thermodynamic parameters for the transition. For protein unfolding transitions, the model 
can be a "two-state" model or a multi-state process. The transition enthalphy (AH) is obtained by 
integration of the experimental curve of C, versus temperature. This model-free measure of AH is 
then compared with the van't Hoff transition enthalphy (AH), which is calculated from the shape 
of the modeled DSC curve and is a measure of the cooperativity of unfolding: the sharper the 
transition, the greater the AHv, and the greater the cooperativity [181]. Such a comparison gives 
information about the thermodynamics of the order-disorder transition observed. If the model of 
unfolding is correct then AH = AHv; if not, discrepancies between the two enthalpies are of interest 
[182]. For example, AH <AHv  can arise from dimerisation, aggregation, or from not all the protein 
being correctly folded in the first place [183]. The melting temperature (Tm) refers to the 
temperature at which 50% of the protein molecules are unfolded [183]. 
Figure 4.18 shows the profiles obtained from a DSC study of the GABAB R1aCP 
fragments. The DSC profile of CP2 (Figure 4.18 a) was fitted with a "non two-state" unfolding 
model giving a good agreement between AH and AH. The profile is a sharp with a relatively high 
melting temperature (70.8°C) as expected for a protein that has a stable and well-defined tertiary 
structure (cooperative unfolding). In comparison the DSC profile obtained for WT-CPI (Figure 
4.18 b) shows no transition, indicating that endothermic unfolding did not occur, i.e. the fragment 
absorbed no excess energy. A similar result was found in our laboratory with the Herpes simplex 
virus triplex protein (VP23) [184]. VP23 was found to exist as a molten globule, and absence of 
endothermic unfolding transition was also observed, consistent with the lack of rigid tertiary 
structure generally observed in the molten globule state. The absence of endothermic unfolding as 
monitored by DSC for WT-CPI does not agree with its near-UV CD data that is suggestive of the 
presence of tertiary structure. Aggregation could provide an explaination for the lack of 
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Figure 4.18: Differential scanning calorimetry studies on GABAB Ria CP fragments. 
Studies were performed on a MC-2 differential scanning calorimeter (Microcal, Northampton, MA-
USA). The cell volume was 1.5 ml, heating rate was 1°C min 1, and excess of pressure was kept 
equal to 80 bar. 
CP2, 40 J.L1VE in 20 mM sodium acetate pH 4. 
WT-CPI — deglycosylated, 76 IM in 20 mM sodium acetate pH 4. 
WT-CP12 — deglycosylated, 40 IM in 20 mM sodium acetate pH 4. 




Interestingly, the DSC profile for WT-CP 12 (Figure 4.18 c) shows two transitions. These 
data were also fitted with a "non two-state" unfolding transition yielding discrepancy between the 
two enthalpy: AH <AHv  in both observed transitions. Such discrepancies can arise from several 
factors; one of them is incorrect baseline correction. Baseline correction is achieved subtracting a 
blank, recorded with buffer solution in both measurement and reference cells, to the measurement. 
The WT-CP12 sample used in this study was buffer-exchanged using an ultra-filtration 
concentrator. Ultra-filtration does not lead to a full equilibrium between sample and buffer (Dr 
Alan Cooper - Glasgow University - personal communication), and it would have been better to use 
dialysis (note: dialysis was employed for both WT-CPI and CP2). Nevertheless the major 
transition has a Tm close to that of the CP2 fragment (69.6°C) and could account for the melting of 
the second module in the module-pair fragment. The first transition, with a Tm of 53°C, (if real) 
could be accounted by an aggregation effect or from the melting of the seven-residue extension. In 
a previous study [34], Dr Marina Kirkitadze found only one transition for the thermal unfolding of 
the TR-CP12 fragment with a Tm of 64°C (see Figure 4.18 d). It is therefore tempting to speculate 
that the second transition arises form the seven-residue extension. Alternatively, this lower 
transition could be accounted for by CPI if it was more structured in the context of the module pair. 
New measurements on dialysed samples will be the focus of future work. 
152 
Biophysical studies 
4.4 	Fluorescence spectroscopy studies 
The GABAB  Rla- CPI has a conserved tryptophan, as well as an extra tryptophan 
residue in the predicted first loop. The CP module consensus structure has been well characterised 
and the conserved tryptophan side-chain is known to be mainly buried within the hydrophobic core 
of the module, adjacent to the first disulphide bond and close to the N-terminus. Fluorescence 
spectroscopy can be used to assess the extent to which tryptophan side-chains are buried within a 
protein interior. Excitation at 295 nm results in a tryptophan fluorescence emission spectrum with a 
maximum at 340 nm [185]. Upon denaturation, this maximum is in general shifted towards 350-
355 nm; however, it is difficult to predict how the intensity will change, and both increased and 
decreased intensity have been observed upon denaturation [185]. An increase in fluorescence 
emission intensity at 340 nm upon unfolding has been observed for some CP modules of 
complement receptor 1 (CR1) [179, 186]. CR1 	module showed a seven-fold increase in 
fluorescence emission intensity at 340 nm in 7 M GdnHCI, as well as a shift in the maximum to 351 
nm. 
Protein fluorescence measurements on WT-CPI showed that as the GdnHCI concentration 
was increased, a buried tryptophan side-chain became exposed to the solvent; presumably this is the 
side-chain of the conserved tryptophan residue (Figure 4.19 a). Conclusions from fluorescence 
unfolding experiments of proteins containing multiple tryptophan residues are difficult to draw, but 
the main transition appears to be real and is likely to correspond to the exposure of the buried side-
chain of the conserved tryptophan residue. Interestingly, CR115-16, CR116-17, and CRI-16 
fluorescence unfolding measurements all showed a transition at 3.3-3.6 M GdnHCI [179, 186]; and 
are consistent with the main transition observed for the GABAB R1a- WT-CPI. 
However, examples of molten globule where a tryptophan side-chain is hidden from the 
solvent have been observed. As mentioned earlier, Herpes simplex virus triplex protein (VP23) was 
found to exist as a molten globule [184] with an unfolding transition detected by fluorescence 
taking place around 3 M GdnHCI. The VP23 transition was found to be poorly cooperative, which 
was attributed to the lack of defined tertiary structure. Native-like or residual tertiary structure 
could therefore account for the transition observed in WT-CP I. 
A sensitive test to probe partial folding is binding of 8-anihino-1-naphtalenesulfonate (ANS) to a 
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Figure 4.19: Fluorescence studies on WT-CP1 
Fluorescence measurements were recorded on an Edinburgh analytical instrument-F900 
spectrofluorimeter in a 100 tl cuvette of 0.3 cm path length at 26.2°C. The protein concentration in 
all experiments was 71 M (0.67 mg/ml) in NMR buffer (20 mM deuterated sodium acetate, pH 4). 
Protein fluorescence: excitation wavelength was 295 nm and the emission spectra were 
recorded between 300 and 500 nm. 
ANS fluorescence: ANS was purchased from Molecular Probes, and was added to protein 
samples to a final concentration of 10 pM. Plots were obtained from data integration corrected 
from free ANS in NMR buffer value. 
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ANS binds to the exposed hydrophic regions in partially folded proteins, although ANS has also been 
shown to bind to solvent-accessible non-polar groups in native proteins; binding to a partially folded 
state is in general much stronger compared to the native or fully denatured state [184]. 
ANS was found to bind tightly to purified, undenatured WT-CPI (Figure 4.19 b). Measurements of 
the unfolding dependence of ANS fluorescence intensity at 470 nm showed that as the GdnHCI 
concentration was increased, fluorescence intensity decreases rapidly. They also showed that the 
fluorescence of ANS in the absence of WT-CPI or in the presence of its denatured form in 6 M 
GdnHCI were insignificant. ANS fluorescence intensity was rapidly quenched upon addition of 
GdnHCI; most of the intensity was quenched by 1 M GdnHCl and it was completely lost at 2 M 
GdnHCI. In a recent study, Bailey et a! [187] showed that clusterin, a ubiquitous protein with several 
binding partners, exists as a molten globule. In this study, clusterin and other proteins along with their 
pH-induced molten globules were compared in their ability to bind ANS. Two proteins 
(apomyoglobin and cc-lactalbumin) were found to bind ANS in either their native or molten globule 
states (with different intensities). However, different unfolding profiles as monitored by ANS binding 
were found for the native and molten globule states. Native state unfolding profiles for both proteins 
were sigmoidal and consistent with cooperative unfolding. On the other hand, unfolding profiles for 
their molten globule states were non-sigmoidal and therefore consistent with non-cooperative 
unfolding as previously observed for other molten globules. Furthermore native states required higher 
denaturant concentration to induce ANS fluorescence loss compare to molten globule states; complete 
loss was observed at 2 M urea for molten globule states while 3-6 M was needed for native proteins 
[187]. The profile obtained for the GABAB  Ria'-' WT-CP1 is similar to clusterin and others molten 
globules described in Bailey's study; more data points will be needed between 0-1 M GdnHCI to 
further characterise such a profile. 
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4.5 	Light scattering and analytical centrifugation 
The poor quality of CPI NMR data could be accounted for by the protein being an aggregate, 
despite the lack of improvement upon dilution. Early in this study, samples of the GABAB R1a- TR-
CP12 at NMR concentration (1 mM) were submitted to different collaborators for molecular mass 
determination. Dr. Kormelia Jumel performed analytical centrifugation studies at Nottingham 
University in Dr. Stephen Harding's laboratory, and Dr. Jacqueline Doman at the Institute of Cell and 
Molecular Biology in Edinburgh University, performed light scattering studies. 
Analytical ultracentrifugation is a powerful tool with which to measure a protein's molecular 
weight, shape and association properties. Two types of experiments can be performed with an 
analytical ultracentrifuge: at low speed, sedimentation equilibrium provides data for molecular mass 
determination [188, 189]; while at high speed, sedimentation velocity provides data for molecular size 
and shape determination [188, 189]. Analysis of TR-CP12 at a concentration of 1 mM by 
sedimentation equilibrium revealed a molecular mass of 14400 Da. This molecular weight is smaller 
than the expected 15428-15628 Da but the discrepancy can be attributed to the high concentration of 
the sample, as concentration is also involved in the equilibrium process (Dr Kormelia Jumel - 
personal communication). From this result it was concluded that the CP module pair was mornoneric 
at the NMR concentration. 
In the light-scattering technique, a beam of monochromatic light is directed through a sample 
and the fluctuation of the intensity of scattered light by the molecules is analyzed with a photodiode, 
which counts the number of photons detected as a function of time [190]. From these data the 
translation diffusion coefficient, DT, can be extracted, which is then used to calculate the 
hydrodynamic radius, RH, from the Stokes' equation (RH = kbT /67rflDT, where kb is the Boltzman's 
constant, T is the temperature, and i is the solvent viscosity). Finally the molecular weight is 
estimated from the RH [190]. Light scattering for the GABAB R1a TR-CP12 at the NMR 
concentration gave an RH  value of 3.6 nm with an estimate molecular weight of 63 kDa. Such a 
molecular weight is consistent with a tetramer of the GABAB R 1 a- TR-CP12. Interestingly, the 
sample has good monodispersity as judged by a polydispersity factor of only 16%. 
Data from these two studies are in disagreement and it will be of interest to repeat the 
sedimentation equilibrium experiment on WT-CPI as well as to perform sedimentation velocity 
studies. It is worth mentioning that TR-CP12 was found to run as a single peak on analytical gel 
filtration with a higher than expected molecular weight of about 25 kDa, although this observation 
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was also made for other CP modules pairs such as VCP23 (data not shown). These results are also in 
disagreement with the 15N T2 measurements, which suggests some degree of aggregation for TR-
CP12 (section 4.1). It will be necessary to repeat the dynamic light scattering experiment as such 
method is prone to errors such as dust contamination. 
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CHAPTER FIVE: NMR STRUCTURES OF THE TWO CONFORMERS OF THE 
GABAB  RECEPTOR Ria COMPLEMENT MODULE TWO 
The data shown in chapter four provided evidence that CP2 is a well-folded domain, and NMR 
experiments yielded data of good quality. Subsequently, a "N/"C-labelled sample of CP2 was 
produced. Standard sets of NMR experiments were collected, analysed, and used as a basis for three-
dimensional structure calculations. In the course of the analysis of NMR data, it was determined that 
CP2 exists as two stable conformers in solution that do not inter-convert on the NMR-time scale. 
Consequently, a new protocol for structure calculation was devised to attempt simultaneous structure 
calculation of both conformers. The preliminary results of structure calculations are presented in this 
chapter. 
5.1 	Strategies for resonance assignment and NMR experiments utilised 
Analysis of NMR spectra provides information about inter-atomic distances and torsion 
angles that form the basis for structure calculations. First, however, each resonance must be 
associated with a specific nucleus in the molecule. This process is called assignment. Amino acids 
have characteristic cross-peak patterns in certain 2D and 3D NMR spectra that reflect the scalar 
coupling of the spill 1/2 nuclei they contain. Such patterns are referred to as spin-systems. In general, 
resonance assignment is achieved in three sequential steps: spin-system identification, sequence-
specific assignment, and assignment of the side-chain resonances. 
Strategies for assignment are dependent on the size of the protein and the type of isotopic 
labelling. When only homonuclear and '5N heteronuclear experiments are available, both TOCSY-, 
and NOESY-type experiments are needed for sequence-specific assignment. TOCSY-type spectra 
only provide information about spin-systems as they rely on 3J coupling. They are analysed by 
matching theoretical spin-systems to experimental ones (COSY-type experiments may also be used in 
this part of the process). NOESY-type experiments contain cross-peaks that correlate nuclei close in 
space and therefore also contain the spin-system information found in the TOCSY experiments. 
Identified spin-systems from TOCSY experiments can be sequentially connected using NOESY-type 
experiments: some resonances identified from TOCSY spectra for a residue at position (1) in the 
primary sequence will exhibit cross-peaks with resonances of the residue at position (i+1) in the 
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NOESY spectra (Figure 5.1). Initially, only a limited number of amino acid spin-systems are 
unambiguously identified from their characteristic patterns in TOCSY-type experiments (alanine, 
glycine, threonine, valine, isoleucine). The remaining spin-systems are identified from a 
consideration of the possible identities of a particular spin-system in TOCSY spectra in the context of 
the possibilities for its sequence specific assignment in NOESY spectra. 
When triple resonance experiments are possible, sequence specific assignment relies on 
sequential correlations via 'J and 2J heteronuclear coupling. This allows complete sequence specific 
assignment without knowledge of the complete spin-systems. Knowledge of the sequence-specific 
assignments obtained from triple resonance experiments is then used in the analysis of TOCSY-type 
experiments to obtain spin-system assignments. 
Once spin-systems have been identified and placed sequentially, the full side-chain assignments are 
deduced; this is also an opportunity to assess the previous assignments. 
Once all the spin-systems are fully and correctly assigned, the remainder of the NOE cross-peaks can 
be assigned, providing they are unambiguous. NOEs are subsequently integrated, converted into inter-
atomic distance restraints, and used as input for a 3D-structure calculation. Ambiguous, unassigned, 
NOEs can also be of use as the relative contributions from the various components can be resolved in 
an iterative manner during the structure calculation process. 
5.2 	Methods used for CP2 
Homonuclear and heteronuclear experiments for CP2 were collected (see table 5.1, and 5.2). All 
experiments were recorded at 600 MHz, 37'C, on a Varian INOVA NMR spectrometer at the 
University of Edinburgh, except for the ' 3C-edited NOESY experiment, which was recorded at 800 
MHz at the University of Cambridge NMR facility. Homonuclear, and 15N heteronuclear experiments 
were collected with the assistance of Dr. Dusan Uhrin and Dr. Brian Smith; triple resonance 
experiments were collected in collaboration with Dr. Dusan Uhrin. All samples were of 1 mM 
concentration in 20 mM deuterated sodium acetate, pH 4, and contained 10% D20. Spectra were 
processed using the AZARA software package (http://www.bio.cam.ac.uk]azara), and maximum 
entropy reconstruction was employed for the indirectly detected dimensions in all 3D spectra. For 
resonance assignment, spectra were viewed within the ANSIG (assignment of NMR spectra by 
interactive graphics - Per Kraulis [191]) software package. Cross-peaks were manually picked and 
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Figure 5.1: Principle of resonance assignment in '5N-edited experiments 
Expected NOE connections in '5N-edited NOESY (depending on secondary structure). 
The Asn159 NH "strip" may have connections with Va! 158 as indicated by arrows. The NHi-NHi+ 1 
NOE may also be observed. 
Schematic of the 3D '5N-edited TOSCY and NOESY experiments for the Val 158 and Asn159 
"strips". 
View from the ANSIG setup. Left window: 15N-edited TOCSY focused on Va1158 NH "strip". 
Right window: '5N-edited NOESY focused on Asn159 NH "strip". 
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5.3 	Assigning the two conformers of CP2 
The CP2 assignment was initiated using only ' 5N-edited TOCSY and NOESY experiments. The 
sequence specific assignment identified two distinct sets of resonances for 17 residues in the region of 
the sequence near Pro l 19. Dual resonances were also observed for a number of residues in vicinity of 
Cys99 and Cys 144 (these form the first, I-Ill, disulphide bond). Such observations suggested the 
presence of two (cis/trans) isomers for the peptidyl-Pro 119 bond. This hypothesis was consistent 
with data from a model of CP2 [3 4] in which Pro 119 is predicted to be close in space to the first 
disulphide bond and to the N-terminus. Thus cis/trans isomerisation of peptidyl-Pro 119 bond 
provided a plausible explanation for the two distinct sets of resonances. Since proline residues lack an 
amide proton, they are absent from ' 5N-edited spectra. The proline isomerisation state is in general 
identified from NOEs in 1 H-2D NOESY. Medium to strong NOEs between proline H8 and alpha or 
amide protons of the previous residue in the sequence is characteristic of a trans conformation. 
Alternatively, strong NOEs between proline Ha and alpha or amide protons from the previous residue 
in the sequence is characteristic of a cis conformation. Such discrimination requires identification of 
the proline spin-system. In the case of CP2, the additional resonances arising from residues affected 
by the cisitrans isomerisation process caused additional spectral overlap in the region of interest. 
Consequently, to allow reliable proline spin-system assignment, ' 5N/'3C-isotope labelling was 
undertaken. 
Triple resonance experiments allowed full assignment of proline residues due to the additional 
chemical shift dispersion afforded by 13C.  Backbone resonance assignment (N, HN, CO, Ca), along 
with complete sequence specific assignment was rapidly achieved using the combination of 
experiment pairs (see chapter three), 3D-I-lIN(CA)CO/3D-HNCO and 3D-CBCA(CO)NHI3D-
HNCACB. This second pair of experiments allowed assignment of the different spin systems for the 
two conformers of Pro l 19. The two distinct sets of assignments for the two conformers were 
manipulated by having two sets of residues in the ANSIG sequence file. One set was equivalent to the 
CP2 sequence numbered as in its primary sequence from Va196-Asn 159 (residues from the cloning 
artefact were named Glu92, A1a93, Glu94, and Phe95). The other set was equivalent to the first one, 
but with 1000 added to every residue number, resulting in a Val 1096-Asn1159 sequence. The trans 
conformer was attributed the set numbered from 96-159, while the cis conformer was attributed the 
1096-1159 set. 
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Table 5.1: NMR experiments collected on unlabelled and '5N-labelled CP2 
Experiment Sweep width Complex data Matrix size Processing method I Mixing 
(Hz) points after time 
processing (ms) 
'H 
2D COSY [130] 10000 x 700035 4096 x 1536 4096 x 2048 FFT (sinb 90, sinb 90) 
2D TOCSY [192] 8000 x 7000.35 2048 x 1024 2048 x 1024 FFT (sinb2 90, sinb 2 90) 65 
2D NOESY [135] 8000 x 7000.35 2048 x 1024 2048 x 1024 FFT (sinb2 90, slob2 90) 120 
15  N 
2D HSQC [140, 141] 5000 x 2212.6 1024 x 192 1024 x 256 FFT (sinb2 90, sinb' 90) 
2D HSQC (folded) 5000 x 1223 1024 x 64 1024 x 128 FFT (sinb 2 90, sinb 2 90) 
3D ' 5N-edited HSQC-TOCSY 5000 x 7000 x 1223 1024 x 180 X 56 1024 x 512 x 128 MEM (sinb2 90) 60.9 
3D ' 5N-edited HSQC-NOESY [193] 5000 x 7000 x 1223 1024 x 180 x 64 1024 X 512 x 128 MEM (sinb2 90) 100 
2D SCT-HMSQC-HA [194] 8000 x 2000 2048 x 256 2048 x 256 FFT(slnb2 90, sinb2 90) 
3D HINI-IB [195] 5000 x 6000 x 1223 1024 x 120 x 48 2048 x 256 x 128 MEM(sinb2 90) 
2D HSQC in D20 5000 x 2015 1024 x 128 2048 x 128 FFT (sinb' 90, sinb2 90) 
WEXII [196] 8000 x 1223 2048 x 128 2048 x 128 FFT (gauss, sinb2 75) 
I All experiments recorded at 37°C and 600 MHz 	
I 
FFT: Fast Fourier Transformation, MEM: Maximum Entropy Method. Window functions are indicated in 
dimension 1, dimension 2, dimension 3 order as featured in the AZARA processing scripts; for MEM, a 
window function was only applied in dimension 1 (acquisition dimension). Sin2b <angle> corresponds to a 
multiplication of the data by a sine function squared with the given angle. Gauss corresponds to a 
multiplication of the data by a gaussian function with a line broadening of 20 Hz, and a sharpening factor of 
1.3. 
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Table 5.2: NMR experiments collected on 15N/13C-labelled CP2 
Experiment Sweep width (Hz) Complex Matrix size 'Processing method Mixing 
data points after time 
processing (ms) 
2D ' 3C-HSQC [197] 10000 x 16000 2048 x 256 2048 x 256 FFT (gauss, sinb2 90) 
2D ' 3C-HSQC (folded) 10000 x 6211.18 2048 x 128 2048 x 512 MEM (gauss) 
3D H1'CO [198] 8000 x 1780.38 x 1223.01 2048 x 128 x 56 2048 x 256 x 128 MEM (sinb2 90) 
3D HN(CA)CO [199] 8000 x 1780.38 x 1223.01 2048 x 42 x 56 2048 x 256 x 128 MEM (sinb2 90) 
3D CBCA(CO)NH [200] 
3D I-[NCACB [200] 
8000 x 10559.66 x 1223.01 
8000 x 10559.66 x 1223.01 
2048 x 128 x 56 
2048 x 128 x 56 
2048 x 256 x 128 
2048 x 256 x 128 
MEM (sinb2 90) 
MEM (sinb2 90) 
3D HBHA(CO)NH [201] 8000 x 10559.66 x 1223.01 2048 x 160 x 56 2048 x 512 x 128 MEM (sinb2 90) 
3D HBHANI-1 [202] 8000 x 10559.66 x 1223.80 2048 x 128 x 56 2048 x 256 x 128 MEM (sinb2 90) 
3D (H)C(CO)NH-Tocsy [203] 
3D H(C)(CO)NJ-J-Tocsy [203] 
8000 x 10559.66 x 1223.80 
8000 x 5599.88 x 1223.80 
2048 x 128 x 56 
2048 x 128 x 56 
2048 x 512 x 128 
2048 x 256 x 128 
MEM (5mb2 60) 
MEM (sinb2 90) 
22.2 
20.4 
3D HCCH-TOCSY [204] 8000 x 5599.88 x 4659.83 1024 x 160 x 64 1024 x 512 x 128 MEM (sinb2 60) 22.2 
3D (J-1)CCH-TOCSY-CI-13 [205] 5000 x 10559.66 x 2750.08 1024 x 128 x 152 1024 x 128 x 256 FFT (sinb2 90, sinb2 90, 
sinb2 90) 
20.4 
3D H(C)CH-TOCSY-CH3 [205] 5006.25 x 3600.03 x 2750.08 1024 x 96 x 152 1024 x 128 x 256 FFT (sinb2 60, sinb2 60, 
sinb2 60) 
20.4 
2D (HB)CB(CGCD)HD [206] 8000 x4000 2048 x 64 2048 x 128 MEM (sinb2 60) 
2D (HB)CB(CGCDCE)HE [206] 8000 x 4000 2048 x 64 2048 x 128 MEM (sinb2 65) 
3D ' 3C-edited-NOESY [193] 10000 x 8064.51 x6211.18 2048x256x64 2048x512x 128 MEM (sinb2 9O) 146.5 
All experiments recorded at 37°C and 600 MHz -except for 3D '3C-edited -NOESY recorded at 800 MHz 
FFT: Fast Fourier Transformation, MEM: Maximum Entropy Method. Window functions are indicated in 
dimension 1, dimension 2, dimension 3 order as featured in the AZARA processing scripts; for MEM, a 
window function was only applied in dimension 1 (acquisition dimension). Sin 2b <angle> corresponds to a 
multiplication of the data by a sine function squared with the given angle. Gauss corresponds to a 
multiplication of the data by a gaussian function with a line broadening of 20 Hz, and a sharpening factor of 
1.3. 
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Characteristic, sequential, NOE cross-peaks confirmed the presence of both cis and trans peptidyl-
Proll9 bonds. NOE cross-peaks were identified between Leu 118 NH and Pro 119 Ha in the ' 5N - 
edited NOESY, and between Leu 118 CHa and Pro! 19 Ha in the ' 3C-edited NOESY, characteristic of 
the cis conformer (Figure 5.2 - top). NOE cross-peaks were also observed between Leu 118 NH and 
Pro 119 CH26  in the 15N-edited NOESY, and between Leu 118 CHa and Pro 119 CH26 in the 13C_ 
edited NOESY characteristic of the trans conformer (Figure 5.2 - bottom). 
Side-chain resonances were assigned in two steps. First the pair of experiments, 3D-HBHA(CO)NH/ 
and 3D-HBHANH, was used to obtain Ha and HP residue shifts, then the 3D-H(C)(CO)NH-TOCSY 
experiment was used to achieve the remainder of the side-chain proton shifts. A similar strategy was 
adopted for carbon resonance assignments of the side-chains using the pair of experiments, 3D-
CBCA(CO)NH!3D-HNCACB, in combination with the 3D-(H)C(CO)NH-TOCSY. Assignment of 
methyl resonances was also facilitated by use of the 3D-H(C)CH-TOCSY-CH3 and the 3D-(H)CCH-
TOCSY-CH3. 
Aromatic side-chain assignments were performed through analysis of the 2D experiment pair: 
(HB)CB(CGCD)HD/(HB)CB(CGCDCE)HE, which correlates C13  of the aromatic residue to the Ho 
and Hc protons respectively. Aromatic residue side-chain assignment was then confirmed in the ' 3C 
edited NOESY. 
Backbone and side-chain assignments were subsequently used to assign the 3D-HCCH-
TOCSY, which was then used to assign the 3D-' 3C edited NOESY spectrum. Similarly, the 3D-' 5N 
edited TOCSY and NOESY were assigned as far as possible. Both 3D-' 5N edited NOESY and 3D-
' 3C edited NOESY spectra contained NOEs consistent with the two distinct conformations for Pro! 19 
mentioned above. 
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Figure 5.2: Identification of cis and trans isoforms. 
Top: ANSIG view from 3D 13Cedited-NOESY experiment - strip for Leu 118 CHa in the cis 
conformer (noted 11 I8LCA [in Fl] - 11 18La [in F3]) showing NOE to Pro 119 Ha (noted 
11 19Pa [in F2]). 
Bottom: ANSIG view from 3D 13C-edited-NOESY experiment - strip for Leu 118 CHa in the 
trans conformer (noted 118LCA [in Fl] - 118La [in F3]) showing NOE to both Pro 119 
H28 protons (noted I l9Pdl and 1 19Pd2 [in F2]). 
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5.4 	Analysis of chemical shift differences between the two conformers 
The 'H-' 5N 2D projection of the 3D 1-INCO experiment proved useful at an early stage for resolving 
the higher than expected number of 'H-' 5N cross-peaks, and in particular for resolving dual peaks 
arising from cis/trans conformers that were close in terms of their chemical shifts. (All of these were 
later confirmed by assignment of 3D spectra) (Figure 5.3, and 5.4). CP2 has 68 residues (including 
residues from cloning artefact), the first residue was not seen in the NMR spectra, and there are four 
proline residues. Therefore, 63 backbone NH peaks are expected, while 86 peaks are effectively 
observed, in the 'H-' 5N 2D projection of the 3D 1-INCO experiment. These extra backbone NH 
resonances were identified as belonging to 23 residues that exist in both a major and a minor 
conformation (see table 5.3). The cis and trans conformations of Pro l 19 correspond to the minor and 
major conformation respectively; the three other proline residues are in the trans conformation. A 
ratio of trans to cis conformer populations of 3:2 was measured from their 1 H-15N HSQC peaks 
intensity ratios. 
In addition to the 23, a further three residues (Leul 13, G1y123, Arg125) were subsequently 
found to have dual NH cross-peaks but one of each pair was overlapped with other NI-I cross-peaks. 
11e98 also yielded a doubled NH cross-peak that became observable after a period of 1-2 months. In 
total therefore, 27 residues were judged to have doubled ("non-degenerate") NH cross-peaks. In 
addition, Arg 129, Cys 144, Lys 153 did not exhibit extra backbone NH cross-peak but exhibited dual 
peaks elsewhere in the spectrum (see below). Out of the 27 residues, 17 residues were found in the 
sequence spanning residues Vail 11 to Phe 128. 
The remainder of the 27 residues are located in two other stretches of the protein sequence 
that are in the vicinity of the cysteine residues involved in the first disulphide bond. The first 
conserved cysteine residue, Cys99, was found to exhibit a large NH chemical shift difference (both in 
' 5N, and 'H) between the two conformations, while the third conserved cysteine, Cys144, has 
degenerate ' 5N and 'H resonances even though it is part of a stretch of residues that have doubled 
cross-peaks. This stretch also contains the conserved tryptophan residue, Trp 149, and both backbone 
NH and side-chain NEHE resonances are non-degenerate between the two conformers. Trp149 has 
two distinct shifts for its HM, C2 and 1-1ç2. These atoms are located on the same side of the 
tryptophan side-chain. Other aromatic residues with duplication of NH cross-peaks (Phe 128, Phe 112) 
did not display doubled resonances for atoms in their side-chains. 
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Triple resonance-experiments allowed identification of other residues with some non-
degenerate resonances between conformers: Cys 144 does not have an extra backbone NI-I cross-peak 
but has a specific H131  resonance for each conformer; similarly for each conformer, Argl4l has a 
different Ha resonance, and Gin 146 has a different Hc21 resonance. A complete assignment table can 
be found in appendix C, and the magnitude of the chemical shift differences between conformers for 
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Figure 5.3: 'H-15N HSQC of the GABA5 Rla-CP2 
Assigned residues with non-degenerate chemical shift are coloured blue for both conformers, cis conformer 
resonances were assigned with the same residue number as the trans conformer but one thousand was added 
to each of them to allow numbering distinction. Peaks of negative intensity are coloured red. 
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Figure 5.4: 'H-15N 2D projection of the 3D HNCO experiment for the GABAB Rla-CP2 
Assigned residues with non-degenerate chemical shift are coloured blue for both conformers, cis conformer 
resonances were assigned with the same residue number as the trans conformer but one thousand was added 
to each of them to allow numbering distinction. Peaks of negative intensity are coloured red. Arrows 
indicate large chemical shift variation between conformers. 
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Table 5.3: Analysis of chemical shift differences between conformers 
Residue 
Non-de Yenerate chemical shifts 
Degenerate chemical shifts in ' 3C-
NOESY and '5N-NOESY 
_____________________________ 15N chemical shift '3C chemical shift 'H chemical shift 
Arg97 N  HN complete in ' 3C-NOESY and "N-NOESY 
11e98 N (developed with time) CG2, CID  HN (developed with 
time), HB,HG2#, HDI# 
CAHA 
Cys99 N CB FIN, RBI, HB2 CAHA 
SerlOO N  FIN CAHA, CBHB# + complete in ' tN-NOESY 
Lys 101 N CG HN, 1`1132, HGs CAHA, CBI-tBl, CDI-lDs 
VaIl II N 
___________  
HN complete in 'tC -No ESY + complete ' tN- 
NOESY 
Phel 12 N 
___________  
FIN CAHA, CBHBs and rest of side-chain in ' tC- 
NOESY 
Len l 13 N (overlap with Gin 107) CD1,CD2 1-IN, HA, HB2, 1-10, 
HD I #,HD2#  
CBHBI 
Thri 14 N CA, CB, CG2 FIN, HA, HB, HG24 
Glyl 15 N HN CAHAI and CAHA2 
Glyll 6 N CA HN, HAs 
Asp] 17 N CA, CB HN, HA, HBs 
Len ll8 N CA, CB, CID HN, HA, HBs, HDs CGHG 
Pro l 19 CA, CB, CG, CD HA, FIBs, HGs, 1-IDa 
Ala120 N CA, CB HA,HB#  
Len 121 N CA, CB, CD2 HN,HA, HBs, HD2# CGHG and CDIHDI# 
Asp 122 N FIN CAHA, I22CBHB2 and I I22CBFIB# 
Gly123 N(overlap with G1y138) CA HN,HAs 
Ala124 N CA, CB HN,HA,HBI 
Arg125 N (overlap with Seri 40) CB HN, HA,HBs, CGHGI CGHG2, and CDHD# + NEHE 
Val 126 N FIN, HA CBHB, CGIHGI#, and CG2HG2 
G1u127 N FIN CAHA, CBHBs, and CGHGs 
P1se128 N FIN 
_____________________ 
CAHA, CBHBs and rest of side-chain in ' tC- 
NOESY + complete in "N-NOESY -  
Argi4l HA complete in, and "N-NOESY 
VaI143 N FIN, HA, CBHB,CGIHGFIt,CG2HG29 
Cys144 CB HB1 complete in 13C-NOESY and 5N-NOESY 
G1n146 N HN,HE2I complete in 13C-NOESY and "N-NOESY 
Glyl 47  N FIN complete in ' 3C-NOESY and ' 5N-NOESY 
Gin 148 N I-SN complete in 13C-NOESY and "N-NOESY 
Trpl49 N, NEI HN, HE], HDI, HZ2 complete in 13C-NOESY and 5N-NOESY 
Total extra 
resonances in 'H 
' tN HNCO 2D 
23 
projectionI  
A=cx, B=13, G='y, D=6, E=, Z=. 
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Figure 5.5: Chemical shift differences for the two conformers (A6)0.01 ppm) versus 
residue number for the two isoforms of CP2 
Positive values represent downfield shifts and negative values upfleld shifts for the minor cis-
Prol 19 conformer, relative to the major trans-Prol 19 conformer. 
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5.5 	Conversion of NOESY cross-peaks to distance restraints 
NOEs are the principle source of structural data, and prior to the determination of the structure of a 
protein by NMR, these must be converted into relevant distance restraints. The relationship, NOE a 
rij 	relates NOB intensities to the distance, r, between two protons, i and j. Derivation of distances 
from NOE volumes is, however, inaccurate in practice because local internal motions, relaxation or 
exchange, cross-peak overlap and possibly spin diffusion introduce significant errors. Typically, 
NOE intensities are classified in broad distance ranges. A strong NOE is assigned to an inter-proton 
distance below 2.7 A, a medium NOE to a distance below 3.3 A, a weak NOE to a distance below 5 
A, and a very weak NOB to a distance below 6 A. In the current study, ANSIG software [191] was 
used to integrate NOE cross-peaks from ' 5N-edited NOESY and 13C-edited NOESY spectra. Relative 
volumes for each cross-peak were calculated from the normalization of the cross-peaks volumes, and 
subsequently categorized as strong, medium, weak, or very weak sets of inter-proton distances. 
The starting point of a structure calculation is a chemical shift table that should be as 
complete as possible, and a partially assigned list of integrated NOB cross-peaks. These data are 
created from the ANSIG cross-peaks file that contains all cross-peaks from the different NMR spectra 
used for assignment, together with a list of integrated cross-peaks from the NOESY spectra. This file 
is converted into a relational database management (RDB) system format for subsequent 
manipulation using a set of shell scripts that are run in a sequential manner. The output is a chemical 
shift table of protons and their attached heavy atoms. 
The connect program from the AZARA package is then used to match the chemical shift 
values of an integrated NOB cross-peak with value in the previously obtained chemical shift list 
within the error bound (in this work 0.03 ppm was used for 1H chemical shift and 0. 3 ppm was used 
for ' 5N/13C chemical shifts). The connect program produces three files, one for unambiguous distance 
restraints, one for the ambiguous distance restraints, and one for the unmatched NOEs. Unambiguous 
and ambiguous restraints are used as input for CNS structure calculation software, while unmatched 
cross-peaks are inspected to detect any possible assignment problems or peak-picking errors. 
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5.6 	Structure calculation protocol 
5.6.1 General principle 
NOEs provide the primary experimental information on the local spatial relationship of 
protons. The positions of other atoms have to be derived from protein chemistry; this a priori 
information is conveniently expressed as energy functions within a molecular dynamics force field. 
Finding conformations of the molecule that satisfy both the experimental data and the force field 
describing the covalent structure and non-bonded interactions is equivalent to finding conformations 
that minimize a hybrid energy function (Ehybrid), which has contributions from both experimental data 
and the force field: Ehybrid = Echem + o nmr Enmr where ECHEM describes empirical chemical information. 
Enmr  represents the NMR data by describing the difference between observed and calculated data, and 
0 NMR is its weighting factor. The empirical energy is a sum of energy terms: Eche, =(ocovEcov + (0vdw 
Evd where E 0  describes covalent geometry (bond lengths, bond angles, and planarity) and cov  is 
its weighting factor. Evd is the van der Waals function and corresponds to a purely repulsive 
function; Wvdw is its weighting factor. Electrostatic interactions and van der Waals attractive functions 
are usually only included in structure calculations at the refinement stage. A common form of Enm, 
describes NOE derived distance restraints and dihedral angle restraints derived from J-coupling 
constants: coNmR Enmr = Wnoe Enoe  + COdihedral Edihedral. 
The CNS software was used to calculate 3D structures from randomised coordinates using 
simulated annealing with Cartesian dynamics under NOE-derived distance restraints. This type of 
optimisation of the hybrid energy function uses molecular dynamics based on simulated annealing 
[207]. Molecular dynamics (MD) consists of simulating the motion of a system of particles, here the 
atoms of the molecule. MD is equivalent to solving Newton's equations of motion as a function of 
time by computer simulation techniques: a1= -- = - V Eliybrjd = m -4-, where a1 is the acceleration; mi 	 dt 
F1 the force exerted; m, is the mass, and ri  is the coordinates of atom i. Atoms are given initial 
velocities taken at random for a low temperature, then simulation is performed for a few picoseconds; 
the sum of the forces exerted on each atom induces a change in velocity, which is used to find their 
new positions and their associated Ehybrid. In this type of simulation, the temperature is held constant 
and atomic velocities are adjusted to remove excessive kinetic energy. The potential energy of the 
system as a function of the atomic coordinates defines an energy surface, whose wells represent the 
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different possible stable or metastable structures of the molecule. Molecular dynamics can overcome 
local energy barriers in Ehybrid but large energy barriers can only be crossed at high temperature. In 
simulated annealing (SA), the system is heated at high temperature (up to 2000 K) followed by a slow 
cooling period; and this process is repeated to obtain the global energy minimum. The independent 
scaling of each contribution in Ehybrid gives rise to a large number of possible SA schemes. But 
generally the bad geometry of the initial structure dictates that covalent geometry terms must start 
with very low weights, and these are gradually increased during the calculation. Convergence is 
achieved through a multi-stage protocol starting from random Cartesian coordinates, followed by 
several steps of SA and MD, and other mathematical energy minimization methods (Powell, and 
conjugate gradient minimisation). A script referred to as the "wrapper" script was used to drive the 
sequence of the calculation and to invoke appropriate restraint files (Raiiie, Smith, and Domaille-
unpublished, see appendix D-l). Each round of calculations includes three steps; randomisation 
(rand.cns - see appendix D-2), regularisation (rrsaswap.cns - see appendix D-3) and a final 
refinement step (rejIne swap.cns - see appendix D-4). These steps correspond to three versions of the 
XPLOR protocols rand.inp, rrsa.inp (DGSA.inp) and refine.inp that have been modified to allow 
floating stereochemistry and include active swapping of pro-chiral centers [208] (methyl, methylene, 
side-chain amide). Only floating assignment assures that the assignment of such groups is consistent 
in the structure. Approximate treatment of pro-chiral groups with pseudo-atoms or sum averaging 
leads to a loss of information, i.e. the correlation of NOEs to the single protons or methyl group of the 
pro-chiral group is lost. 
The ARIA (Ambiguous Restraints for Iterative Assignment) suite of scripts [209] within CNS 
is often employed for iterative automated NOE assignment. In this study, a more conservative 
approach was used [210], and no iterative automated NOE assignments were performed. ARIA was 
utilised only as an analytic tool to select ambiguous NOE contributions from calculated structures that 
showed convergence. 
An ambiguous NOE corresponds to a sum of potential individual contributions. It can be used 
to construct an ambiguous distance restraint that is added to the restraint lists and used for structure 
calculation. Then Enoe  is calculated by defining an effective distance; this is a "summed distance" with 
contributions from more than one proton pair [211]. 
The XPLORICNS averaging option 'sum' was used to impose ambiguous distance restraints in 
No 	—1/6 
the calculation according to the following equation: D 	 where a runs through 
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all No contributions to a cross-peak, c/a is the distance between two protons corresponding to the at 
contribution, and Ninonomei- is use to scale the distances corresponding to ambiguous NOE cross-peaks in 
symmetric multimers. The 'sum' averaging option (above) is generally preferred to the ensemble 
average option (<d 6>"6) as it produces an effective distance, which is closer to the desired result for an 
ambiguous NOE cross-peaks [212]. The difference between sum average and ensemble average is that 
in the sum average option, each contribution is treated separately and summed to give an effective 
distance rather than been an average. 
A first round of calculation is generally performed in which 20 structures are calculated using NOE-
derived restraints and the three-step protocol described above. Structures are normally analysed in 
terms of energy statistics, such that structures with the lowest NOE energies are selected and analysed 
for NOE violations (>0.5 A) using the ARIA based script, analyse (see appendix B-i). The calculated 
structures are also analysed to monitor convergence. This first iteration is repeated until all NOB 
violations are resolved (by re-examination of the spectra and the cross-peak lists), then selected 
structures with lowest NOE energy are used to filter the original ambiguous NOE restraints with the 
ARIA based script [209], filter (see appendix E-2). Small contributions to ambiguous NOEs are 
discarded, and a new iteration is run to generate new structures. Duplicate NOE restraints are also 
discarded with the ARIA based script [209], check (see appendix E-3). This process is repeated until 
structures with lowest NOE energy and data do not change significantly. To assess convergence the 
root-mean-square difference (RMSD) between corresponding atoms amongst the ensemble of 
structures is computed [207]. The UWMN (Hartson and Caves - University of York) program was 
used to calculated RMSDs for structure ensembles; in particular the RMSDs of the backbone atoms 
(Ca, N, and CO) from each structure in the ensemble relative to the mean structure are often used to 
assess convergence. 
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5.6.2 Protocol for calculation of the two conformers and preliminary structures 
In the case of CP2, proline isomerisation seems to induce only localized perturbations. 
Therefore (as described earlier) while many cross-peaks are doubled, most cross-peaks are degenerate 
and can arise from either of the two conformers. It is clearly impossible to distinguish the exact 
contribution of each conformer to the degenerate NOE peak. Different strategies have been reported 
to deal with cis-trans peptidyl-proline conformers. One of them is simply to avoid the problem, and 
use site-directed mutagenesis [213, 214] to exchange the proline residue for a glycine. However, 
such an approach is only sensible if the mutant protein remains functional, and the structure is known 
not to be perturbed in any way. In the case of CP2 both biological function, and the configuration of 
the peptidyl-proline bond in the intact protein, are unknown - therefore the determination of the 
structures of both conformers is preferable. Another approach is to calculate separate structures for 
the conformers, allowing degenerate NOE cross-peaks to be employed in both conformer 
calculations. Interestingly, it has been shown that when NOEs are equally weighted for both 
conformers, the resulting structures do not satisfy the entire set of restraints [215]. Nevertheless, 
Yuan et al [216] showed that this type of calculation was possible when an appropriate calibration of 
the NOE intensity is used to compensate for the differences in populations of the two forms. 
Proline isomerisation also generates an increased ambiguity when assigning NOE data. 
Manually resolving such ambiguities is laborious. In this study a system where the structures of both 
cis and trans conformers are calculated simultaneously was devised to allow testing of ambiguous 
NOE against cis and trans conformers. This approach does not solve the respective cis/trans 
contribution problem to a NOE, but scaling NOE data according to their respective conformer (see 
above) would require extensive manual assignment. In this study, a restrained non-crystallographic 
symmetry (ncs) term was used to introduce an equal contribution to a NOE from each conformer. 
This represents a reasonable first approximation of the 3:2 trans to cis conformer ratio population 
described in section 5.4. This was done in collaboration with Dr. Brian Smith (Institute of Cell and 
Molecular Biology - Edinburgh University). 
All NOE peaks were treated initially as ambiguous, so that the resolved doubled peaks will be 
correctly assigned to the appropriate conformer by the connect program, while degenerate peaks will 
be ambiguously assigned to either conformer (a distinction must be made here between "ambiguous" 
assignments that arise from resonances within the same conformer, and those that are ambiguous 
because they have essentially the same chemical shift in both conformers). The conformers were 
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declared in CNS as two monomers in the same calculation bath (two segids were declared, as well as 
a monomer statement of two), and symmetry between the two conformers was maintained by use of a 
restrained non-crystallographic symmetry (ncs) term. A least-square superposition of the cis ncs-
equivalent specified atoms onto the trans ncs-equivalent specified atoms is computed, and the 
average x,y,z for each atoms is taken. Each atom is then restrained according to the Encs energy term, 
Encs = co,, (x-<x>)2, where co, is used to weight the restraint. This was necessary because of a 
limitation in the sum averaging treatment of NOEs- once a restraint is satisfied in one of the two 
conformers it does not have to be satisfied in the other one. 
The protocol also restricted Pro l 19 conformation to be cis for the minor form and trans for 
the major form. The rand.inp script was modified to create identical random initial coordinates for 
the two conformers, which were then pulled apart by use of a translation. A chemical shift list was 
built from assigned cross-peaks as described previously, and the chemical shifts for degenerate peaks 
were allocated to both cis and trans conformers. This was achieved by writing an awk routine, 
fihlSh?fts (see appendix F-i) that runs along with the set of shell scripts described in section 5.5. The 
NOE cross-peaks file obtained from ANSIG was stripped of all assignment using a script, written for 
this purpose; striAssignments (see appendix F-2). Subsequently, the modified chemical shift list and 
the NOE cross-peaks file stripped of all assignments were used as input of connect. The connect 
output restraint file was further modified by an awk routine, rdb2orrest.awk, to express ambiguous 
restraint in an or-restraints format (see appendix F-3). This format allows ambiguous restraints to be 
ambiguous only between atoms that are present in the same conformer (see appendix G). 
Each round of calculations produced 20 calculated structures. Five preliminary rounds of 
calculations were necessary to adequately separate the two monomers in the first step of the protocol, 
and to identify incorrect assignments of one Phe residue side-chain. Four to five heavily overlapped 
peaks including some close to the water signal in the 15N-edited NOESY, were discarded. Cis 
conformer structures were poorly defined in the first attempt that did not included the ncs term. This 
symmetry term was subsequently applied to the full molecule (ncs between residues 92-159 and 
residues 1092-1159, mentioned later as "full ncs"). From the last of these preliminary rounds of 
calculation, ten of the lowest NOE energy structures exhibited the CP module-fold, and were without 
any significant NOE violations; these were selected for the first "filtering" step. The filter script was 
used to eliminate assignment possibilities that contributed less than 1% to an ambiguous NOE. The 
output was a new restraint file, which was subsequently used in a new round of structure calculation. 
177 
GA BA B  Rla-CP2 conformer structures 
Eight of the lowest NOE energy structures for each conformer along with their energy statistics are 
presented in Figure 5.6 a, and table 5.4. 
Using the same filtered set of restraints, a new calculation round was performed in which the ncs term 
was maintained only for residues exhibiting degenerate chemical shifts (ncs between residues 92-96, 
102-110, 129-140, 142, 145, 150-159 and residues 1092-1096, 1102-1110, 1129-1140, 1142, 1145, 
1150-1159 respectively). This results in "twisted" structures for the cis conformer, where the 
hypervariable loop (residue 112-120) points towards the core of the module, or in structures having 
poorly define region towards the first disulphide bond, despite a lack of NOE violations. Such an 
observation was consistent with the analysis of the chemical shift differences between conformers as 
presented in table 5.3- only a few "extra" (cis conformer-derived) peaks are observed from those 
residues in the region of the first disulphide bond, and this does not provide enough information to 
fully define this region in the cis conformer. Subsequently, a calculation where the ncs term was 
maintained for the whole molecule, with the exception of residues 111 to 128, was performed (ncs 
between residues 92-111, 128-159 and residues 1092-1111, 1128-1159 respectively, mentioned later 
as "reduced ncs"). These residues, which encompass the "hypervariable" loop exhibit most of the 
double resonances in the molecule. At this stage, 75 3J(HN-H(x) derived dihedral angle restraints derived 
from semi-constant-time 'H-15N —HMSQC-HA experiments [194] for both conformers were added 
into the calculation. In the resulting structures, no NOE violations were observed; 20 of the 75 3J(  
H(,,) values were violated but not by more than one Hz. Eight of the lowest NOE energy structures for 
each conformer along with their energy statistics are presented in Figure 5.6 b, and table 5.5. 
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"hypervanable loop" 
trans 	 cis 
b 
trans 	 cis 
Figure 5.6: Comparison of calculated structures withfull or reduced ncs 
(Views from molmol program [http://www.mol.biol.ethz.ch/wuthrich/software/molmolI)  
Overlay of the eight lowest NOE energy structures calculated withfull ncs. 
Overlay of the eight lowest NOB energy structures calculated with reduced ncs. 
Residues from Cys99 to Cys 156 are coloured red. 
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Table 5.4: Energy statistics for 8 lowest NOE energy structures from round withfu/1 ncs 




total bonds angle 
p. 
-Improper Evdw Enoe Edihedral ncs 
#1 60148 4.41 57.33 5.43 103.33 10.60 236.24 184.11 
#2 626.65 4.93 61.59 6,01 113.35 13.77 262.74 164.23 
#3 653.54 5.21 66.47 5.15 126.89 16.34 242.17 191.29 
#4 691.89 5.70 65.54 6.15 119.16 23.64 250.83 220.84 
45 578.01 4.98 60.73 5.85 122.33 24.07 217.31 142.71 
#6 617.70 5.30 64.42 7.03 121.75 24.19 242.61 152.37 
#7 626.05 4.78 59.28 6.18 111.05 30.17 259.86 154.70 
48 595.85 5.53 61.40 4.76 	j 117.67 31.23 213.16 162.07 
Overall backbone RMSD: Cys99-Cys156 = 0.98 A/Cys1099-Cysl 156 =  1.06A 
Table 5.5: Energy statistics for 8 lowest NOE energy structures from round with reduced 














#1 680.61 4.58 66.31 5.90 123.77 12.86 14.77 304.20 148.18 
#2 724.24 6.25 75.45 9.32 127.38 15.72 16.97 308.92 164.20 
43 642.58 5.88 73.04 7.76 126.65 16.06 17.53 258.27 137.T6- 
#4 665.24 6.52 72.07 5.95 134.83 16.52 20.07 279.07 130.17 
#5 679.92 6.34 70.56 6.24 145 17.1 33.43 276.79 124.42 
#6 662.66 5.89 73.62 8.48 119.44 21.84 18.32 271.50 143.53 
#7 877.53 8.85 105.92 14.09 162.39 21.94 23.21 314.47 226.62 
#8 825.51 6.42 80.08 9.81 126.51 26.24 26.98 324.59 224.85 
Overall backbone RMSD: Cys99-Cys156 = 1.16 A / Cys1099-Cysl 156 = 1.4 A 
Table 5.6: Restraint analysis 
Unambiguous restraint after filtering trans cis 
intra-residue 128 124 
sequential 62 42 
short range (21i-j4) 13 5 
long range (Ii-ii>4) 68 21 
Total 271 192 
Ambiguous NOE left: 2219 (total) -271-192=1756 
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5.7 	Analysis of the preliminary structures 
At this stage of the calculation, average backbone RMSDs (based on C(x, N, and CO atoms of residues 
Cys99-Cys1 56 for each conformer) for the 8 best structures was around 1 A in each conformer when 
full ncs is applied; while average backbone RMSD values for calculation with reduced ncs are 
somewhat higher (1-1.4 A). However, the cis conformer structures calculated without ncs for residues 
Vail I 1-Phe 128 [residues with the most non-degenerate (between conformers) chemical shifts] show 
some differences in this region when compared to structures calculated with lies applied to the full 
molecule (Figure 5.7 a). Even though structures calculated with reduced ncs are less precise, they are 
surely more accurate. It is therefore probably preferable to perform reduced ncs type of calculations, 
and use NOE-derived restraints as well as dihedral angle restraints to define this region of the 
molecule (14 cis-specific dihedral angle restraints are available in the sequence portion spanning from 
Val Ill to Phe 128). Such average backbone RMSD values along with low NOB energy (E ioe) show 
that the structures of each conformer are converging towards a fold that satisfies experimental NOE 
restraints. Both of the conformers calculated using the reduced ncs term are (unsurprisingly) 
relatively similar with the exception of the non-restrained (by symmetry) hypervariable loop region 
(Figure 5.6, 5.7 b, and 5.8). The expected secondary structure elements predicted from sequence 
comparison, 3j "-H values and consensus chemical shift index are found in the preliminary structures 
of both conformers (Figure 5.9). In particular both conformers have the helical turn inferred from the 
consensus chemical shift index [217], although not all of the beta-strands are found using the Kabsch 
and Sander criteria [218] (see Molscript representation [219], Figure 5.10 a, b, and c). 
At this stage of the calculation, structures have high dihedral and ncs energies (Edihedra!, and Encs 
respectively). However high Edihedral values are to be expected, as such values do not correspond to 
one but two molecules. Also the PARALLHDG-5. 1/2 forcefield used in this study introduce dihedral 
angle potentials in the regularisation and refinement stages which improve , ii, and X, angles at a 
	
cost in Ediheciral. Finally, it is worth noting that the 	observed for CP2 cis-trans calculations are four 
times lower than the ones observed in the case of the mouse heterochromatin 1 dimer using the same 
weighting factor [220] (weighting factor is 0.05). 
Future rounds of structure calculation will include hydrogen-bond information, which will 
certainly increase secondary structure element definition. A series of 15N-HSQC spectra acquired on a 
15N labelled of CP2 freshly dissolved in D20 have identified a number of slowly exchanging amides 
likely to be involved in hydrogen-bonds (Figure 5.11). Some of these residues have also been 
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identified from 2D heteronuclear water exchange filter (WEXII-FHSQC) experiments [196]: these are 
Leu104, Va1126 (trans), G1u127 (trans), Aspl3l, Cys144, G1n148 (cis and trans), and G1n157. Also 
to be incorporated are 3J(HaH) values measured from the 3D HNHB experiment [195], which relate to 
X, angles (data not shown). 
Taken together the results obtained to date confirm the expected CP-module fold for both conformers. 
On the basis of sequence alignment Prol 19 was predicted to be located as the last residue in the 
hypervariable loop. In the preliminary structures, Prol 19 is indeed located at the end of the 
hypervariable loop. Such a location would mean that cis-trans peptidyl-Pro 119 isomerisation could 
occur with minimum conformational adjustment of the core of the protein. 
After filtering, a total of 2219 NOE was used in the calculations, from which 1756 were 
ambiguous, while 271 were unambiguous and specific to the trans conformer and 192 were 
unambiguous and specific to the cis conformer (see table 5.6). Although, at the present stage of the 
project, the NMR-derived structures of both conformers are converging, and satisfy NOE restraints, it 
will be necessary to assess more accurately NOE assignments made by the filtering process as these 
statistics do not take into account the number of unambiguous NOEs classified as ambiguous simply 
because these are applied to both conformers. 
As an alternative approach to the novel one described above, it will be of interest to compute 
conformer structures according to Yuan's protocol. This will provide an instructive comparison with 
the current one. 
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a 
) 
trans 	 Cis 
b 
trans 	 C's 
Figure 5.7: Comparison of calculated structures withfull and reduced ncs 
(views from molmol program) 
Overlay of closest to mean structures from the ensemble of eight lowest NOE energy 
structures calculated with full (red) or reduced (blue) ncs. 
Closest to mean structure from the ensemble of eight lowest NOB energy structures 
calculated with reduced ncs. 
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Figure 5.8: Comparison of the cis and trans conformers of CP2 
(Views from molmol program and Insight!! program [BIOSYM]) 
Overlay of closest to mean structures from the ensemble of eight lowest NOE energy 
structures calculated with reduced ncs - red: cis conformer, blue: trans conformer. 
Same as (a)- ribbon plot. 
Same as (a)-the "hypervariable loop" predicted from sequence alignment is coloured green. 
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Figure 5.9: Secondary structure elements observed and predicted in the cis and trans 
conformer of CP2 
The consensus chemical shift index of CP2. 
The consensus chemical shift index was calculated using 'Ha, 13Ca, 13C13, and "CO chemical 
shifts, in the CSI program obtained from the university of Alberta (Canada) [217]; results are 
identical for both conformers. The observed secondary structure is illustrated by a spiral 
symbol for helix and arrow symbols for 3-strands. 
Comparison of the 3J(1{N-H(x) values for the cis and trans conformers, 13-strand are predicted 
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b 	trans 	 c 	cis 
Figure 5.10: Secondary structure elements observed and predicted in the cis and (runs 
conformer of CP2 
Primary sequence of CP2 and consensus secondary structure elements derived from the 
consensus chemical shift and the 3J(HNHa) values. f3-strands are coloured red, and the o-helix is 
coloured cyan. 
Moiscript representation for the trans conformer (closest to mean structure)-reduced ncs. 
Molscript representation for the cis conformer (closest to mean structure)-reduced ncs. 
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Figure 5.11: D20 exchange 1H-15N HSQC experiments 
Sample was freeze-dried and redissolved in D20; time indicates elapsed time after D20 addition 




CHAPTER SIX: DISCUSSION 
The intentions of this short chapter are: to summarise the main findings of the various 
components of this thesis; to draw them together so as to provide overall conclusions; and to consider 
briefly the outcome in the context of the literature, and of the wider field of GABAB Ria structure and 
function. This last aim inevitable involves some rather speculative discussion. 
The basis of this thesis is that the CP modules found in the GABAB receptor are biologically 
significant. No function was assigned to these modules when they were first discovered. Four years 
later, their role still remains a mystery. In this respect, it is worth pointing out that amongst the 
relatively small number of known GABAB  receptor variants, three involve the CP modules (Ria [13], 
Ric (unpublished —Genbank accession number AJ012187) and Rie [50]). Recently a new subtype, 
GABAB  Rig, has been cloned [221], it consists of the sequence of both CP-modules from Ria subunit, 
and an additional 80 residues. In vivo expression of this soluble protein will need to be confirmed, as 
there has been no further reports in the literature of such a variant; but if real, it provides further 
evidence for a role of CP modules. So what has been learnt about the CP modules (and their potential 
ligand(s)) from the current work? 
The first CF module of GABAB Ria 
The sequence of GABAB  Ria corresponding to the first putative CP module (CPI) was 
expressed in useful quantities (8-10 mg per litre of pure protein) in the methylotophic yeast P. pastoris. 
Thus CP1 joins a list of CP modules expressed successfully in this system - membrane cofactor protein 
(CD46) module 1 (Dr. Joanne O'Leary - PhD thesis), VCP (intact and in various fragments) [222], 
CR1'-1 517 (with N-glycosylation sites ablated) [210], DAF (in various fragments of two, three and 
four modules, all of them His-tagged) [223]. Other module-types have also been produced at useful 
yields in P. pastoris; examples include EGF-like modules [224] and CUB modules [225]. In contrast, 
attempts at expressing GABAB RI  CPI in insect cells and E. co/i have not so far proved to be fruitful 
(data not shown). The yield from insect cells has proved to be very low so far. E. coli-expressed 
material is insoluble (cytosolic expression - data not shown) or non-detectable (periplasmic expression 
- not shown). While re-folding of insoluble E. co/i-expressed CP modules has been reported (in the 
case of one- and three-CP fragments from CR1) [226] it appears that there is no generally applicable 
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re-folding protocol for such proteins and time did not allow a full exploration of this kind of strategy. 
Thus it appears that P. pastoris, our original choice of expression vector, is the most consistently 
reliable and efficient one for CPI. 
The recombinant CPI was characterised by mass spectrometry which confirmed the expected 
mass, and further studies using mass spectrometery and other techniques confirmed the expected 
(cysteines 1-111, II-IV) disulphide pairing. Biophysical characterisation revealed that P. pastoris- 
expressed CP1 is highly soluble (- 1 mM) and stable, but does not adopt a well-defined structure. More 
specifically, NMR data were suggestive of the presence of multiple conformers of CPI in intermediate 
exchange, while no transition was observed in DSC. Far-UV CD was consistent with a secondary 
structure-content (high in 13-strands) similar to that of other CPs, but when collected as a function of 
temperature the far-UV CD spectra indicated a lack of a cooperative-unfolding event. Near-UV CD 
and NMR NOESY spectra, however, indicated the presence of some tertiary structure (i.e. buried 
aromatic residues) in the protein. The fact that the 1-I11 and Il-TV disulphides have been formed in CPI 
is also consistent with some tertiary structure formation. Thus it appears that P. pastoris CPI, 
expressed in isolation from the remainder of the receptor, has some characteristics of a molten globule 
(it also binds ANS) but its conformational flexibility is restricted by its disulphide bonds and 
hydrophobic interactions between side-chains. (The status of CP 1 as a "molten globule" was discussed 
at some length in chapter 4). 
The crucial question (and one that will be considered further below) clearly then arises - is this 
recombinant form of CP 1 representative of the conformation of CP 1 in the context of the intact native 
GABAB  receptor? Not only does one need to consider the truncated nature of the expressed fragment 
but it should be remembered that the receptor is glycosylated and contains a second subunit - GABAB  
R2. Unfortunately, since none of the other expression systems tried have yielded useful amounts of 
protein, it has not been possible to properly address the possibility that CP1 expressed in other systems 
than P. pastoris is able to adopt a more defined-fold - in other words the lack of folding could be a P. 
pastoris —specific artefact. This seems unlikely, however, given the successful precedent for use of this 
expression system (see above), and its success in the production of CP2 (see below). The possible 
influence of the N-terminal tail of GABAB  Ria on folding was also explored and it was found to have 
little or none. In a limited way, the importance of glycosylation was also investigated and this too was 
found to be minimal. It was not possible to look in detail at CPI in the full length GABAB Ria, 
however, the influence on structure of the second CP (CP2) was also monitored in the course of this 
investigation (see below). 
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The second CF module of GA BA B  Ria 
Module 2 of GABAB Ria also expresses well in F. pastoris. In contrast with CP1, however, its 
HSQC and NOESY NMR spectra were very promising from the perspective of structure calculation in 
that they contain well-defined, discrete cross-peaks. The marked differences between modules 1 and 2 
were further substantiated by other biophysical studies. For example, DSC showed a strong, sharp, 
transition with a relatively high melting temperature that was consistent with a cooperative unfolding 
event. Far-UV CD-monitored denaturation also showed cooperativity of unfolding with temperature, 
as expected for a protein with a stable and defined structure. Further structural studies identified the 
presence of two conformers for this module arising from cis-trans isomerisation at a peptidyl proline 
bond. The cis-trans conformers were clearly visible in the HSQC of the CP12 module pair but it is not 
known if isomerisation of this kind would be present in the intact receptor. Although cis peptidyl-Pro 
bonds have been noted in CP modules (e.g. factor H-5 [227]), to date cis-trans peptidyl-Pro 
isomerisation has not been reported in other CP modules. It has however been seen in isolated TB 
domains of fibrillins [216] and in an SH3 domain [214]. It is interesting to note that a cis-peptidyl-Pro 
bond was observed in VCP2,3 (the central modules of VCP expressed as a module pair [228]) but in 
the crystal structure of intact VCP, the equivalent bond was trans- [222]. Apart from the presence of 
the two conformers, CP2 looks like a regular CP module with short 13-strands wrapped around a 
hydrophobic core, bounded at the N-terminal and C-terminal ends by the disulphides. This structural 
similarity is not surprising given the similarities in sequence of CP2 to classical CP-modules. 
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The CF module-pair of GABAB  Ria - implications for the extent of regular folding of CP-1 
in the intact receptor 
The CP12 pair from GABAB Ria was expressed in P. pastoris, without the N-terminal 
extension, by Hawrot et al. [34] and used as evidence for the presence of the predicted (on the basis of 
sequence) CP-modules on the basis of CD and DSC. Following isotopic labelling and the development 
of an improved purification protocol (see chapter three), this construct was shown (in the present work) 
to yield NMR spectra of overall poor quality. In the light of the results with the single modules, it is 
clear that the problem with spectra of the double module lies in the folding of module 1. The spectrum 
of CPI2 is, interestingly, not quite the sum of the individual module spectra (i.e. poorly folded CP1 
plus well-folded CP2), indicating that the modules do exert some mutual influence on one another, and 
the spectrum of CPI "improves" (is suggestive of better defined structure) when it is in the context of 
the pair. The importance of intermodular contacts is then brought into question, however, by the 
observation that in the GABAB  Ric subtype, CP2 is missing - that is, it appears unlikely that functional 
CP1 requires the presence of CP2. As with CPI, the possibility was discounted that glycosylation, or 
the presence of the N-terminus, might improve the spectra; moreover a range of different sample 
conditions also failed to improve the spectra. At this stage of the work, the choice was between 
attempting assignments of the module pair using triple resonance experiments on the one hand, or 
performing detailed studies of the more experimentally tractable CP2 on the other. It was decided to 
pursue the latter path with a view to returning to the double module once the second module had been 
fully characterised. The outcome of this work is described in chapter five. 
Nevertheless the work on the double module provided an internal control in the form of CP2 - 
i.e. the fact that CP2 has a well-defined fold, while CP1 does not, supports the hypothesis that this 
property is a function of the amino acid residue sequence, and is not due to an inadequacy of the yeast 
protein production/folding machinery. If other domains within the GABAB Ria subunit of the GABAB  
heterodimer were required for correct CP folding, then intuitively it is CP2, rather than CP1, that one 
would expect to be perturbed by expression in the absence of the remainder of the chain. Further 
(circumstantial) evidence that neither CP is making very extensive, mutually stabilising contacts with 
the rest of the protein is that the (functional, presumably stable) GABAB Rib splice variant lacks the 
CP modules altogether. Therefore, taking all of these arguments together, it is reasonable to 
hypothesise at least that in the functional receptor, module I is indeed not highly structured; by 
extension this leads one to speculate that this low level of structure could have evolved for a specific 
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purpose (the sequence of CPI, unlike CP2, does indeed diverge very significantly from the sequences 
of the CP modules found in, for example, the RCA proteins [34]). In other words it could be critical to 
the biological function of the GABAB Ria subunit. 
There is a growing literature precedent for the importance of intrinsically disordered proteins 
[229, 230]. Such proteins have been reported to exhibit molten globule-like regions that enable diverse 
functions or binding partners. They could represent more than 30% of eukaryotic proteins, according 
to a recent study on 29 genomes [230]. It has been suggested that disorder would be advantageous not 
only for interactions with multiple partners with varying affinities, but also to facilitate rapid response 
in signaling and regulation events [229]. Against this literature background, it is tempting to speculate 
that CPI is indeed an intrinsically disordered domain in the context of the native GABAB receptor that 
would allow the receptor to interact with multiple extracellular proteins thereby providing the range of 
functions that this receptor has been shown to have pharmacologically. 
The fibulin-type module 
If CPI exhibits less conformational freedom in the presence of its binding partner(s) then this 
should become evident from structural studies of its complexes. To facilitate such studies, the FTM 
from fibulin-2 was required. Expression was attempted in P. pastoris, insect cells (not shown) and, 
extensively, in E. coil. Of these, E. coil appears to be the most promising. Further progress could be 
made through the development of a refolding protocol for insoluble material from inclusion material. 
Alternatively, the use of a fusion partner, perhaps combined with re-folding [231] might be attempted. 
It is difficult to explain why P. pastoris did not produce useful quantities of protein; amongst the 
possible explanations are: codon usage, uncertainties in the domain boundaries, and early transcription 
termination [161]. The mutual binding of intrinsically disordered proteins is a possibility for CPI and 
FTM, as seen in the case of ligand-activated transcription factors [232]. These authors found that co-
expression of the two components was advantageous. In their case both proteins were intracellular, 
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APPENDIX A: Pichiapastoris media recipes & protocols 
	
A-i 	stock solutions 
10 x YNB: 13.4% yeast nitrogen base with ammonium sulfate without amino acids. 
'5N-10 x YNB: 13.4% yeast nitrogen base without ammonium sulfate and amino acids, and 
0.2% 15N-ammonjum sulfate. 
500 x B: 0.02% biotin. 
100 x H: 0.4% L-histidine. 
10 x D: 20% dextrose. 
10 x M: 5% methanol. 
10 x GY: 10% glycerol. 
(all solutions sterile by autoclaving or filter sterilisation) 
A-2 	solutions for transformation and maintenance 
YPD:yeast peptone dextrose medium 
1% yeast extract 
2% peptone 
2% dextrose 
20 g of agar per litre if making plates 
Add 1 x D after autoclaving 
MD and MDH: minimal dextrose medium +1- histidine 
1.34% YNB 
4 x 10% biotin 
2% dextrose 
Autoclave water then add I x YNB, 1 x D, 1 x B at 60°C 
To make MDH, add 1 x H 
For plates, add 15 g agar per litre 
YPDS + Zeocin Agar:yeast extract peptone dextrose medium with sorbitol 
1% yeast extract 
2% peptone 
2% dextrose 
I M sorbitol 
+ 2% agar 
+ appropriate concentration of Zeocin ( added at 60°C) 
Autoclave water then add 1 x D 
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A-3 	growth solutions 
100 mM potassium phosphate, pH 6.0 
1.34% YNB 
4 x 10-5  biotin 
1% glycerol (for BMG: buffered minimal glycerol medium) or 0.5% methanol (for BMM: 
buffered minimal methanol medium). 
Autoclave water and cool to room temperature, then add potassium phosphate buffer, pH 6.0, 
I xYNB,1 xB,1 xGYorM 
For '5N labelled growth use '5N-10 x YNB 
For '5N/'3C labelled growth use: 
1-BMD: buffered minimal dextrose medium 
100 mM potassium phosphate, pH6.0 
1.34% '5N-YNB 
4 x 10% biotin 
0.4-0.5% 13C-glucose 
2-13MG: buffered minimal glycerol medium (low concentration) 
100 mM potassium phosphate, pH 6.0 
1.34% '5N-YNB 
4 x 10% biotin 
0.1-0.05% '3C-glycerol 
3-13MM: Buffered Minimal Methanol Medium 
100 mM potassium phosphate, pH 6.0 
1.34% 15N-YNB 
4 x 10% biotin 
0.5% 13C-methanol 
A-4 	induction tests 
For expression tests, individual colonies from transformation plates were used to 
inoculate 5-10 ml of BMG and grown for 48 hat 30°C-250 RPM. Cells were harvested (1500 
g-5 mm-room temperature) and resuspended in 1-2 ml of BMM for induction. Induction 
period was two days with 0.5% methanol final concentration maintained throughout by daily 
addition of 100% methanol stock. 
After induction, 1.5 ml of cells was transferred into an Eppendorf tube and pelleted at 
13,000 RPM for 10 min at room temperature. Supernatant was decanted in clean eppendorf 
tube, and both cell pellet and supernatant were assayed by SDS-PAGE. Protein constructs 
bearing consensus N-glycosylation site(s) were subjected to EfldoHf  treatment (2500 units per 
ml of supernatant) prior SDS-PAGE. 
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APPENDIX B: oligonucleotides sequences 
Note: all sequences are 5' to 3, and annealing temperature was 55°C in all PCR amplifications. 
















same as TR-CP 12 
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B-1.4 TR-CPI & WT-CP1 
[forward EcoRl] 







same as TR-CP 12 








assignment table of the 
two conformers of the 
GABAB Ria CP2 
CA 57.4 HE 
HA 4.65 NHI 
CO 175.2 HHI1 
CB 39.7 HH12 
HBI 3.1 NI-12 
HB2 3.01 HH2I 
CD1 - HH22 
HD - HB# 
CD2 - HG# 
HD2 - HD# 
CEI - HH1# 
HEI - HH2# 
CE2 - NH4 
HE2 - HH# 
CZ - 
HZ - 98 
HB# 3.07 
CD# 132 N 
HD# 7.22 RN 
CE# 131.6 CA 
HE# 7.33 HA 
CO 
96 Val 1096 CB 
FIB 
N 122.7 - CGJ 
RN 7.9 - HG1I 
CA 62.2 62.2 HGI2 
HA 4.01 4.03 CG2 
CO 175.2 175.3 HG2# 
CB 33 33 CDI 
HB 1.95 1.96 HDI# 
CGI - - HG1# 
HGI# 0.87 - 
CG2 - 99 
HG2# 0.84 - 
CG# 21 21 N 
HG 0.86 0.87 RN 
CA 
97 Arg 1097 1-IA 
CO 
N 126.2 126.2 CB 
RN 8.18 8.21 HBI 
CA 55.9 55.8 HB2 
HA 4.34 4.34 HB# 
CO 174.5 174.5 
CB 30.9 30.7 100 
HBI 1.75 1.74 
HB2 1.64 1.64 N 
CG 27.4 - RN 
HG1 1.63 - CA 
HG2 1.58 1.59 HA 
CD 43.7 - CO 
HD  - - CB 
HD2 - - HBI 

























































































































































HG - - HD2 - CG 26.5 
HB# 4.02 4.02 CEI - HG 1.09 - 
HEI - CDI 27.4 - 
101 Lys 1101 CE2 - HD1# 0.64 - 
HE2 - CD2 24 - 
N 127.5 127.2 HH - HD2# 0.48 - 
RN 9.08 9.04 HB# - HB# - - 
CA 58.3 58.2 CD# 131.2 CD# - - 
HA 4.28 4.27 HD# 6.45 HD# - - 
Co 178.3 178.2 CE# 117.7 
CB 31.6 31.7 HE# 6.73 107 Glu 1107 
HBI 2.12 2.1 
HB2 1.94 1.97 104 Leu N 130.2 - 
CG 26.1 25.8 RN 8.7 - 
HGI 1.73 1.66 N 112.1 CA 58 - 
HG2 1.5 1.57 HN 7.34 HA 3.89 - 
CD 29.3 29.4 CA 55.4 CO 177.3 - 
HDI 1.76 1.77 HA 4.18 CB 28.9 - 
HD2 1.68 - CO 176.2 HBI 1.84 - 
CE 42.3 42.3 CB 40.7 HB2 1.78 - 
FIlE! - - HBI 1.88 CG 35.9 - 
HE2 - - HB2 1.83 HGI - - 
NZ - - CG 28.6 HG2 - - 
HZ# - - HG 1.72 CD - - 
HB# - - CD1 25.3 HB# 1.81 - 
HG# - - HD1# 1.04 HG# 2.21 - 
HD# - - CD2 23.4 
HE# 3.01 3.04 HD2# 0.85 108 Asn 1108 
HB# 1.85 
102 Ser Ser CD# - N 118.2 - 
HD# - HN 8.95 - 
N 119 119 CA 55.6 - 
I-IN 8.75 8.75 105 Thr 1105 HA 3.76 - 
CA 60.9 - CO 172.5 - 
HA 4.29 - N 111.6 - CB 36.3 - 
CO 175.4 - HN 7.29 - HBI 1.98 - 
CB 63.1 - CA 60.7 60.6 HB2 1.08 - 
HBI - - HA 4.24 - CG - - 
HB2 - - CO 171.3 - ND2 116.5 - 
HG - - CB 71.5 71.5 HD21 7.44 - 
HB# 4.05 - RB 3.93 - HD22 6.81 - 
CG2 21.3 - HB# - - 
103 Tyr HG! - - HD2# - - 
HG2# 1.08 - 
N 123.1 109 Gly 1109 
HN 7.14 106 Leu 1106 
CA 60.4 N 103.3 - 
HA 3.97 N 125.1 125.3 FIN 7.56 - 
CO 173.1 RN 8.46 8.47 CA 46.4 - 
CB 38.5 CA 53.3 53.2 RA  4.34 - 
HBI 2.44 HA 4.39 - HA2 3.88 - 
HB2 2.22 CO 174.7 - CO 171.9 - 
CD1 - CB 45.7 45.6 HA# - - 
HDI - HBI 1.34 - 
CD2 - HB2 0.95 - 110 Lys 1110 
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CE! - - 116 Gly 1116 
N 121 - HEI - - 
FIN 9.01 - CE2 - - N 106.6 106.1 
CA 54.8 54.8 HE2 - - I-IN 8.45 7.92 
HA 4.6 4.6 CZ 129.4 - CA 46.7 45 
CO 173.5 173.5 HZ 7.2 - HA! - 3.85 
CB 37.7 37.6 HB# - - HA2 - 3.79 
HB! - - CD# 131.9 - CO 173.6 172.7 
HB2 - - HD# 7.15 - HA# 3.77 3.82 
CG 24.9 24.9 CE# 131 - 
HGI 1.32 - HE# 7.17 - 117 Asp 1117 
HG2 1.24 - 
CD 29.2 29.1 113 Leu 1113 N 116.9 120.7 
HDI 1.69 - I-IN 8.5 8.19 
HD2 1.61 - N 130.6 130.1 CA 53.3 52.7 
CE 42.4 42.4 FIN 8.76 8.69 HA 4.61 4.92 
HEI - - CA 54.5 54.6 CO 176.3 175.4 
HE2 - - HA 5.05 5.13 CB 40.2 41.3 
NZ - CO 176 176.1 HB1 - 2.76 
HZ# - - CB 45 44.9 HB2 - 2.54 
HB# 1.51 1.51 HB1 1.88 1.84 CG - - 
HG# - - HB2 1.29 1.31 HB# 2.69 - 
HD# - - CG 27.6 27.7 
HE# 2.95 2.95 HG 1.35 1.48 118 Leu 1118 
CDI 26.7 26.2 
111 Val 1111 HDI# 0.94 0.89 N 124.1 122.1 
CD2 24.1 24.9 HN 7.73 8.14 
N 119.5 119.5 I-11D2# 0.88 0.89 CA 53.7 54.3 
FIN 7.83 7.8 HB# - - HA 4.45 4.19 
CA 61 60.9 CD# - - CO - 176.3 
HA 4.54 4.57 HD# 0.91 0.89 CB 40.7 40.9 
CO 175.5 175.4 HB! 1.6 1.66 
CB 34.4 34.4 114 Thr 1114 HB2 1.47 1.4 
HB 1.62 1.61 CG 24.8 24.8 
CG1 21.7 - N 124.4 121.2 HG 1.42 1.39 
HG14 0.74 0.74 FIN 9.37 9.19 CD! - 25.5 
CG2 21.4 - CA 62.1 61.3 HD1# - 0.93 
HG2# 0.61 0.61 HA 4.56 4.64 CD2 - 23.1 
CG# 21.6 21.6 CO 174 173.7 HD2I - 0.85 
HG# - - CB 70.6 71.5 HB 1.49 - 
HB 4.07 4.09 CD# 22.5 - 
112 Phe 1112 CG2 21.4 21.6 HD# 0.9 - 
HGI - - 
N 127.8 127.5 HG2# 1.26 1.19 119 Pro 1119 
FIN 8.97 8.88 
CA 56.5 56.5 115 Gly 1115 N - - 
HA 4.75 4.76 CA 64.3 63.7 
CO 174.7 174.4 N 113.5 111.3 HA 4.28 4.35 
CB 39.9 40.3 RN 8.9 8.42 CO 178 176.4 
HBI 3.05 3.04 CA 45.9 45.6 CB 31.4 34.9 
H132 2.9 2.88 HA  4.15 4.17 HBI 2.26 2.36 
CDI - - HA2 3.89 3.89 HB2 1.93 2.16 
HD  - - CO 175.4 173.3 CG 27.8 24.6 
CD2 - - }-IA# - - HGI 2.18 1.97 

























































CD 50.7 50.5 HAl 4.33 4.21 HB 
HD1 3.9 3.65 HA2 3.63 3.71 CGI 
HD2 3.7 3.48 Co 174.9 174.1 HGI# 
HB# - - HA# - - CG2 
HG# - - HG2# 
HD# - - 124 Ala 1124 CG# 
HG# 
120 Ala 1120 N 125.6 123.6 
I-IN 8.44 8.26 127 
N 125.6 127 CA 52.9 52.6 
FIN 8.89 8.31 HA 4.43 4.37 N 
CA 53.6 54 CO 175.5 175.4 FIN 
1-IA 3.93 4.3 CB 20.4 20.8 CA 
CO 176 177.3 HB# 1.4 1.34 HA 
CB 18 19.3 CO 
HB# 1.39 1.47 125 Arg 1125 CB 
HB 1 
121 Leu 1121 N 117.4 118.8 H132 
HN 8.49 8.71 CG 
N 112.1 115.8 CA 54.7 54.7 HGI 
FIN 8.18 8.2 HA 5.51 5.42 HG2 
CA 56.5 55.2 CO 175.1 175.5 CD 
HA 3.57 3.96 CB 34.2 33.4 HB# 
CO 175.2 175.9 HBI 1.94 1.9 HG# 
CB 40 41.9 HB2 1.74 1.77 
HB1 2.18 1.83 CG 27.8 27.9 128 
HB2 1.55 1.48 HG1 1.73 1.73 
CG 27.2 27.1 HG2 1.65 1.63 N 
HG 1.56 1.55 CD 44 44 MN 
CD1 26.2 26.2 HDI - - CA 
HDI# 0.92 0.91 HD2 - - HA 
CD2 23.9 23.7 NE 105.6 - CO 
HD2# 0.9 0.76 HE 7.19 - CB 
HB# - - NH1 - - HBI 
CD# - - HHI1 - - HB2 
HD# 0.91 - Fll-I12 - - CD1 
NI-12 - - HD1 
122 Asp 1122 HH2I - - CD2 
HH22 - - HD2 
N 120.4 119.1 HB# - - CE1 
FIN 7.59 7.52 HG# - - HEI 
CA 57.3 57.3 HD# 3.18 3.17 CE2 
HA 4.05 4.07 HH1# - - HE2 
CO 176.3 177.5 H}124 - - CZ 
CB 40.9 41.2 NH# - - HZ 
HB1 2.78 - HH# - FIB 
HB2 2.5 - CD# 
CG - - 126 Val 1126 HD# 
HB# - 2.55 CE# 
N 116.3 116.7 HE# 
123 Gly 1123 UN 8.9 8.9 
CA 58.5 58.3 129 
N 116.3 115.6 HA 5.24 5.3 
1-IN 8.57 8.41 CO 174.6 174.6 N 














CA 54.8 54.8 N - 
HA 4.67 4.67 CA 65.3 135 His 
CO 175.2 - HA 4.44 
CB 34.4 34.4 CO 176.9 N 114 fm  1.89 1.88 CB 32 HN 9.18 
HB2 1.75 1.74 HB1 2.4 CA 53.9 
CG 27.2 - HB2 1.89 I-IA 5.12 
HG! 1.72 - CG 28 CO 172.7 
HG2 1.62 - HGI 2.16 CB 30.9 
CD 43.7 - HG2 2.07 HB1 3.3 
HD1 3.28 - CD 50.5 HB2 3.27 
HD2 3.12 - HD  3.84 ND! - 
NE 105.4 - HD2 3.65 HDI - 
HE 7.1 - HB# - CD2 120.2 
NH! - - HG# - HD2 7 
HHII - - HD# - CE! - 
HH12 - - HE! - 
NH2 - - 133 Asp NE2 - 
HH21 - - HE2 - 
HH22 - - N 114.9 HB# 3.28 
HB# - - HN 8.57 
HG# - - CA 56 136 Leu 
HTJ# - - HA 4.42 
HHI# - CO 173.5 N 126.2 
HH2# - - CB 38.7 HN 8.72 
NH# - - HB1 2.89 CA 56.5 
HH# - - HB2 2.81 HA 4.26 
CG - CO 176.6 
130 Cys I-TB# 2.83 CB 43.2 
HB! 1.74 
N 121.4 134 Phe HB2 1.46 
HN 8.99 CG 27.4 
CA 55.2 N 117.8 HG 1.15 
HA 5.04 RN 8.32 CDI 26.4 
CO 174.3 CA 56.8 HD!# 0.63 
CB 41.5 HA 4.93 CD2 25.5 
HBI 3.06 CO 175.1 HD2# 0.54 
HB2 2.56 CB 43.4 HB# - 
HB# - HBI 3.23 CD# - 
HB2 2.52 HD# 0.58 
131 Asp CD! - 
HD! - 137 Val 
N 125.5 CD2 - 
HN 8.98 HD2 N 130.1 
CA 54 CE! - RN 8.92 
HA 4.7 HE1 - CA 62.6 
CO 173.3 CE2 - HA 4.13 
CB 38 HE2 - CO 174.7 
FIBI 2.9 CZ 129.9 CB 32.3 
11B2 2.4 HZ 7.29 HB 1.17 
CG - HB# - CG1 - 
HB# - CD# 131.5 HG!# 0.86 
HD 6.8 CG2 - 
132 Pro CE# 131.6 HG2# 0.8 

































141 Arg 1141 
N 119.3 - 
HN 7.67 7.67 
CA 54.8 54.8 
HA 5.57 5.6 
CO 175.4 - 
CB 34.6 - 
HBI 1.9 - 
HB2 1.77 - 
CG 27.3 - 
HGI 1.69 - 
HG2 1.61 - 
CD 43.8 - 
HD  - - 
HD2 - - 
NE 105.9 - 
Appendix C 
HE 7.34 - 
NHI - - 145 Ser 1145 
HHI1 - - 
HH12 - - N 124.6 124.6 
NI-12 - - FIN 8.4 8.42 
HH21 - - CA 56.9 56.9 
HH22 - - HA 4.77 4.72 
HB# 1.85 - CO 174.5 174.4 
HG# - - CB 64.5 64.4 
HD# 3.17 - HBI 3.73 3.72 
HHI# - - HB2 3.63 3.63 
HH2# - - HG - - 
NH# - - HB# - - 
HH# - - 
146 Gin 1146 
142 Ser 1142 
N 126.4 126 
N 117.3 - HN 9.4 9.41 
HN 8.59 - CA 56.7 56.7 
CA 59.1 59 HA 3.75 3.77 
HA 4.74 4.72 CO 176.3 176.3 
CO 173 173 CB 26.9 26.8 
CB 67.2 67 HBI 2.17 2.17 
HBI 3.85 - HB2 2.03 2.04 
HB2 3.8 - CG 34.3 34.2 
HG - HGI 2.36 2.36 
HB# 3.82 3.82 HG2 2.29 2.3 
CD - - 
143 Val 1143 NE2 112.5 112.5 
HE2I 7.46 7.42 
N 124.1 123.8 HE22 6.7 6.73 
HN 8.94 8.91 HB# - 
CA 60.8 60.7 HG# 2.32 2.32 
HA 5.3 5.37 HEN - - 
CO 174.9 175 
CB 35.8 35.8 147 Gly 1147 
HB 2.04 2.04 
CG1 21.4 21.4 N 104.5 104.5 
HG1# 0.97 0.97 FIN 8.18 8.32 
CG2 20.6 20.6 CA 46.2 46.2 
HG2# 0.92 0.91 HAl 3.77 3.77 
CG# - - HA2 3.22 3.21 
HG 0.94 - CO 172.7 - 
HA# - - 
144 Cys 1144 
148 Gin 1148 
N 130 129.9 
I-IN 8.79 8.8 N 118.7 118.2 
CA 54.8 54.8 I-IN 7.53 7.5 
HA 4.26 4.27 CA 53.7 53.7 
CO 174.2 174.1 HA 4.5 4.49 
CB 39.3 39.4 CO 175.5 175.3 
HBI 2.72 2.54 CB 32.6 32.6 
HB2 0.65 0.63 14B  2.02 2.01 
HB# - - HB2 1.85 1.85 
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CG 33.6 33.6 CB 70.8 HA 4.72 - 
HGI - - HB 4.53 Co 173.6 - 
HG2 - - CG2 22.3 CB 33.5 - 
CD - - HGI - HB1 1.88 - 
NE2 112.5 - HG2 1.49 HB2 1.42 - 
HE21 7.53 - CG 26.6 - 
HE22 6.79 - 152 Pro 1152 HGI 1.49 - 
HB# - - HG2 0.38 - 
HG# 2.27 2.26 N - - CD 49.7 - 
HE2# - - CA 62.3 62.3 HDI 2.9 - 
HA 4.68 4.68 HD2 1.81 - 
149 Trp 1149 CO 176.4 176.4 HB# - - 
CB 32.4 32.3 HG# - - 
N 127.1 126.7 HBI 2.45 2.45 HD# - - 
1-IN 8.37 8.37 H132 1.78 1.77 
CA 57 56.9 CG 27.6 27.6 155 His 
HA 5.13 5.13 HGI 2.1 - 
CO 179.7 179.7 HG2 2.04 - N 109.2 - 
CB 30.9 30.9 CD 51.5 51.5 1-IN 7.9 - 
HB1 3.41 3.4 HDI 3.99 3.98 CA 54.4 - 
HB2 2.62 2.62 HD2 3.73 3.72 HA 4.71 - 
CD1 127.1 127.2 HB# - - CO 172.4 
HDI 6.4 6.43 HG# 2.08 2.08 CB 31.8 - 
NEI 130.5 129.9 HD# - - HB1 3.07 - 
HE! 10.22 10.09 HB2 3.03 - 
CE3 120.8 - 153 Lys 1153 NDI - - 
HE3 7.26 - HDI - 
CZ2 113.2 113.3 N 129.6 129.5 CD2 120.1 - 
HZ2 6.92 6.97 HN 8.37 8.35 HD2 7.05 - 
CZ3 122.8 - CA 54.7 54.6 CEI - - 
HZ3 6.82 - HA 3.44 3.42 HEI - - 
CH2 122.9 - CO 174.7 174.7 NE2 - - 
HH2 6.63 6.63 CB 33.1 33.1 HE2 - - 
HB# - - HB1 1.21 1.2 HB# 3.05 - 
HB2 0.53 0.53 
150 Ser 1150 CG 24.3 - 156 Cys 1156 
HGI 1.11 - 
N 117.8 - HG2 0.36 - N 121.4 - 
FIN 9.24 9.23 CD 30.1 - HN 9.31 - 
CA 60.8 - HID! 1.2 - CA 54.6 - 
HA 4.29 - HD2 0.99 - HA 5.07 5.06 
CO 174.7 - CE 42.8 - CO 173.6 - 
CB 63.6 - HE1 2.86 - CB 40.9 - 
HB1 - - HE2 2.75 - HB1 2.67 2.67 
HB2 - - NZ - - HB2 2.55 2.54 
HG - - HZ# - - HB# - - 
HB# 4.3 - HB# - - 
HG# - - 157 GIn 1157 
151 Thr HD# - - 
HE# - - N 126.8 127.2 
N 111.9 HN 9.06 9.06 
FIN 7.62 154 Pro CA 53.7 - 
CA 58.9 HA 4.84 4.84 
HA 5.19 N - - CO 174.6 - 
CO 172.7 CA 63.1 - CB 32.3 - 
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HIB1 1.68 	1.68 
HB2 1.32 1.32 
CG 33.3 	- 
HG1 - - 
HG2 - 	- 
CD - - 
NE2 113.3 	- 
HE21 7.72 - 
HE22 6.92 	- 
HB# - - 
HG# 2.45 	- 
































APPENDIX D: CNS scripts for structure calculation 
D-1 	wrapper script 
!@NODE_NAME: 
{=>} evaluate ($fileroot 
{==>} evaluate ($startcount=l) 
{=>} evaluate ($endcount=lQ) 
{=>} evaluate ($seed = 1879) 
parameter 
reset 
evaluate ($par nonbonded = PROLSQ) (5  Set forecefield to use 5)  
@@PROTOCOLS:. ./PARALLI-IDG_5.1 /parallhdg5.l pro 
end 
struct reset @@../mtf/M2.mtf end 
Read experimental restraints 
noe 
reset 




set echo off message offend 
class c @../restraints/restraint_files .06 1201 /orc-noesy.tbl 
class n @/restraints/restraint_files_0620 I/or NOESY HSQC.tbl 
set echo on message on end 
monomers 2 
averaging * sum 
potential soil 
scale 	* 1.0 
sqconstant * 1.0 
sqexponent * 2 
Soexponcnt * I 
rswitch * 1.0 
sqoffset * 0.0 
asymptote * 2.0 
end 
phi angle restraints 
coupling 
reset 
class = scthmsqcha 
coefficients 6.98 -1.38 1.72 -60 
potential=square 
force = 1.0 
set echo off message offend 
./restraints/avujhnha.tbl 
set echo on message on end 
end 
print thresh= l 0000.0 noe 







equi ((resid 92:111) or (resid 128:159)) 
equi ((resid 1092:111 l)or(resid 1128:1159)) 
weight = 0.05 
end 
end 
Append node name (if any set) to $fileroot 
if (Sexist node name = TRUE) then 
evaluate ($fileroot = $fileroot + 	+ $node name) 
end if 
Multiply $seed by Snode_id (if set) 
if($existnodeid TRUE) then 











D-2 	rand cns script 
remarks randpartial.inp 
remarks Reference: 
remarks Nilges, M. (1994) 
remarks Modified for 4-D ambiguity by Andrew Raine 14/2/95 
if ($exist start count = FALSE) then 
	
{=>} evaluate ($startcounl=l) 	{* number of structures *} 
end if 
if ($exist end count = FALSE) then 
(=>) evaluate ($end count= l0) 	{* number of structures *} 
end if 
if ($exist seed= FALSE) then 
evaluate ($seed = 1872) 
end if 
evaluate ($seed = $seed * ($start count + I 
Set seed $seed end 
evaluate ($init_t = 2000) 
evaluate ($bath = $initt) 
do (refx = 15.0) (resid 92:159) 
do(refl= 15.0) (resid 1092:1159) 
do (re& = 0) (all) 
do (refz = 0) (all) 
evaluate ($kharm = 0.0001) 
do (harm = $kharm) (all) 
do (mass=100) (all) 
evaluate ($count = $start count) 
while ($count <= $end count ) loop main 
{* 0 ===-============ initial values *} 
do (x = (randomo-0,5)*20) (all) 
do (y = (randomo-0.5)520) (all) 
do (z = (random()0.5)*20) (all) 
this bit spreads the monomers out 
coor 
orient selection=(resid 92:159) 
end 
translate A along x axis so A & B end up a bit spread after rotation below 
coor 
translate vector=(-1,00) distance=] 5.0 
end 
copy coordinates from A to B 
set message off echo offend 
identify (store9) (resid 92:159) 
show min (store9) (resid 92:159) 
evaluate ($acounter = $result) 
show max (store9) (resid 92:159) 
evaluate ($aend = Sresult) 
evaluate ($natoms = $send $acounter + 1) 
do (store9=0) (all) reset store9 
while ($acounter le $aend) loop counter 
evaluate ($bcounter = $acounter + $natoms) assume segid B follows A 
show element (x) (Id Sacounter) 
do (x = $result) (id $bcounter) 
show element (y) (id $acounter) 
do (y = $result) (id $bcounter) 
show element (z) (id $acounter) 
do (z = $result) (id $bcounter) 
evaluate ($acounter = $acounter +1) 
end loop counter 
translate B along x axis so A & B end up a bit spread out 
coor 















evaluate ($knoe = 0.5) 
one scale * $knoe end 
evaluate ($kcoup = $knoe/25) 
coupling force=$kcoup end 
evaluate ($kbon = 0.0005 ) bonds increased ARCR 21/12/95 
evaluate ($kang = 0.0005 ) angles 
evaluate ($kvdw = 0.1) vdw 
evaluate (Skimp = 0.0) impropers (added by ARCR, 'cos MN missed it out) 
evaluate ($kdihe = 0.0) dilserals (added by BUS, for PARALLHDG5. 1) 
*1 ==========-___.___==_============= minimization * 
Setup selection (in store I) for heavy atoms in 'reduced representation' 
@PROTOCOLS:setsp_reduced.cns 
igroup 
interaction (not atorel) (all) 
weights bond $kbon angl $kang impr Skimp dihe $kdihe vdw 0 dec 0 end 
interaction (store]) (atorel) 
weights bond $kbon angl $kang impr Skimp dihe $kdihe vdw $kvdw end 
interaction (resid 92:159) (resid 1092:1159) 
weights vdw 0 end 
end 
flags exclude * include vdw (harm) end 
minimize powell nstep 50 end 
flags exclude include bonds angle {impr} (dihe) vdw noe coup ncs (harm) end 
{* 2 =- 	------==-.-_-___==== high temperature dynamics *} 
do (vx = maxwell($init t)) (all) 
do (vy = maxwell($initt)) (all) 
do (vz = maxwell($init 0) (all) 
do (fbeta=lO) (all) 
evaluate (Stimestep = 0.03) 
evaluate (Snatep = 300) 
while ($kbon <0.01) loop stage  
evaluate ($kbon = nsin(0.25, $kbon * 1.25)) 
evaluate ($kang = $kbon) 
igroup 
interaction (not atorel) (all) 
weights bond $kbon angl Skang impr Skimp dihe $kdihe vdw 0 elec 0 end 
interaction (store 1) (store I) 
weights bond Skbon angl $kang impr Skimp dihe $kdihe vdw $kvdw end 
interaction (resid 92:159) (resid 1092:1159) 
weights vdw 0 end 
end 
dynamics cartesian 
nstep=$nstep timestep=$timestep tcoupling=true 
temperature=$bath nprint=50 
end 
end loop stage  
(*4 	 ----===----========= now with all atoms 5) 









evaluate ($knoe = 5.0)! ARCR + pJ1J 
noe scale * $knoe end 
evaluate ($kcoup = $knoe/25) 
coupling force=$kcoup end 
igroup 
interaction (all) (all) 
weights bond 0.02 angl 0,02 impr 0 dihe 0 vdw 0.002 elec 0 end 
interaction (resid 92:159) (resid 1092:1159) 
weights vdw 0 end 
end 
do (lbeta=10.0) (all) 







interaction (all) (all) 
weights bond 0.05 angl 0.05 impr 0 dihe 0 vdw 0.005 dec 0 end 
interaction (resid 92:159) (resid 1092:1159) 
weights vdw 0 end 
end 
dynamics cartesian 




interaction (all) (all) 
weights bond 0.1 angl 0.1 impr 0 dike 0 vdw 0.01 elec 0 end 
interaction (resid 92:159) (resid 1092:1159) 
weights vdw 0 end 
end 
do (fbeta=l0.0) (all) 
dynamics cartesian 
nstep=500 timestep=0.002 tcoupling=true 
temperature=$bath nprint=50 
end 
remarks seed = $seed 
evaluate ($filename = rand' + $fileroot + "" + encode($count) + ".pdb') 
write coordinates output =$filenaine end 
evaluate ($courst = $count + I) 
end loop main 
Belt and braces effort to make sure that all the nbonds stuff is right for 
the next stage 
parameter 
nbonds 
nbxmod=-2 	{' initial value for nbxmod - modified later *} 





D-3 	rrsa_swap. cns script 
REMARKS ITsa_partial.inp 
REMARKS DGSA.inp from the x-plor manual. 
if ($exist start count = FALSE) then 
(===} evaluate (Sstartcount=O) 	{ number of structures } 
end if 
if($existendcosint = FALSE) then 
(====>) evaluate (Send count=5) 	{* number of structures *} 
end if 
if (Sexist seed= FALSE) then 
evaluate ($seed = 8764) 
end if 
evaluate ($seed = $seed * ($start count + I)) 
{* Doubled high_steps and cool_steps 21/8/95 *} 
{====>} evaluate ($init_t = 2000) 	{* initial simulated annealing temp *} 
(====>) evaluate ($high_steps = 4000 ) { total number of steps at high temp *} 
{* includes loop anne' with swapping } 














averaging * sum 
potential * soft !BOS 
scale 	* 25 'PJD 
sqconutant * 1.0 
asymptote * 1,0 1BOS 
	
rswitch 	1.0 DOS 
end 




evaluate ($count = $start count) 
while ($count <= Send—count ) loop main 
{====>} evaluate ($nreasSign = 0) 	{* number of times velocity reassigned * 
{===>} evaluate ($bath = $init_t) {* reset temperature *} 
evaluate ($filename="rand" ± $fileroot + '_" + eneode($count)-i-".pdb") 
1* test for the correct enantiomer 	 *) 
{* if you want to by-pass this test because the substructures *} 
* were tested previously, simply remove the -1 from the next *} 
{ * statement 	 *} 
for $image in (I -1 ) loop imag 
coor initialize end 
coor @@Sfilename 
do (x='x * Situsge) ( known) 
identify (store 1) (not known) 	(I  set store  to unknowns *} 
create local ideal geometry by template fitting *} 
this takes also care of unknown atoms 	*} 
act message=off echo=off end 
coor copy end 	{* store current coordinates in comparison set *} 
{* the user has to supply a template coordinate set *} 
coor @@../template/M2_template.pdb 
for Sid in id (tag) loop fit 	* loop over residue tags 
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coordinates 	{* Isq fitting using known coordinates *} 
fit select = ( byresidue (Id $id) and not store  
end 
{* store fitted template coordinates for this residue *} 
coor copy selection=( byresidue (id $id) ) end 
end loop fit 
coor swap end 
set inessageon echo=on end 
1*2 	 minimization of bonds, vdw and NOEs *} 
coupling force-0.2 end 
parameter nbonds nbxmod=-2 repel=0.64 end end 
igroup interaction (all) (all) weights * I. vdw 20. end end 
flags exclude * include (bond) vdw floe coup ncs end 
energy end 
while ($ncs >50.0) loop symm 
flags exclude * include (bond) vdw (noe) (coup) ncs end 
minimize powell nstep=400 nprint=20 end 
flags exclude * include (bond) vdw floe coup ncs end 
minimize powell nstep=400 nprint=20 end 
end loop symm 
flags exclude * include bond vdw noe coup ncs end 
minimize powell nstep=400 nprint=20 end 
{* 3 ==================================. include angles *) 
flags include angl end 
minimize powell nstep=400 nprint=20 end 
{* 4 	 dynamics, slowly introducing chsirahity and planarity *) 
evaluate ($nstepl = int($high_steps/l 6)) 
evaluate ($nstep2 = int($lsighsteps/8)) 
flags include impr dihe end 
do (mass= 100) (all) 
do (fbeta=10.0) (all) 
group inter (all) (all) weights * 0.1 impr 0.005 dihe 0.005 vdw 20. end end 
dynamics cartesian 
nntep=Snstepl time=0.003 
tcouptrue temperature=$bath nprint= 100 
end 
igroup inter (all) (all) weights * 0.1 impr 0.05 dihe 0.05 vdw 20. end end 
dynamics cartesian 
nstep$nstep I time=0.003 
tcoup=true temperature=$bath nprint=h 00 
end 
igroup inter (all) (all) weights * 0.2 impr 0.1 dihe 0.1 vdw 20. end end 
dynamics cartesian 
nstep=$nstepl time=0.003 
tcoup=true temperature=$bath nprint=l 00 
end 
parameter nbonds repel=l .28 end end 
igroup inter (all) (all) weights * 0.2 impr 0.2 dihe 0.2 vdw 0.01 end end 
dynamics cartesian 
nstep=$nstep I time=0.003 
tcoup=true temperature=$bath nprint= 100 
end 
parameter nbonds nbxmod=-3 end end 
igroup inter (all) (all) weights * 0.4 impr 0.4 dihe 0.4 vdw 0.003 end end 
dynamics Cartesian 
nntep=$nstep2 time=0.003 
tcoup=true temperature=$bath nprint= 100 
end 
igroup inter (all) (all) weights * 1.0 impr 1.0 dihe 1.0 vdw 0.003 end end 
dynamics cartesian 
nstep=$nstep2 time=0.003 
tcoup=true temperature=$bath tsprint= I 00 
end 
if($image = I) then 
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do (store7=x) all ){ *store first image in stores *} 
do (store8y) ( all 
do (store9z) ( all 
do (store4=vx) ( all  ) 
do (store5=vy) ( all  ) 
do (store6=vz) ( all 
end if 
end loop imag 
* 5 	 establish the correct handedness of the structure * 
energy end 
evaluate ($eminus=$ener) 
coor copy end 
do (x=store7) ( all  ) 
do (y=store8) ( all  ) 
do (z=store9) all 
energy end 
evaluate ($eplus=$ener) 
if( $eplus> Se minus) then 
evaluate ($hand=- I 
coor swap end 
else 
evaluate ($hand= I 
do (vx=store4) (all) 
do (vy=stores) ( all 
do (vz=store6) ( all  ) 
end if 
display $cpu 
Here is where we do some dynamics with the prochiral centers swapping 
define prochiral centres to be swapped & floated 





evaluate ($nstepl=int($high steps / 20.0)) 
do (vx = maxwell($bath)) (all) 
do (vy = maxwell($bsth)) (all) 
do (vz = maxwell($bath)) (all) 
evaluate (Sini floe = 5.0) 	evaluate (Sfin noe = 50.0) 
evaluate ($k_noe = $ini floe) 
evaluate ($noe fac = ($fin noe/$ini noe)^(1/l 0.0)) 
evaluate ($lsightemp_count = 0) 
while ($hightemp count < 10) loop anne 
evaluate ($hightemp count = $highternp_count + 1) 
evaluate ($k noe = $k—noe * $noe_fac) 
noe scale * $k noe end 
display $cpu 
Do swaps 
@PROTOCOLS :swap metropolis ens 
toswap = methyl amido (methylene); 
swap_sel=&swap_sel; 





include angl bond impr dihe vdw noe coup ncs 
end 
evaluate ($kvdw = $k—noe * 0.002) 









if($critical> 2.0) then 
evaluate ($nreauuign = $nreasuign + 1) 
mini powell nstep 100 nprint 10 end 
do (=maxwelI($bath)) ( all 
do (vy=maxwell($bath)) all 
do (vz=maxwell($bath)) all 
end if 
end loop anne 
(stop) 
(* 6 ---- 	 increase vdw interaction and cool *) 
coupling force=l .0 end 
evaluate ($final t = 100) 	( K 
evaluate (Stemputep = 50) K 
evaluate ($ncycle = ($init_t-$finalj)/$teinpalep) 
evaluate ($nstep = int($cool_stepa/$ncycle)) 
evaluate ($ini rad = 1.28) 	evaluate ($fin rad = 1.0) 
evaluate (Sini con = 0.012) evaluate ($fin conS 16.0) 
evaluate ($ini fit = 25,0) 	evaluate ($fin fit = 500.0) 
evaluate ($k fit = $ini fit) 
evaluate (Sflt fac = ($fin fit/$ini fit)^( I /$ncycle)) 
evaluate ($bath = $initt) 
evaluate ($k—vdw = Sini con) 
evaluate ($k vdwfact = ($fin_con/$ini,,,,con)^(1/$ncycle)) 
evaluate ($radius= $inirad) 
evaluate ($radfact ($finrad/$inirad)'( I /$ncycle)) 
evaluate ($i cool = I) 
while ($1 cool <$ncycle) loop cool 
evaluate ($icool=$icool+l) 




parameter nbonds repel=$radisis rcon=$k vdw end end 
parameter 
angle (store3) (all) (store3) $k fit TOKEN 
angle (all) (all) (store3) $k_flt TOKEN 
end 
group interaction (all) (all) weights * I. vdw $k vdw end end 
do (fbeta=lO.0) (all) 
Do swaps 
@PROTOCOLS:uwap_metropoliu.cnu 
touwap = methyl arnido {methylene}; 
uwapsel=&swapael; 








tcoup=true temperature=$bath nprint=$nutep 
end 
>) 	 { abort condition * 
evaluate (Scritical=$(empf$bath) 
if(Scritica! >2.0) then 
evaluate ($nreasuign = $nreasuign + I) 
mini powell nstep 100 nprint 10 end 
do (vx=maxwell($bath)) all 
do (vy=maxwell($bath)) ( all 




end loop cool 
)* 7 	 final minimization *} 
Do swaps) 
display $cpu 
@PROTOCOLS swap metropolis.cns 
toawap = methyl amido methylene; 
swap_sel=&swap set; 
bath=$bath; 	(needs $bath) 




include angl bond irnpr dihe vdw noe coup ncs 
end 
minimize powell nstep= 400 nprint=50 end 
lash up to avoid ids overflowing b & q fields of pdb) 
do (b = 0.0) (all) 
do (q = 1.0) (all) 








evaluate ($filename=rrsa + $fileroot + ""+ encode($count)+.pdb) 
remarks final noe energy $noe 
remarks final coup energy $coup 
remarks violations noe: $violations noe coup: $violations_coup 
remarks seed = $seed 
remarks velocity reassigned $nreassign times 
remarks swaps tried immediately before minimization: $swap_ststs.tries 
remarks swaps rejected: $swap stals.rejectpc percent 
write coordinates output =$filename end 
evaluate ($count=$count+ 1) 
end loop main 




D-4 	refine.cns script 
REMARK refine_partial.inp 
REMARK refinement protocol with ambiguous restraints 
REMARK Nilges, M. (1993).Proteins 17, 297-309. 
if ($exist start count = FALSE) then 
===>) evaluate ($startcount=0) 	{* number of structures 
end if 
if ($exist end count = FALSE) then 
{==>} evaluate ($endcount=5) 	{* number of structures *} 
end if 
if ($exist seed= FALSE) then 
evaluate ($aeed = 8764) 
end if 
evaluate ($seed = $ueed * ($utsrt count + I)) 
{* Doubled high steps and cool steps 21/8/95 ) 
evaluate (Thigh_steps = 10000) 
evaluate ($cool_steps_! = 10000) 
evaluate ($cool_stepu_2 = 4000) 
evaluate ($init t = 2000.01) 
----------------------------------------------------------------------
set the weights for the experimental energy terms 
evaluate ($knoe = 25.0) noes 
evaluate ($asym = 0.1) slope of NOE potential 
evaluate ($kcdi = 0.0) torsion angles 
one 
averaging * sum 
potential * soft 
scale 	* 25 
aqconstant * 1.0 
sqexponent * 2 
soexponent * I 
rswitch * 0.5 
sqoffset * 0.0 
asymptote * 0.1 
end 




evaluate ($rcon = 0.003) 
flags 
exclude * 
include angi bond impr vdw floe coup dihe nes 
end 
evaluate (Scount = $start count) 
while (Scount <= $end count) loop utru 
evaluate ($filename=rrsa ' + $fileroot + "' + encode($count)+".pdb") 
coor mit end 
coor @@$filename 
evaluate ($bath = $initt) 
do (mass = 100.0) (all) 
do (theta = 10.0) (all) 
define prochiral centres to be swapped & floated 




* ============= high temperature stage (reduced non-bonded) * 
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evaluate ($knoe = 25.0) noes 
evaluate ($asym = 0.1) I slope of NOE potential 
noe 
averaging * sum 
potential * soft 
scale 	* $knoe 
sqconstant * 1.0 
sqexponent * 2 
soexponent 1 
rswitch * 0.5 
sqoffset * 0,0 





wmin = 0.01 warning off 
cutnb = 100 nonbonded cutoff 
tolerance 45 
repel = 1.54 scale factor for vdW radii = I ( L-J radii) 
rexp = 4 	exponents in (r'irex - R0"irex)"rexp 
irex = 





interaction (not store I) (all) 
weights * I angl 0.4 impr 0.1 dihe 0.1 vdw 0 dec 0 end 
interaction (store 1) (store 1) 





tcoupling = true 
temperature = $bath 
nprinl=50 
ntrfr = 99999999 
end 




wmin = 0.01 warning off 
cutnb = 7.0 nonbonded cutoff 
tolerance 0.5 
repel = 1.28 scale factor for vdW radii = I ( L-J radii) 
rexp = 4 I exponents in (rirex - R0"irex)'rexp 
irex = 1 
rcon = 4.0 actually set the vdW weight 
end 
end 
first cooling stage *} 
evaluate ($final t = 1000) 	{ K 
evaluate (Stempatep = 50) { K 
evaluate ($ncycle = ($inil_t-$final_t)/Stempstep) 
evaluate ($nstep = int($cool_steps I /$ncycle)) 
evaluate (Sini rad = 1.28) 
evaluate (Sini con = 0.012) 
evaluate ($ini_ang = 0.25) 
evaluate ($ini_imp = 0.1) 
evaluate ($isi_dihe = 0.1) 
evaluate ($ini asy = 0.1) 
evaluate ($ini fit = 25.0) 
evaluate ($fin rad = 1.0) 
evaluate ($fin con = 16.0) 
evaluate ($fin_ang = 1.0) 
evaluate ($fin_imp 1.0) 
evaluate ($fin dihe = 1.0) 
evaluate ($fin asy = 1.0) 
evaluate ($fin fit = 500.0) 
evaluate ($k vdw = $ini con) 
evaluate ($k_vdwfact = ($finconl$inicon)'( l/$ncycle)) 
evaluate ($radius= $inirad) 
evaluate ($radfsct = ($fin_rad/$inirad( 1/Sncycle)) 
evaluate ($k ang = $iniang) 
evaluate (Sang fac = (Sfin_sngl$ini,ang)^(lI$ncycle)) 
evaluate ($k imp = $ini_imp) 
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evaluate ($imp fac = ($fin_imp/$ini imp)^( I /Sncycle)) 
evaluate ($k dihe = Sinidihe) 
evaluate ($dihe fac = (Sfln dihe/$ini dihe)^( I /Sncycle)) 
evaluate ($asym = Siniasy) 
evaluate ($asy fac = (Sfin_asy/$ini asy)A(l /Sncycle)) 
evaluate ($k fit = $ini fit) 
evaluate ($flt fac = ($fin fltl$ini flt)^(1 /$ncycle)) 
do (vx = maxwell($bath)) (all) 
do (vy = maxwell($bath)) (all) 
do (vz = maxwell($bath)) (all) 
evaluate ($i cool = I) 
while (Si cool <$ncycle) loop cool! 
evaluate (Si cool=$icool+ I) 
evaluate ($bath = $bath - $tempstep) 
evaluate ($k..vdw=min($fincon,$kvdw*$kvdwfact)) 
evaluate (Sradius=max($finrad5radius*Sradfact)) 
evaluate ($k_ang = Sk_ang*$angfac) 
evaluate ($k_imp = Skjmp*$impfac) 
evaluate (5k dihe = $kdihe*$dihefac) 
evaluate ($asym = $asym*$asyfac) 
evaluate ($k fit = $kflt*$fitfac) 
group interaction (all) (all) weights 
* I angles $k_ang improper $k_imp dihedral Sk_dihe 
end end 
parameter nbonds 
cutnb=7.0 rcon=$k vdw nbxmod=5 repel=$radius 
end 	end 
parameter 
angle (store3) (all) (store3) $k fit TOKEN 
angle (all) (all) (store3) RJR TOKEN 
end 
noe 
asymptote * $asym 
end 
Do swaps 
@PROTOCOLS swap_metropolis. ens 
toawap = methyl amido methylene; 
swap_sel=&swapsel; 
bath=Sbath; 	(needs $bath) 
swap stats=Sswap stats; 
flags 
exclude * 




tcoupling true temperature =  $bath nprint=$nstep 
ntr& = 99999999 
end 
end loop cool  
second cooling stage *) 
evaluate (Sfinalt = 100) 	{ K 
evaluate ($tempstep = 50) { K 
evaluate ($ncycle = ($bath-$finalt)/$tempstep) 
evaluate ($nstep = int($cool steps 2/$ncycle)) 
evaluate (Si_cool = I) 
while ($i cool < Sneycle) loop cool2 
evaluate (Si cool=$i cool+ I) 
evaluate (Sbath = $bsth - $tempatep) 
Do swaps) 
@PROTOCOLS:swap_metropolis.cns 
toswap = methyl amido methylene; 
swap_sel=&swapsel; 









tcoupling true temperature = $bath nprint=$nstep 
ntrfr = 99999999 
end 
end loop cool2 
evaluate ($stats = 2 * $nstep) 
dynamics cartesian 
nstep=$ststs timestep=0.003 
tcoup!Ing = true temperature = $bath nprint=$nstep 
ntrfr = 99999999 
end 
Powell energy minimization --------- ----====== 
Do swaps 
@PROTOCOLS :swap_downhull.cns 
toswap = methyl amido methylene; 
swap_se!=&swap_se!; 




include angl bond impr vdw floe coup dihe ncs 
end 
mini powell nstep= 500 nprint= 50 end 
Do swaps) 
@PROTOCOLS:swap_downhill,cns 
toswap = methyl smido methylene; 
swap sel=&swap sel; 




include angl bond impr vdw noe coup dihe ncs 
end 
mini powell nstep= 500 nprint= 50 end 
Do swaps> 
@PROTOCOLS:swap_downhill.cns 
toswap = methyl smido methylene; 
swap _sel=&swsp set; 




include angi bond impr vdw noe coup dihe ncs 
end 
mini powell nstep= 500 nprint= 50 end 
lash up to avoid ids overflowing b & q fields of pdb and producing havoc in PROCHECK with cp0.0J 
do (b = 0.0) (all) 
do (q = 1.0) (all) 
evaluate ($violfile = $fileroot + encode($count) + 'viol) 
set print $violflle end 








print tlsres=0.018 bonds 	(6*sigma  Engh & Huber) 
evaluate ($nnsbond=$result) 
print thres=3.04 angles 	(65eigma Engh & Huber) 
evaluate ($rms_angl=$result) 
print thres=5. impropers 
evaluate (Srms_impr=$result) 
print thres=5. dihedrals 
evaluate ($rmsdihe=$result) 
close $violfile end 
set print file=OIJTPUT end 
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remarks 	 - 
remarks overall,bondssnglesimproper,vdw,noecoupdjhencs 
remarks energies: $ener, $bond, $angl, $impr, $vdw, Snoe, $coup, $dihe, $ncs 
remarks 
remarks 	bonds,angles,irnpropers,noe,cosip,djhencs 
remarks rms-d: $rms_bond,$rmsangl,$rmsinspr,$rrnsnoe,$rmscoup,$rmsdjh5$555 
remarks 
remarks 	floe, coup 
remarks violations.: $violations_noe, $violations_coup 
remarks 
remarks seed = $seed 
evaluate ($file = "ref'ine_" + $fileroot + ""+ encode($costnt) + .pdb) 
write coor output= $file end 
evaluate (Scount = $count + 1) 
end loop stru 
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APPENDIX E: Aria-based scripts for structure analysis 
Note: the anal_NOESY HSQC. inp script, the flit NOESYHSQC. inp script are equivalent to the anal c-
noesy.inp, and the filt_c-noesy.inp script respectively; but applies to the 15N-edited noesy experiment. 
E-1 	analyse script 
setenv PROTOCOLS .1. ./../protocols/swapping+J 
ens solve < anal_c-noesy.inp> anal _c-noesy.log 
ens_solve < anal_NOESY_HSQC.inp > anal_NOESYFISQC.log 
ens_solve < anal_J.inp> anal J.log 
E-1.1 anal c-noesy.inp script 
Script to analyse ensemble of structures and the ambiguous NOE used 
to generate them in order to produce new restraints for the next 
iteration of Michael Nilges ARIA approach 
received from Andrew Raine March, 1997 











Set up equivalences for methyls and aromatics etc. 
set echo off message offend 
inline @define_rnethyls.cns 
set echo on message on end 
To get around a bug in the noe analyse statements, we need to 
look at all the restraint files individually (actually, we could do them 
all at the same time if we were prepared to put them all into one class) 
Read experimental restraints 
noe 
reset 





nrestramnts = 50000 { allocate space for NOEs 
ceiling = 1000 { maximum force constant that is allowed 
set message off echo offend 
class 	c @@../../../restraints/restraint_files_041201/or_cnoesy.tbl 
set message on echo on end 
averaging c sum 
monomers c 2 
potential c soft 
scale 	c I { initial scale 
sqoffset c 0.0 
sqconstant c 1.0 
sqexponent c 2 
soexponent c I 
asymptote c 2.0 
rswitch 	c 1.0 
set echo on message on end 
averaging * sum 
potential * soft 
scale 	* 1.0 
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sqconstant * 1.0 
sqexponent * 2 
soexponent * I 
rswitch * 1.0 
sqoffset * 0.0 
asymptote * 2.0 
end 










evaluate ($count = 0) 
evaluate ($endcount=30) 
while ($count < $end count) loop main 
evaluate ($count=$count+l) 
evaluate ($file="refine+encode($coutst)+'pdb') 
coord mit end 
coord @@$file 
aria 
analyse 	 ( Accumulate info about all the restraints over 
mini 	all the structures. Each restraint will be associated 








print threshold 0.3 noe 
end loop main 
(This section for an analysis of each violated restraint (in the log file)) 
aria countviol 
list * 0,0 (fraction of ensemble in which restraints are violated) 
0.0 means list all restraints violated at all, 1.0 means) 
all restraints violated in ALL structures 
end end 
(This section for table of nuclei contributing to each restraint) 
set print .Jcontributions/contrib c.txt end 
aria analyse 	( report on the stats gathered earlier 
minnumber I 
maxstumber 1000 
cutoff 10.0 	( distance - nothing further than this) 
level 1.0 fraction contribution list all possibilities making) 
up to tlsis fraction of the intensity) 
sort * 	Lists all possibilities for each restraint which 
satisfy the criteria above, in order of contribution 
(to total intensity (ISPA!) 
end end 
{ 
(This section for new restraint table excluding violated restraints and nuclei) 
(contributing less than a set fraction of the intensity of the crosspeak) 
set print . ,/restraints/c,tbl end 
aria 
countviol 
exclude S 1.0 { fraction of ensemble is which restraints are violated) 
0,0 means exclude ANY violations 
0.01 <x <0.99 means exclude restraints violated in 




analyse 	( report on the stats gathered earlier 
minnumber I 
maxnumber 1000 
cutoff 10.0 	{ distance 
level 0.99 { fraction contribution) 
or-restraint * 	{ Creates new .tbl from the restraints taking into 
account the exclusions due to violations and the 






E-1.1 anal J.inp script 
Script to analyse ensemble of structures and the coupling constants used 
iteration of Michael Nilges ARIA approach 
received from Andrew Raine March, 1997 










Set up equivalences for methyls and aromatics etc. 
net echo off message offend 
inline @define_methyls.cns 
net echo on message on end 
To get around a bug in the noe analyse statements, we need to 
look at all the restraint files individually (actually, we could do them 
all at the same time if we were prepared to put them all into one class) 
Read experimental restraints 
noe 
reset 





class = SCT 
coefficients 6.98 -1.38 1.72 -60 
coefficients 6.51 -1.76 1.60 -60 
potential square 
force 1.0 
net echo off message offend 
J../../restraintn/avujhnha.tbl 





evaluate ($count = $file - "../pdbs/refine 	- ".pdb) 
evaluate (Scount = decode($count)) 
evaluate (Scount = 0) 
evaluate ($endcount=30) 
while ($count < $end count) loop main 
evaluate (Scount=$count+l) 
evaluate (Sfile=../pdbs/refine_"+encode(Scount)+".pdb) 
evaluate (Wile = "../pdbs/" + encode($count) + 
evaluate (Sphifile = . ./pdba/" + encode($count) + "phi") 
coord mit end 
coord @@$file 
set print file = $Jfile end 
coupling 
print threshold 1.0 all 
print threshold 0.0 all 
end 
close $Jfile end 
set print_file = OUTPUT end 
set display = Sphifile end 
display reaid 	phi 
display N N 
evaluate ($resi = 92) 
while ($resi < 1159) loop phi 
242 
Appendix E 
evaluate ($resim I = $resi - I) 
pick dihedral (resid $resiml and name C) (resid $resi and name N) 
(resid $resi and name CA) (resid $resi and name C) geometry 
evaluate ($phi.$count.$resi = $result) 
display $resi 	$phi$count.$resi 
evaluate ($resi = $resi + I) 
end loop phi 




E-2 	filter script & fill c-noesy.inp script 
E-2.1 filter script 
setenv PROTOCOLS .1..!. ./protocols/swapping+J 
ens solve <lilt c-noesy.inp> filt_c-noesy.log 
ens _solve < filt_NOESY_HSQC.inp > filt_NOESY HSQC. log 
E-2.2 flit c-noesy.inp script 
Script to analyse ensemble of structures and the ambiguous NOE used 
to generate them in order to produce new restraints for the next 
iteration of Michael Nilges' ARIA approach 
received from Andrew Raine March, 1997 










Set up equivalences for methyls and aromatics etc. 
set echo off message offend 
inline @define_meihyls.cns 
set echo on message on end 
To get around a bug in the noe analyse statements, we need to 
look at all the restraint files individually (actually, we could do them 
all at the same time if we were prepared to put them all into one class) 
Read experimental restraints 
noe 
reset 





nrestraints = 50000 { allocate space for NOEs 
ceiling = 1000 { maximum force constant that is allowed 
set message off echo offend 
class 	c @@J../../restrainis/restrsint_files_250801/or_c_noesy.tbl 
set message on echo on end 
averaging c sum 
monomers c 2 
potential c soft 
scale 	c I { initial scale 
sqoffset c 0.0 
sqconstant c 1.0 
sqexponent c 2 
soexponent c I 
asymptote c 2.0 
rswitch c LO 
set echo on message on end 
averaging * sum 
potential * soft 
scale 	* 1.0 
sqconstant * 1.0 
sqexponent * 2 
soexponent * I 
rswitch * 1.0 
sqoffset * 0.0 














evaluate ($count = 0) 
evaluate ($endcount=30) 
!while ($count <Send count) loop main 
evaluate ($count=$count+l) 
evaluate ($file="refine"+encode($counO+".pdb") 
coord mit end 
coord @@Sfile 
aria 
analyse { Accumulate info about all the restraints over 
all the structures. Each restraint will be associated 
minimum 	{ with either the minimum 
average ( or mean 








!print threshold 0.5 floe 
end loop main 
(This section for an analysis of each violated restraint (in the log file)) 
aria countviol 
list * 0.0 (fraction of ensemble in which restraints are violated) 
0.0 means list all restraints violated at all, 1.0 means) 
all restraints violated in ALL structures 
end end 
{ ******************************************t**********************************) 
(This section for table of nuclei contributing to each restraint) 
set print ../contributions/contrib_c-noesy.txt end 
aria analyse 	( report on the stats gathered earlier 
minnuinber I 
maxnumber 1000 
cutoff 10.0 	( distance - nothing further than this) 
level 1.0 ( fraction contribution - list all possibilities making) 
up to this fraction of the intensity) 
sort * 	{ Lists all possibilities for each restraint which 
satisfy the criteria above, in order of contribution 
to total intensity (ISPAl) 
end end 
{ *****************************************************************************) 
(This section for new restraint table excluding violated restraints and nuclei) 
(contributing less than a set fraction of the intensity of the crosspeak) 
set print ../restraints/filt c-noesy.tbl end 
aria 
countviol 
exclude * 1.0 ( fraction of ensemble in which restraints are violated) 
0.0 means exclude ANY violations 
0.01 <x <0.99 means exclude restraints violated in 




analyse 	( report on the stats gathered earlier 
ininnumber I 
maxnuinber 1000 
cutoff 10.0 	( distance 
level 0.99 { fraction contribution} 
or-restraint * 	{ Creates new tb! from the restraints, taking into 
account the exclusions due to violations and the 






E-3 	check script & check _all _nocaLinp script 
E-3.1 check script 
setenv PROTOCOLS ../../../protocols/swapping+J 
cns_solve < check_aIl_nocal.inp> check_all_nocal.Iog 
E-3.2 check all 	script 
Script to analyse ensemble of structures and the ambiguous NOE used 
to generate them in order to produce new restraints for the next 
iteration of Michael Nilges' ARIA approach 
received from Andrew Raine March, 1997 










Set up equivalences for methyls and aromatics etc. 
Set echo off message offend 
inline @define_methyls.cns 
set echo on message on end 
To get around a bug in the noe analyse statements, we need to 
look stall the restraint files individually (actually, we could do them 
all at the same time if we were prepared to put them all into one class) 
Read experimental restraints 
noe 
reset 





nrestraints = 50000 { allocate space for NOEs 
ceiling = 1000 maximum force constant that is allowed 
set message off echo offend 
class 	c 	./restraints/filt_c-noesy.tbl 
@@../restraints/filt_NOESY.HSQC.tbl 
set message on echo on end 
averaging c sum 
monomers c 2 
potential c soft 
scale 	c I (initial scale 
sqoffset c 0.0 
sqconstant c 1.0 
sqexponent c 2 
soexponent c 1 
asymptote c 2.0 
rswitch 	c 1.0 
set echo on message on end 
averaging * sum 
potential * soft 
scale 	* 1.0 
sqconstant * 1.0 
sqexposent * 2 
soexponent * I 
rswitch * 1.0 
sqoffset * 0.0 














evaluate (Scount = 0) 
evaluate (Send count=30) 
while ($count < Send count) loop main 
evaluate ($count=$count+l) 
evaluate ($file="refine-I-encode($count)+"pdb") 
coord mit end 
coord @@$file 
aria 
analyse 	Accumulate info about all the restraints over 
all the structures. Each restraint will be associated 
minimum 	( with either the minimum 
average ( or mean 








print threshold 0.5 noe 
end loop main 
(This section for an analysis of each violated restraint (in the log file)) 
aria countviol 
list * 0.0 (fraction of ensemble in which restraints are violated) 
0.0 means list all restraints violated at all, 1.0 means) 
all restraints violated in ALL structures 
end end 
{ 
This section for table of nuclei contributing to each restraint) 
set print ../contributions/contrib noexcl all nocal.txt end 
aria analyse 	I report on the stats gathered earlier) 
minnumber I 
maxnumber 1000 
cutoff 10.0 	distance - nothing further than this) 
level 1.0 ( fraction contribution - list all possibilities making) 
up to this fraction of the intensity) 
sort 	( Lists all possibilities for each restraint which 
satisfy the criteria above, in order of contribution 
to total intensity (ISPA!) 
end end 
{ ***** * * *5*5*5* *5 * * * *5*5* * *5*55 * * * * ** * *5 * * * * * ** * **** * **** **** *55* * 5* * * 5*5*5 * 
(This section for new restraint table excluding violated restraints and nuclei) 
(contributing less than a set fraction of the intensity of the crosspeak) 
net print ../reutraints/check all nocaLtbl end 
aria 
countviol 
exclude * 1.0 ( fraction of ensemble in which restraints are violated) 
(0.0 means exclude ANY violations 
(0.01 <x <0.99 means exclude restraints violated in 
more than this fraction of ensemble 
end 





cutoff 10.0 	{ distance 
level 1.0 { fraction contribution) 
check * 
or-restraint * 	{ Creates new .tbl from the restraints, taking into 
account the exclusions due to violations and the 
end 	





APPENDIX F: scripts for restraints formatting 
F-i 	fillShfls procedure 
#/bin/tcsh -f 
row resid Ic 159 < shifts summary.rdb I\ 
compute resid = resid + 1000 I\ 
column resid -c resname resname.maj -c atname atname.maj 
-c shift shift maj -c delta delta.maj 
>! major summary renurnrdb 
row resid le 159< shifts summary.rdb>! shifts_summary_filled.rdb 
row resid ge 1092 <shifIs_summary.rdb>! minor_summary.rdb 
nawk -f substitutel in2.awk minor summaryrdb major summary renum.rdb 
>! minor summary filled.rdb 
headchg -del <minor_summary filled.rdb >> shifts summary fjlled.rdb 
F-2 	stripAssignment procedure 
foreach file (NOESY HSQC c-noesy) 
compute atnamel = null \; atname2 = null \; atname3 = null < {$file}.rdb 
> $fiIe).stripped.rdb 
end 
F-3 	rdb2orrest.awk procedure 
convert match table from connect to OR format CNS/ARIA restraints with 
# inter-monomer possibilities removed 
# usage: nawk -f rdb2orrest.awk match c-noesy.rdb>! or_c-noesytbl 
8 
BEGIN { xpk=-I; 
if (NR >2) 
if( sqrt((Sl - $4)"2) <70) 
if($8 = xpk) { 
xpk = $8; 
printfASSI {%s}\n,$8; 
prtntf' ((resid %s and name %s))\n ((resid %s and name %s))\n,$ I ,$3,$4,$6; 
printf %s %s 0.0 peak %s weight 0.10000E+01 volume %s ppml 0.0 ppm2 0.0\n,$9,$9,$8,$7; 
else 
printf'OR {%s}\n,$8; 
printf ((resid %s and name %s))\n ((resid %s and name %s))\n,$l,$3,$4,$6; 
250 
Appendix G 
APPENDIX G: GABAB Ria CP2 list of constraints 
251 
